<SEC-DOCUMENT>0001193125-14-110466.txt : 20140321
<SEC-HEADER>0001193125-14-110466.hdr.sgml : 20140321
<ACCEPTANCE-DATETIME>20140321164636
ACCESSION NUMBER:		0001193125-14-110466
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		8
CONFORMED PERIOD OF REPORT:	20140318
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20140321
DATE AS OF CHANGE:		20140321

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TherapeuticsMD, Inc.
		CENTRAL INDEX KEY:			0000025743
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				870233535
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-00100
		FILM NUMBER:		14710728

	BUSINESS ADDRESS:	
		STREET 1:		6800 BROKEN SOUND PARKWAY NW
		STREET 2:		THIRD FLOOR
		CITY:			BOCA RATON
		STATE:			FL
		ZIP:			33487
		BUSINESS PHONE:		561-961-1911

	MAIL ADDRESS:	
		STREET 1:		6800 BROKEN SOUND PARKWAY NW
		STREET 2:		THIRD FLOOR
		CITY:			BOCA RATON
		STATE:			FL
		ZIP:			33487

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMHN, Inc.
		DATE OF NAME CHANGE:	20090930

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CROFF ENTERPRISES INC
		DATE OF NAME CHANGE:	19970915

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CROFF OIL CO
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d693672d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 8-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>CURRENT REPORT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT
TO SECTION 13 OR 15(d) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>OF THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Date of Report (Date of earliest event reported): March&nbsp;18, 2014 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>TherapeuticsMD, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name of Registrant as Specified in its Charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Nevada</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>000-16731</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>87-0233535</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or Other Jurisdiction</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>of Incorporation)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Commission</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>File Number)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(IRS Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>6800 Broken Sound Parkway NW, Third Floor </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Boca Raton, FL 33487 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of Principal Executive Office) (Zip Code) </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code: (561)&nbsp;961-1900 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (<I>see</I> General Instruction A.2 below): </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD ALIGN="left" VALIGN="top">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </TD></TR></TABLE> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;1.01.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Entry into a Material Definitive Agreement. </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;20, 2014, TherapeuticsMD,
Inc. (the &#147;Company&#148;) entered into an underwriting agreement (the &#147;Underwriting Agreement&#148;) by and among the Company, Jefferies LLC and Stifel, Nicolaus&nbsp;&amp; Company, Incorporated, as representatives of the several
underwriters named in Schedule B thereto (the &#147;Underwriters&#148;), and the selling stockholders named in Schedule A thereto (the &#147;Selling Stockholders&#148;) relating to the sale in a public offering of 9,000,000&nbsp;shares of our common
stock, par value $0.001 per share (&#147;Common Stock&#148;), by the Selling Stockholders at the public offering price of $7.10 per share. Pursuant to the Underwriting Agreement, certain of the Selling Stockholders have granted the Underwriters a
30-day option to purchase up to an additional 1,350,000 shares of Common Stock. The Company will not sell any shares in the public offering, and will not receive any of the proceeds from the public offering. The public offering is expected to close
on or about March&nbsp;26, 2014, subject to customary closing conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The offering is being made pursuant to the Company&#146;s shelf
registration statement on Form S-3 that was filed with the Securities and Exchange Commission (&#147;SEC&#148;) on January&nbsp;24, 2014, which was declared effective by the SEC on February&nbsp;3, 2014 (Registration Statement No.&nbsp;333-193558),
and a preliminary and final prospectus supplement thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Underwriting Agreement contains customary representations, warranties,
covenants and agreements by the Company and the Selling Stockholders, customary conditions to closing, indemnification obligations of the Company, the Selling Stockholders, and the Underwriters, including for liabilities under the Securities Act of
1933, as amended, other obligations of the parties, and termination provisions. The foregoing description of the Underwriting Agreement is qualified in its entirety by reference to the Underwriting Agreement, a copy of which is filed as Exhibit 1.1
to this Form 8-K and is incorporated herein by reference. A copy of the opinion of Greenberg Traurig, LLP relating to the validity of the Common Stock to be sold in the offering is attached hereto as Exhibit&nbsp;5.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company issued press releases on March&nbsp;18, 2014 and March&nbsp;20, 2014, announcing the commencement of the offering and the pricing
of the offering, respectively, which press releases are attached hereto as Exhibits 99.1 and 99.2, respectively. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;9.01.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Financial Statements and Exhibits. </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(d)</TD>
<TD ALIGN="left" VALIGN="top"><I>Exhibits.</I> </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="92%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:26.20pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Exhibit<BR>Number</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:37.25pt; font-size:8pt; font-family:Times New Roman">Description</P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;1.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Underwriting Agreement, dated March 20, 2014</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;5.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Opinion of Greenberg Traurig, LLP</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consent of Greenberg Traurig, LLP (set forth in Exhibit 5.1)</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release from TherapeuticsMD, Inc., dated March 18, 2014, entitled &#147;TherapeuticsMD Announces Launch of Secondary Offering&#148;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release from TherapeuticsMD, Inc., dated March 20, 2014, entitled &#147;TherapeuticsMD Announces Pricing of Secondary Offering&#148;</TD></TR>
</TABLE></DIV>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: March&nbsp;20, 2014</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" COLSPAN="3">THERAPEUTICSMD, INC.</TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ <I>Daniel A. Cartwright</I></P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Daniel A. Cartwright</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Chief Financial Officer</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:26.20pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Exhibit<BR>Number</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:37.25pt; font-size:8pt; font-family:Times New Roman">Description</P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;1.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Underwriting Agreement, dated March 20, 2014</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;5.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Opinion of Greenberg Traurig, LLP</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consent of Greenberg Traurig, LLP (set forth in Exhibit 5.1)</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release from TherapeuticsMD, Inc., dated March 18, 2014, entitled &#147;TherapeuticsMD Announces Launch of Secondary Offering&#148;</TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release from TherapeuticsMD, Inc., dated March 20, 2014, entitled &#147;TherapeuticsMD Announces Pricing of Secondary Offering&#148;</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>d693672dex11.htm
<DESCRIPTION>EX-1.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-1.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 1.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>9,000,000 Shares </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TherapeuticsMD, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>UNDERWRITING AGREEMENT </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">March 20, 2014 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">JEFFERIES LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">STIFEL, NICOLAUS&nbsp;&amp; COMPANY, INCORPORATED </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">As Representatives of the several Underwriters </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Jefferies LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">520 Madison Avenue </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10022 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Stifel, Nicolaus&nbsp;&amp;
Company, Incorporated </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">One Montgomery Street, Suite 3700 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San
Francisco, CA 94104 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Introductory.</B> The stockholders of TherapeuticsMD, Inc., a Nevada corporation (the &#147;<B>Company</B>&#148;), named in <U>Schedule
A</U> (the &#147;<B>Selling Stockholders</B>&#148;), propose to sell to the several underwriters named in <U>Schedule B</U> (the &#147;<B>Underwriters</B>&#148;) an aggregate of 9,000,000 shares of the Company&#146;s common stock, par value $0.001
per share (the &#147;<B>Shares</B>&#148;). The 9,000,000 Shares to be sold by the Selling Stockholders are called the &#147;<B>Firm Shares</B>.&#148; In addition, certain of the Selling Stockholders have severally granted to the Underwriters an
option to purchase up to an additional 1,350,000 Shares, with each Selling Stockholder selling up to the amount set forth opposite such Selling Stockholder&#146;s name in <U>Schedule A</U>, as provided in Section&nbsp;2. The additional 1,350,000
Shares to be sold by certain of the Selling Stockholders pursuant to such option are collectively called the &#147;<B>Optional Shares</B>.&#148; The Firm Shares and, if and to the extent such option is exercised, the Optional Shares are collectively
called the &#147;<B>Offered Shares</B>.&#148; Jefferies LLC (&#147;<B>Jefferies</B>&#148;) and Stifel, Nicolaus&nbsp;&amp; Company, Incorporated (&#147;<B>Stifel</B>&#148;) have agreed to act as the representatives of the several Underwriters (in
such capacity, the &#147;<B>Representatives</B>&#148;) in connection with the offering and sale of the Offered Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has
prepared and filed with the Securities and Exchange Commission (the &#147;<B>Commission</B>&#148;) a shelf registration statement on Form&nbsp;S-3, File <FONT STYLE="white-space:nowrap">No.&nbsp;333-193558,</FONT> including a base prospectus (the
&#147;<B>Base Prospectus</B>&#148;) to be used in connection with the offering and sale of the Offered Shares. Such registration statement, as amended, including the financial statements, exhibits and schedules thereto, in the form in which it
became effective under the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder (collectively, the &#147;<B>Securities Act</B>&#148;), including all documents incorporated or deemed to be incorporated by reference
therein and any information deemed to be a part thereof at the time of effectiveness pursuant to Rule&nbsp;430A or 430B under the Securities Act, is called the &#147;<B>Registration Statement</B>.&#148; Any registration statement filed by the
Company pursuant to Rule&nbsp;462(b) under the Securities Act in connection with the offer and sale of the Offered Shares is called the &#147;<B>Rule 462(b) Registration Statement</B>,&#148; and from and after the date and time of filing of any such
Rule&nbsp;462(b) Registration Statement the term &#147;Registration Statement&#148; shall include the Rule&nbsp;462(b) Registration Statement. As used herein, the term &#147;<B>Prospectus</B>&#148; shall mean the prospectus supplement to the Base
Prospectus that describes the Offered Shares and the offering thereof (the &#147;<B>Prospectus</B> </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<B>Supplement</B>&#148;), together with the Base Prospectus, in the form first used by the Underwriters to confirm sales of the Offered Shares or in the form first made available to the
Underwriters by the Company to meet requests of purchasers pursuant to Rule 173 under the Securities Act. As used herein, &#147;<B>Applicable Time</B>&#148; is 6:00 p.m. (New York City time) on March 20, 2014. As used herein, &#147;<B>free writing
prospectus</B>&#148; has the meaning set forth in Rule 405 under the Securities Act, and &#147;<B>Time of Sale Prospectus</B>&#148; means the Base Prospectus, as amended or supplemented (including, without limitation, by the filing of any prospectus
supplement to the Base Prospectus pursuant to Rule 424 under the Securities Act) immediately prior to the Applicable Time, together with the free writing prospectuses, if any, identified in <U>Schedule&nbsp;C</U> hereto and the pricing information
identified in <U>Schedule&nbsp;D</U> hereto. As used herein, <B>&#147;Road Show&#148;</B> means a &#147;road show&#148; (as defined in Rule 433 under the Securities Act) relating to the offering of the Offered Shares contemplated hereby that is a
&#147;written communication&#148; (as defined in Rule 405 under the Securities Act). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All references in this Agreement to the Registration
Statement, the Base Prospectus, the Time of Sale Prospectus and the Prospectus shall include the documents incorporated or deemed to be incorporated by reference therein. All references in this Agreement to financial statements and schedules and
other information which are &#147;contained,&#148; &#147;included&#148; or &#147;stated&#148; in, or &#147;part of&#148; the Registration Statement, the Rule 462(b) Registration Statement, the Base Prospectus, the Time of Sale Prospectus or the
Prospectus, and all other references of like import, shall be deemed to mean and include all such financial statements and schedules and other information which is or is deemed to be incorporated by reference in the Registration Statement, the Rule
462(b) Registration Statement, the Base Prospectus, the Time of Sale Prospectus or the Prospectus, as the case may be. All references in this Agreement to amendments or supplements to the Registration Statement, the Base Prospectus, the Time of Sale
Prospectus or the Prospectus shall be deemed to mean and include the filing of any document under the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder (collectively, the &#147;<B>Exchange
Act</B>&#148;) that is or is deemed to be incorporated by reference in the Registration Statement, the Base Prospectus, the Time of Sale Prospectus, or the Prospectus, as the case may be. All references in this Agreement to (i)&nbsp;the Registration
Statement, the Base Prospectus, the Time of Sale Prospectus or the Prospectus, any amendments or supplements to any of the foregoing, or any free writing prospectus, shall include any copy thereof filed with the Commission pursuant to its Electronic
Data Gathering, Analysis and Retrieval System (&#147;<B>EDGAR</B>&#148;) and (ii)&nbsp;the Prospectus shall be deemed to include any &#147;electronic Prospectus&#148; provided for use in connection with the offering of the Offered Shares as
contemplated by Section&nbsp;3(A)(n) of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event that the Company has only one subsidiary, then all references herein
to &#147;subsidiaries&#148; of the Company shall be deemed to refer to such single subsidiary, <U>mutatis</U> <U>mutandis</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Company and each of the Selling Stockholders hereby confirms their respective agreements with the Underwriters as follows: </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;1. Representations and Warranties.</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>A. Representations and Warranties of the Company</B>. The Company hereby represents, warrants and covenants to each Underwriter, as of the
date of this Agreement, as of the First Closing Date (as defined in Section&nbsp;2) and as of each Option Closing Date (as defined in Section&nbsp;2), if any, as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a) </B><B><I>Compliance with Registration Requirements</I></B><B>.</B> The Registration Statement has become effective under the Securities
Act. The Company has complied with all requests of the Commission for additional or supplemental information, if any. No stop order suspending the effectiveness of the Registration Statement is in effect and no proceedings for such purpose have been
instituted or are pending or, to the knowledge of the Company, are contemplated or threatened by the Commission. At the time the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Company&#146;s Annual Report on Form 10-K for the year ended December&nbsp;31, 2013 (the &#147;<B>Annual Report</B>&#148;) was filed with the Commission, or, if later, at the time the
Registration Statement was originally filed with the Commission, the Company met the then-applicable requirements for use of Form&nbsp;S-3 under the Securities Act. The Company meets the requirements for use of Form S-3 under the Securities Act
specified in FINRA Conduct Rule&nbsp;5110(b)(7)(C)(i). The documents incorporated or deemed to be incorporated by reference in the Registration Statement, the Time of Sale Prospectus and the Prospectus, at the time they were or hereafter are filed
with the Commission, or became effective under the Exchange Act, as the case may be, complied and will comply in all material respects with the requirements of the Exchange Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b) </B><B><I>Disclosure</I></B><B>.</B> The Prospectus when filed complied in all material respects with the Securities Act and, if filed
by electronic transmission pursuant to EDGAR, was identical (except as may be permitted by <FONT STYLE="white-space:nowrap">Regulation&nbsp;S-T</FONT> under the Securities Act) to the copy thereof delivered to the Underwriters for use in connection
with the offer and sale of the Offered Shares. Each of the Registration Statement and any post-effective amendment thereto, at the time it became or becomes effective and at all subsequent times, complied and will comply in all material respects
with the Securities Act and did not and will not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary to make the statements therein not misleading. As of the Applicable Time,
the Time of Sale Prospectus (including any prospectus wrapper) did not, and at the First Closing Date (as defined in Section&nbsp;2) and at each applicable Option Closing Date (as defined in Section&nbsp;2), will not, contain any untrue statement of
a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading. The Prospectus (including any Prospectus wrapper), as of its date, did not, and
at the First Closing Date and at each applicable Option Closing Date, will not, contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances
under which they were made, not misleading. The representations and warranties set forth in the three immediately preceding sentences do not apply to statements in or omissions from the Registration Statement or any post-effective amendment thereto,
or the Prospectus or the Time of Sale Prospectus, or any amendments or supplements thereto, made in reliance upon and in conformity with written information relating to any Underwriter furnished to the Company in writing by the Representatives
expressly for use therein, it being understood and agreed that the only such information consists of the information described in Section&nbsp;9(c) below. There are no contracts or other documents required to be described in the Time of Sale
Prospectus or the Prospectus or to be filed as an exhibit to the Registration Statement which have not been described or filed as required. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c) </B><I></I><B></B><B><I>Free Writing Prospectuses; Road Show.</I></B><B></B><I></I> As of the determination date referenced in Rule
164(h) under the Securities Act, the Company was not, is not or will not be (as applicable) an &#147;ineligible issuer&#148; in connection with the offering of the Offered Shares pursuant to Rules 164, 405 and 433 under the Securities Act. Each free
writing prospectus that the Company is required to file pursuant to Rule 433(d) under the Securities Act has been, or will be, filed with the Commission in accordance with the requirements of the Securities Act. Each free writing prospectus that the
Company has filed, or is required to file, pursuant to Rule 433(d) under the Securities Act or that was prepared by or on behalf of or used by the Company complies or will comply in all material respects with the requirements of Rule 433 under the
Securities Act, including timely filing with the Commission or retention where required and legending, and each such free writing prospectus, as of its issue date and at all subsequent times through the completion of the offer and sale of the
Offered Shares did not, does not and will not include any information that conflicted, conflicts or will conflict with the information contained in the Registration Statement, the Time of Sale Prospectus, or the Prospectus and not superseded or
modified. Except for the free writing prospectuses, if any, identified in <U>Schedule C</U>, and electronic road shows, if any, furnished to you before first use, the Company has not prepared, used or referred to, and will not, without your prior
written consent, prepare, use or refer to, any free writing prospectus. Each Road Show, when considered </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
together with the Time of Sale Prospectus, did not, as of the Applicable Time, contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements
therein, in the light of the circumstances under which they were made, not misleading. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d) </B><B><I>Distribution of Offering Material
By the Company</I></B><B>.</B> The Company has not distributed and will not distribute, prior to the completion of the Underwriters&#146; distribution of the Offered Shares, any offering material in connection with the offering and sale of the
Offered Shares other than the Registration Statement, the Time of Sale Prospectus, the Prospectus or any free writing prospectus reviewed and consented to by the Representatives, if any, identified on <U>Schedule&nbsp;C</U> hereto. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e) </B><B><I>The Underwriting Agreement</I></B><B>.</B> This Agreement has been duly authorized, executed and delivered by the Company.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f) </B><B><I>Authorization of the Offered Shares</I></B><B>.</B> The Offered Shares have been duly authorized and are validly issued,
fully paid and nonassessable, and, when sold by the Selling Stockholders, will not be subject to any preemptive rights, rights of first refusal or other similar rights of the Company or granted by the Company to subscribe for or purchase the Offered
Shares, except for such rights as have been validly waived. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(g) </B><B><I>No Applicable Registration or Other Similar
Rights</I></B><B>.</B> There are no persons with registration or other similar rights to have any equity or debt securities registered for sale under the Registration Statement or included in the offering contemplated by this Agreement, other than
the Selling Stockholders with respect to the Offered Shares included in the Registration Statement, except for such rights as have been duly waived. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(h) </B><B><I>No Material Adverse Change</I></B><B>.</B> Except as otherwise disclosed in the Registration Statement, the Time of Sale
Prospectus and the Prospectus, subsequent to the respective dates as of which information is given in the Registration Statement, the Time of Sale Prospectus and the Prospectus: (i)&nbsp;there has been no material adverse change, or any development
that could reasonably be expected to result in a material adverse change, in the condition, financial or otherwise, or in the earnings, business, properties, operations, assets, liabilities or prospects, whether or not arising from transactions in
the ordinary course of business, of the Company and its subsidiaries, considered as one entity (any such change being referred to herein as a &#147;<B>Material Adverse Change</B>&#148;); (ii)&nbsp;the Company and its subsidiaries, considered as one
entity, have not incurred any material liability or obligation, indirect, direct or contingent, including without limitation any losses or interference with its business from fire, explosion, flood, earthquakes, accident or other calamity, whether
or not covered by insurance, or from any strike, labor dispute or court or governmental action, order or decree, that are material, individually or in the aggregate, to the Company and its subsidiaries, considered as one entity, or has entered into
any material transactions not in the ordinary course of business; and (iii)&nbsp;there has not been any material decrease in the capital stock or any material increase in any short-term or long-term indebtedness of the Company or its subsidiaries
and there has been no dividend or distribution of any kind declared, paid or made by the Company or, except for dividends paid to the Company or other subsidiaries, by any of the Company&#146;s subsidiaries on any class of capital stock, or any
repurchase or redemption by the Company or any of its subsidiaries of any class of capital stock. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i) </B><B><I>Independent
Accountants</I></B><B>.</B> Rosenberg Rich Baker Berman&nbsp;&amp; Company, which has expressed its opinion with respect to the financial statements (which term as used in this Agreement includes the related notes thereto) filed with the Commission
as a part of the Registration Statement, the Time of Sale Prospectus and the Prospectus, is (i)&nbsp;an independent registered public accounting firm as required by the Securities Act, the Exchange Act and the rules of the Public Company Accounting
Oversight Board (&#147;<B>PCAOB</B>&#148;), (ii)&nbsp;in compliance with the applicable requirements relating to the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
qualification of accountants under Rule&nbsp;2-01 of Regulation S-X under the Securities Act and (iii)&nbsp;a registered public accounting firm as defined by the PCAOB whose registration has not
been suspended or revoked and who has not requested such registration to be withdrawn. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(j) </B><B><I>Financial
Statements</I></B><B>.</B> The financial statements filed with the Commission as a part of the Registration Statement, the Time of Sale Prospectus and the Prospectus present fairly the consolidated financial position of the Company and its
subsidiaries as of the dates indicated and the results of their operations, changes in stockholders&#146; equity and cash flows for the periods specified. Such financial statements have been prepared in conformity with accounting principles
generally accepted in the United States of America applied on a consistent basis throughout the periods involved, except as may be expressly stated in the related notes thereto. The interactive data in eXtensible Business Reporting Language included
or incorporated by reference in the Registration Statement fairly presents the information called for in all material respects and has been prepared in accordance with the Commission&#146;s rules and guidelines applicable thereto. No other financial
statements or supporting schedules are required to be included in the Registration Statement, the Time of Sale Prospectus or the Prospectus. To the Company&#146;s knowledge, no person who has been suspended or barred from being associated with a
registered public accounting firm, or who has failed to comply with any sanction pursuant to Rule 5300 promulgated by the PCAOB, has participated in or otherwise aided the preparation of, or audited, the financial statements, supporting schedules or
other financial data filed with the Commission as a part of the Registration Statement, the Time of Sale Prospectus and the Prospectus. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(k) </B><B><I>Company&#146;s Accounting System</I></B><B>.</B> The Company and each of its subsidiaries make and keep accurate books and
records and maintain a system of internal accounting controls sufficient to provide reasonable assurance that: (i)&nbsp;transactions are executed in accordance with management&#146;s general or specific authorization; (ii)&nbsp;transactions are
recorded as necessary to permit preparation of financial statements in conformity with generally accepted accounting principles and to maintain accountability for assets; (iii)&nbsp;access to assets is permitted only in accordance with
management&#146;s general or specific authorization; (iv)&nbsp;the recorded accountability for assets is compared with existing assets at reasonable intervals and appropriate action is taken with respect to any differences; and (v)&nbsp;the
interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement, the Time of Sale Prospectus and the Prospectus fairly presents the information called for in all material respects and is
prepared in accordance with the Commission&#146;s rules and guidelines applicable thereto. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(l) </B><B><I>Disclosure Controls and
Procedures; Deficiencies in or Changes to Internal Control Over Financial Reporting</I></B><B>.</B> The Company has established and maintains disclosure controls and procedures (as defined in Rules&nbsp;13a-15 and 15d-15 under the Exchange Act),
which (i)&nbsp;are designed to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to the Company&#146;s principal executive officer and its principal financial officer by others within
those entities, particularly during the periods in which the periodic reports required under the Exchange Act are being prepared; (ii)&nbsp;have been evaluated by management of the Company for effectiveness as of the end of the Company&#146;s most
recent fiscal quarter; and (iii)&nbsp;are effective in all material respects to perform the functions for which they were established as of the end of the Company&#146;s most recent fiscal quarter. Since December&nbsp;31, 2013, there have been no
significant deficiencies or material weakness in the Company&#146;s internal control over financial reporting (whether or not remediated) and no change in the Company&#146;s internal control over financial reporting that has materially affected, or
is reasonably likely to materially affect, the Company&#146;s internal control over financial reporting. The Company is not aware of any change in its internal control over financial reporting that has occurred during its most recent fiscal quarter
that has materially affected, or is reasonably likely to materially affect, the Company&#146;s internal control over financial reporting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(m) </B><B><I>Incorporation and Good Standing of the Company</I></B><B>.</B> The Company has
been duly incorporated and is validly existing as a corporation in good standing under the laws of the jurisdiction of its incorporation and has the corporate power and authority to own, lease and operate its properties and to conduct its business
as described in the Registration Statement, the Time of Sale Prospectus and the Prospectus and to enter into and perform its obligations under this Agreement. The Company is duly qualified as a foreign corporation to transact business and is in good
standing in the State of Florida and each other jurisdiction in which such qualification is required, whether by reason of the ownership or leasing of property or the conduct of business, except where the failure to be so qualified or in good
standing could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect (as defined below). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(n)
</B><B><I>Subsidiaries</I></B><B>.</B> Each of the Company&#146;s &#147;subsidiaries&#148; (for purposes of this Agreement, as defined in Rule 405 under the Securities Act) has been duly incorporated or organized, as the case may be, and is validly
existing as a corporation, partnership or limited liability company, as applicable, in good standing under the laws of the jurisdiction of its incorporation or organization and has the power and authority (corporate or other) to own, lease and
operate its properties and to conduct its business as described in the Registration Statement, the Time of Sale Prospectus and the Prospectus. Each of the Company&#146;s subsidiaries is duly qualified as a foreign corporation, partnership or limited
liability company, as applicable, to transact business and is in good standing in each jurisdiction in which such qualification is required, whether by reason of the ownership or leasing of property or the conduct of business, except where the
failure to be so qualified or in good standing could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect (as defined below). All of the issued and outstanding capital stock or other equity or ownership
interests of each of the Company&#146;s subsidiaries have been duly authorized and validly issued, are fully paid and nonassessable and are owned by the Company, directly or through subsidiaries, free and clear of any security interest, mortgage,
pledge, lien, encumbrance or adverse claim. The Company does not own or control, directly or indirectly, any corporation, association or other entity other than vitaMedMD, LLC, a Delaware limited liability company, and BocaGreenMD, Inc., a Nevada
corporation. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(o) </B><B><I>Capitalization and Other Capital Stock Matters</I></B><B>.</B> The authorized, issued and outstanding
capital stock of the Company is as set forth in the Registration Statement, the Time of Sale Prospectus and the Prospectus (other than for subsequent issuances, if any, pursuant to employee benefit plans, or upon the exercise of outstanding options
or warrants, in each case described in the Registration Statement, the Time of Sale Prospectus and the Prospectus). The Shares (including the Offered Shares) conform in all material respects to the description thereof contained in the Time of Sale
Prospectus. All of the issued and outstanding Shares (including the Shares owned by the Selling Stockholders) have been duly authorized and validly issued, are fully paid and nonassessable and have been issued in compliance with all federal and
state securities laws. None of the outstanding Shares was issued in violation of any preemptive rights, rights of first refusal or other similar rights to subscribe for or purchase securities of the Company. There are no authorized or outstanding
options, warrants, preemptive rights, rights of first refusal or other rights to purchase, or equity or debt securities convertible into or exchangeable or exercisable for, any capital stock of the Company or any of its subsidiaries other than those
described in the Registration Statement, the Time of Sale Prospectus and the Prospectus. The descriptions of the Company&#146;s stock option, stock bonus and other stock plans or arrangements, and the options or other rights granted thereunder, set
forth in the Registration Statement, the Time of Sale Prospectus and the Prospectus accurately and fairly presents the information required to be shown with respect to such plans, arrangements, options and rights. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(p) </B><B><I>Stock Exchange Listing; Exchange Act Registration</I></B><B>.</B> The Shares are registered pursuant to Section&nbsp;12(b) or
12(g) of the Exchange Act and are listed on the NYSE MKT exchange (the &#147;<B>NYSE MKT</B>&#148;), and the Company has taken no action designed to, or likely to have the effect of, terminating the registration of the Shares under the Exchange Act
or delisting the Shares from the NYSE MKT, nor has </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Company received any notification that the Commission or the NYSE MKT is contemplating terminating such registration or listing. The Company has complied in all material respects with the
applicable listing requirements of the NYSE MKT. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(q) </B><B><I>Non-Contravention of Existing Instruments; No Further Authorizations or
Approvals Required</I></B><B>.</B> Neither the Company nor any of its subsidiaries is in violation of its charter or by-laws, partnership agreement or operating agreement or similar organizational documents, as applicable, or is in default (or, with
the giving of notice or lapse of time, would be in default) (&#147;<B>Default</B>&#148;) under any indenture, loan, credit agreement, note, lease, license agreement, contract, franchise or other instrument (including, without limitation, any pledge
agreement, security agreement, mortgage or other instrument or agreement evidencing, guaranteeing, securing or relating to indebtedness) to which the Company or any of its subsidiaries is a party or by which it or any of them may be bound, or to
which any of their respective properties or assets are subject (each, an &#147;<B>Existing Instrument</B>&#148;), except for such Defaults as would not reasonably be expected, individually or in the aggregate, to have a material adverse effect on
the condition (financial or other), earnings, business, properties, operations, assets, liabilities or prospects of the Company and its subsidiaries, considered as one entity (a &#147;<B>Material Adverse Effect</B>&#148;). The Company&#146;s
execution, delivery and performance of this Agreement, consummation of the transactions contemplated hereby and by the Registration Statement, the Time of Sale Prospectus and the Prospectus and the sale of the Offered Shares (i)&nbsp;have been duly
authorized by all necessary corporate action and will not result in any violation of the provisions of the charter or by-laws, partnership agreement or operating agreement or similar organizational documents, as applicable, of the Company or any
subsidiary (ii)&nbsp;will not conflict with or constitute a breach of, or Default or a Debt Repayment Triggering Event (as defined below) under, or result in the creation or imposition of any lien, charge or encumbrance upon any property or assets
of the Company or any of its subsidiaries pursuant to, or require the consent of any other party to, any Existing Instrument, except as could not be expected, individually or in the aggregate, to have a Material Adverse Effect, and (iii)&nbsp;will
not result in any violation of any law, administrative regulation or administrative or court decree applicable to the Company or any of its subsidiaries. No consent, approval, authorization or other order of, or registration or filing with, any
court or other governmental or regulatory authority or agency, is required for the Company&#146;s execution, delivery and performance of this Agreement and consummation of the transactions contemplated hereby and by the Registration Statement, the
Time of Sale Prospectus and the Prospectus, except such as have been obtained or made by the Company and are in full force and effect under the Securities Act and such as may be required under applicable state securities or blue sky laws or FINRA.
As used herein, a &#147;<B>Debt Repayment Triggering Event</B>&#148; means any event or condition which gives, or with the giving of notice or lapse of time would give, the holder of any note, debenture or other evidence of indebtedness (or any
person acting on such holder&#146;s behalf) the right to require the repurchase, redemption or repayment of all or a portion of such indebtedness by the Company or any of its subsidiaries. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(r) </B><B><I>Compliance with Laws.</I></B> Except where failure to be so in compliance would not reasonably be expected, individually or in
the aggregate, to have a Material Adverse Effect, the Company and its subsidiaries and, to the knowledge of the Company, its respective directors, officers, employees and agents,&nbsp;have been and are in compliance with all applicable laws, rules
and regulations, including, without limitation: the Federal Food, Drug and Cosmetic Act and implementing regulations applicable to the Company and its subsidiaries relating to the ownership, testing, development, manufacture, packaging, processing,
use, distribution, marketing, labeling, promotion, sale, offer for sale, storage, import, export or disposal of any product manufactured or distributed by or on behalf of the Company; the federal Anti-kickback Statute (42 U.S.C. &#167; 1320a-7b(b)),
the Anti-Inducement Law (42 U.S.C. &#167; 1320a-7a(a)(5)), the civil False Claims Act (31 U.S.C. &#167;&#167; 3729 et seq.), the administrative False Claims Law (42 U.S.C. &#167; 1320a-7b(a)), the federal Physician Payment Sunshine Act (42 U.S.C.
Section&nbsp;1320a-7h), the applicable provisions of the Health Insurance Portability and Accountability Act of 1996 (42 U.S.C. &#167; 1320d et seq.), as amended by the Health Information Technology for Economic and Clinical Health Act (42 U.S.C.
&#167;&#167; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
17921 et seq.), the exclusion laws (42 U.S.C. &#167; 1320a-7), the Medicare program (Title XVIII of the Social Security Act), the Medicaid program (Title XIX of the Social Security Act), the
regulations promulgated pursuant to such laws, and any other similar local, state or federal law, each as amended from time to time. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(s) </B><B><I>No Material Actions or Proceedings</I></B><B>.</B> Except as otherwise disclosed in the Registration Statement, the Time of
Sale Prospectus, and the Prospectus, there is no action, suit, proceeding, inquiry or investigation brought by or before any governmental entity now pending or, to the knowledge of the Company, threatened, against or affecting the Company or any of
its subsidiaries, which could reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect or materially and adversely affect the consummation of the transactions contemplated by this Agreement or the performance by
the Company of its obligations hereunder; and the aggregate of all pending legal or governmental proceedings to which the Company or any such subsidiary is a party or of which any of their respective properties or assets is the subject, including
ordinary routine litigation incidental to the business, if determined adversely to the Company, could not reasonably be expected to have a Material Adverse Effect. None of the Company or any of its subsidiaries is a party to or has any ongoing
reporting obligations pursuant to any corporate integrity agreement, deferred prosecution agreement, monitoring agreement, consent decree, settlement order, plan of correction or similar agreement imposed by any governmental authority. No material
labor dispute with the employees of the Company or any of its subsidiaries, or with the employees of any principal supplier, manufacturer, customer or contractor of the Company, exists or, to the knowledge of the Company, is threatened or imminent.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(t) </B><B><I>Intellectual Property Rights</I></B><B>.</B> Except as disclosed in the Registration Statement, the Time of Sale
Prospectus and the Prospectus, the Company and its subsidiaries own, or have obtained valid and enforceable licenses for, the inventions, patent applications, patents, trademarks, trade names, service names, copyrights, trade secrets and other
intellectual property described in the Registration Statement, the Time of Sale Prospectus and the Prospectus as being owned or licensed by them or which are necessary for the conduct of their respective businesses as currently conducted or as
currently proposed to be conducted (collectively, &#147;<B>Intellectual Property</B>&#148;). Except as disclosed in the Registration Statement, the Time of Sale Prospectus and the Prospectus, the Company has not granted to any third party any rights
or licenses under the Intellectual Property other than non-exclusive licenses granted in the ordinary course of business. Except as disclosed in the Registration Statement, the Time of Sale Prospectus and the Prospectus, there are no liens or
security interests in the Intellectual Property. To the Company&#146;s knowledge: (i)&nbsp;there is no infringement by third parties of any Intellectual Property and the Company is unaware of the occurrence of any event that with notice or the
passage of time would constitute infringement of any Intellectual Property; and (ii)&nbsp;except as disclosed in the Registration Statement, the Time of Sale Prospectus and the Prospectus, there is no infringement by the Company or its subsidiaries
of any patent, trademark, trade name, service name, copyright, trade secret or other proprietary rights of others and the Company is unaware of the occurrence of any event that with notice or the passage of time would constitute infringement. Except
as disclosed in the Registration Statement, the Time of Sale Prospectus and the Prospectus, there is no pending or, to the Company&#146;s knowledge, threatened action, suit, proceeding or claim by others: (A)&nbsp;challenging the Company&#146;s
rights in or to any Intellectual Property, and the Company is unaware of any facts which would form a reasonable basis for any such action, suit, proceeding or claim; (B)&nbsp;challenging the validity, enforceability or scope of any Intellectual
Property, and the Company is unaware of any facts which would form a reasonable basis for any such action, suit, proceeding or claim; or (C)&nbsp;asserting that the Company or any of its subsidiaries infringes or otherwise violates, or would, upon
the commercialization of any product or service described in the Registration Statement, the Time of Sale Prospectus or the Prospectus as under development, infringe or violate, any patent, trademark, trade name, service name, copyright, trade
secret or other proprietary rights of others, and the Company is unaware of any facts which would form a reasonable basis for any such action, suit, proceeding or claim. The Company and its subsidiaries have complied with the terms of each agreement
pursuant to which Intellectual Property has been licensed to the Company or any subsidiary, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and all such agreements are in full force and effect. No Intellectual Property has been obtained or is being used by the Company or its subsidiaries in violation of any contractual obligations
binding on the Company or in violation of any contractual rights of the Company&#146;s employees. Except as disclosed in the Registration Statement, the Time of Sale Prospectus and the Prospectus, the product candidates described in the Registration
Statement, the Time of Sale Prospectus and the Prospectus as under development by the Company or any subsidiary fall within the scope of the claims of one or more patents owned by, or exclusively licensed to, the Company or any subsidiary. To the
Company&#146;s knowledge, (x)&nbsp;all patent applications and patents within the Intellectual Property have been diligently prosecuted and no person having a duty of candor to the United States Patent Office with respect to the prosecution of such
patent applications and patents has breached such duty, and (y)&nbsp;there is no material defect in such prosecution that would preclude the issuance of patents with respect to such patent applications or that would render any such issued patents
invalid or unenforceable. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(u) </B><B><I>All Necessary Permits, etc</I></B><B>.</B> The Company and its subsidiaries possess such
certificates, approvals, clearances, authorizations or permits, and all supplements or amendments thereto, required by state, federal or foreign regulatory agencies or bodies (&#147;<B>Regulatory Agencies</B>&#148;) to conduct their respective
businesses as currently conducted and as described in the Registration Statement, the Time of Sale Prospectus or the Prospectus (&#147;<B>Permits</B>&#148;). Neither the Company nor any of its subsidiaries is in violation of, or in default under,
any Permit or has received any notice of proceedings relating to the revocation or modification of, or non-compliance with, any such Permit. The Company and its subsidiaries have fulfilled and performed all of their obligations with respect to the
Permits and, to the Company&#146;s and its subsidiaries&#146; knowledge, no event has occurred which allows, or after notice or lapse of time would allow, revocation or termination thereof or results in any other material impairment of the rights of
the holder of any Permit. All such Permits are in full force and effect. The Company, and to the Company&#146;s knowledge, its subsidiaries have each operated and currently are in compliance in all material respects with all applicable laws, rules,
regulations and policies of the Regulatory Agencies. Neither the Company nor any of its subsidiaries has received any FDA Form 483, notice of adverse finding, warning letter, untitled letter or other correspondence or notice from any other
Regulatory Agency alleging or asserting noncompliance with any applicable laws or any Permit. The Company, and to the Company&#146;s knowledge, its subsidiaries have submitted all applications, notifications, submissions, information, claims,
reports and statistics, filings, and other data and conclusions derived therefrom (collectively, the &#147;<B>Submissions</B>&#148;) to the FDA or other Regulatory Agencies as required for the conduct of their respective businesses as currently
conducted, and all such Submissions, when submitted to the FDA or other Regulatory Agency were true, complete and correct in all material respects as of the date of submission, and any necessary or required updates, changes, corrections or
modification to such Submissions have been submitted to the FDA or other Regulatory Agency. The claims for the Company&#146;s and its subsidiaries&#146; products as disclosed in the Registration Statement, the Time of Sale Prospectus and the
Prospectus comply in all material respects with applicable law, and are supported by valid and proper research, design, testing, analysis and disclosure. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(v) </B><B><I>Clinical Data and Regulatory Compliance.</I></B> (i)&nbsp;To the knowledge of the Company, the preclinical tests and clinical
trials that are described in, or the results of which are referred to in, the Registration Statement, the Time of Sale Prospectus or the Prospectus were and, if still pending, are being conducted in all material respects in accordance with the
protocols established for each such preclinical test or clinical trial and all applicable laws, rules, and regulations of the Regulatory Agencies, including, without limitation, 21 C.F.R. Parts 50, 54, 56, 58 and 312; (ii)&nbsp;each description of
the results of such preclinical tests and clinical trials is accurate and complete in all material respects and fairly presents the data derived from such preclinical tests and clinical trials, and the Company and its subsidiaries have no knowledge
of any other preclinical tests and clinical trials the results of which are inconsistent with, or otherwise call into question, the results described or referred to in the Registration Statement, the Time of Sale Prospectuses or the Prospectus; and
(iii)&nbsp;neither the Company nor any of its subsidiaries has received </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
any notice of, or correspondence from, any Regulatory Agency requiring the termination, suspension or material modification of any preclinical tests or clinical trials that are, or whose results
of which are, described or referred to in the Registration Statement, the Time of Sale Prospectus or the Prospectus. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(w)
</B><B><I>Exclusion.</I></B> None of the Company, its subsidiaries nor, to the knowledge of the Company, any of its respective officers, directors or managing employees (as defined in 42 U.S.C. &#167;&nbsp;1320a-5(b)) is or has been excluded,
suspended or debarred from participation in any state or federal health care program, or made subject to any pending or, to the Company&#146;s knowledge, threatened or contemplated action which could reasonably be expected to result in such
exclusion, suspension or debarment. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(x) </B><B><I>Title to Properties</I></B><B>.</B> The Company and its subsidiaries have good and
marketable title to all of the real and personal property and other assets reflected as owned in the financial statements referred to in Section&nbsp;1(A)(j) above (or elsewhere in the Registration Statement, the Time of Sale Prospectus or the
Prospectus), in each case free and clear of any security interests, mortgages, liens, encumbrances, equities, adverse claims and other defects, except such as could not reasonably be expected, individually or in the aggregate, to have a Material
Adverse Effect. The real property, improvements, equipment and personal property held under lease by the Company or any of its subsidiaries are held under valid and enforceable leases, with such exceptions as are not material and do not materially
interfere with the use made or proposed to be made of such real property, improvements, equipment or personal property by the Company or such subsidiary. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(y) </B><B><I>Tax Law Compliance</I></B><B>.</B> The Company and its subsidiaries have filed all federal, state, local and foreign tax
returns required to be filed or have properly requested extensions thereof, and all such tax returns are true, complete and accurate in all material respects. The Company and its subsidiaries have paid all taxes required to be paid by any of them
and, if due and payable, any related or similar assessment, fine or penalty levied against any of them except as may be being contested in good faith and by appropriate proceedings. The Company and its subsidiaries have made adequate charges,
accruals and reserves in the applicable financial statements referred to in Section&nbsp;1(A)(j) above in respect of all federal, state, local and foreign taxes not yet due and payable in accordance with U.S. generally accepted accounting
principles, and neither the Company nor any of its subsidiaries has received written notice of any actual or proposed additional material tax assessment from a tax authority of any jurisdiction. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(z) </B><B><I>Insurance</I></B><B>.</B> Each of the Company and its subsidiaries are insured by recognized, financially sound and reputable
institutions with policies in such amounts and with such deductibles and covering such risks as are generally deemed adequate and customary for their businesses including, but not limited to, policies covering real and personal property owned or
leased by the Company and its subsidiaries against theft, damage, destruction, acts of vandalism and earthquakes and policies covering the Company and its subsidiaries for product liability claims and clinical trial liability claims. The Company has
no reason to believe that it or any of its subsidiaries will not be able (i)&nbsp;to renew its existing insurance coverage as and when such policies expire or (ii)&nbsp;to obtain comparable coverage from similar institutions as may be necessary or
appropriate to conduct its business as now conducted and at a cost that could not be expected to have a Material Adverse Effect. Neither the Company nor any of its subsidiaries has been denied any insurance coverage which it has sought or for which
it has applied. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(aa) </B><B><I>Compliance with Environmental Laws</I></B><B>.</B> Except as would not reasonably be expected,
individually or in the aggregate, to have a Material Adverse Effect: (i)&nbsp;neither the Company nor any of its subsidiaries is in violation of any federal, state, local or foreign statute, law, rule, regulation, ordinance, code, policy or rule of
common law or any judicial or administrative interpretation thereof, including any judicial or administrative order, consent, decree or judgment, relating to pollution or protection of human health, the environment (including, without limitation,
ambient air, surface water, groundwater, land surface or subsurface strata) or wildlife, including, without limitation, laws and regulations relating to the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
release or threatened release of chemicals, pollutants, contaminants, wastes, toxic substances, hazardous substances, petroleum or petroleum products (collectively, &#147;<B>Hazardous
Materials</B>&#148;) or to the manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials (collectively, &#147;<B>Environmental Laws</B>&#148;); (ii)&nbsp;the Company and its subsidiaries
have all permits, authorizations and approvals required under any applicable Environmental Laws and are each in compliance with their requirements; (iii)&nbsp;there are no pending or threatened administrative, regulatory or judicial actions, suits,
demands, demand letters, claims, liens, notices of noncompliance or violation, investigation or proceedings relating to any Environmental Law against the Company or any of its subsidiaries; and (iv)&nbsp;there are no events or circumstances that
might reasonably be expected to form the basis of an order for clean-up or remediation, or an action, suit or proceeding by any private party or governmental body or agency, against or affecting the Company or any of its subsidiaries relating to
Hazardous Materials or any Environmental Laws. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(bb) </B><B><I>Periodic Review of Costs of Environmental Compliance</I></B><B>.</B> In
the ordinary course of its business, the Company conducts, from time to time, a review reasonable in light of the Company&#146;s business of the effect of Environmental Laws on the business, operations and properties of the Company and its
subsidiaries, in the course of which it identifies and evaluates associated costs and liabilities (including, without limitation, any capital or operating expenditures required for clean-up, closure of properties or compliance with Environmental
Laws or any permit, license or approval, any related constraints on operating activities and any potential liabilities to third parties). No facts or circumstances have come to the Company&#146;s attention that could result in costs or liabilities
due to the violation of any Environmental Laws that could be expected, individually or in the aggregate, to have a Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(cc) </B><B><I>ERISA Compliance</I></B><B>.</B> The Company and its subsidiaries and any &#147;employee benefit plan&#148; (as defined under
the Employee Retirement Income Security Act of 1974, as amended, and the regulations and published interpretations thereunder (collectively, &#147;<B>ERISA</B>&#148;)) established or maintained by the Company, its subsidiaries or their &#147;ERISA
Affiliates&#148; (as defined below) are in compliance in all material respects with ERISA. &#147;<B>ERISA Affiliate</B>&#148; means, with respect to the Company or any of its subsidiaries, any member of any group of organizations described in
Sections&nbsp;414(b), (c), (m)&nbsp;or (o)&nbsp;of the Internal Revenue Code of 1986, as amended, and the regulations and published interpretations thereunder (the &#147;<B>Code</B>&#148;) of which the Company or such subsidiary is a member. No
&#147;reportable event&#148; (as defined under ERISA) has occurred or is reasonably expected to occur with respect to any &#147;employee benefit plan&#148; established or maintained by the Company, its subsidiaries or any of their ERISA Affiliates.
No &#147;employee benefit plan&#148; established or maintained by the Company, its subsidiaries or any of their ERISA Affiliates, if such &#147;employee benefit plan&#148; were terminated, would have any &#147;amount of unfunded benefit
liabilities&#148; (as defined under ERISA). Neither the Company, its subsidiaries nor any of their ERISA Affiliates has incurred or reasonably expects to incur any liability under (i)&nbsp;Title&nbsp;IV of ERISA with respect to termination of, or
withdrawal from, any &#147;employee benefit plan&#148; or (ii)&nbsp;Sections&nbsp;412, 4971, 4975 or 4980B of the Code. Each employee benefit plan established or maintained by the Company, its subsidiaries or any of their ERISA Affiliates that is
intended to be qualified under Section&nbsp;401(a) of the Code is so qualified and nothing has occurred, whether by action or failure to act, which could reasonably be expected to result in cause the loss of such qualification. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(dd) </B><B><I>Company Not an &#147;Investment Company.&#148;</I></B> The Company is not, and will not be, either after receipt of payment
for the Offered Shares or after the application of the proceeds therefrom as described under &#147;Use of Proceeds&#148; in the Registration Statement, the Time of Sale Prospectus or the Prospectus, required to register as an &#147;investment
company&#148; under the Investment Company Act of 1940, as amended (the <B>&#147;Investment Company Act&#148;)</B>. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ee) </B><B><I>No Price Stabilization or Manipulation; Compliance with Regulation
M</I></B><B>.</B> Neither the Company nor any of its subsidiaries has taken, directly or indirectly, any action designed to or that might reasonably be expected to cause or result in stabilization or manipulation of the price of the Shares or of any
&#147;reference security&#148; (as defined in Rule 100 of Regulation M under the Exchange Act (<B>&#147;Regulation&nbsp;M&#148;</B>)) with respect to the Shares, whether to facilitate the sale or resale of the Offered Shares or otherwise, and has
taken no action which would directly or indirectly violate Regulation M. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ff) </B><B><I>Related-Party Transactions</I></B><B>.</B>
There are no business relationships or related-party transactions involving the Company or any of its subsidiaries or any other person required to be described in the Registration Statement, the Time of Sale Prospectus or the Prospectus that have
not been described as required. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(gg) </B><B><I>Exchange Act Compliance</I></B>. The documents incorporated or deemed to be incorporated
by reference in the Prospectus (the &#147;<B>Incorporated Documents</B>&#148;), when they became effective or were filed with the Commission, as the case may be, conformed in all material respects to the requirements of the Securities Act or the
Exchange Act, as applicable, and were filed on a timely basis with the Commission and none of such documents contained an untrue statement of a material fact or omitted to state a material fact necessary to make the statements therein, in the light
of the circumstances under which they were made, not misleading; any further Incorporated Documents, when filed with the Commission, will conform in all material respects to the requirements of the Exchange Act, and will not contain an untrue
statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(hh) </B><B><I>Sarbanes-Oxley</I></B>. The Company is in compliance with all applicable provisions of the Sarbanes-Oxley Act and the rules
and regulations of the Commission thereunder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ii) </B><B><I>FINRA Matters</I></B><B>.</B> All of the information provided to the
Underwriters or to counsel for the Underwriters by the Company, its counsel, its officers and directors and the holders of any securities (debt or equity) or options to acquire any securities of the Company in connection with the offering of the
Offered Shares is true, complete, correct and compliant with FINRA&#146;s rules and any letters, filings or other supplemental information provided to FINRA pursuant to FINRA Rules or NASD Conduct Rules is true, complete and correct. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(jj) </B><B><I>Parties to Lock-Up Agreements</I></B><B>.</B> The Company has furnished to the Underwriters a letter agreement in the form
attached hereto as <U>Exhibit&nbsp;D</U> (the &#147;<B>Lock-up Agreement</B>&#148;) from the Selling Stockholders and each of the persons listed on <U>Exhibit&nbsp;E</U>. Such <U>Exhibit&nbsp;E</U> lists under an appropriate caption the directors,
officers and certain stockholders, warrant holders and stock option holders of the Company. If any additional persons shall become directors or officers of the Company prior to the end of the Company Lock-up Period (as defined below), the Company
shall cause each such person, prior to or contemporaneously with their appointment or election as a director or officer of the Company, to execute and deliver to the Representatives a Lock-up Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(kk) </B><B><I>Statistical and Market-Related Data</I></B><B>.</B> All statistical, demographic and market-related data included in the
Registration Statement, the Time of Sale Prospectus or the Prospectus are based on or derived from sources that the Company believes, after reasonable inquiry, to be reliable and accurate. To the extent required, the Company has obtained the written
consent to the use of such data from such sources. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ll) </B><B><I>No Unlawful Contributions or Other Payments</I></B><B>.</B> Neither
the Company nor any of its subsidiaries nor, to the best of the Company&#146;s knowledge, any employee or agent of the Company or any subsidiary, has made any contribution or other payment to any official of, or candidate for, any federal,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
state or foreign office in violation of any law or of the character required to be disclosed in the Registration Statement, the Time of Sale Prospectus or the Prospectus. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(mm) </B><B><I>Foreign Corrupt Practices Act</I></B><B>.</B> Neither the Company nor any of its subsidiaries nor, to the knowledge of the
Company, any director, officer, agent, employee, affiliate or other person acting on behalf of the Company or any of its subsidiaries has, in the course of its actions for, or on behalf of, the Company or any of its subsidiaries (i)&nbsp;used any
corporate funds for any unlawful contribution, gift, entertainment or other unlawful expenses relating to political activity; (ii)&nbsp;made any direct or indirect unlawful payment to any domestic government official, &#147;foreign official&#148;
(as defined in the U.S. Foreign Corrupt Practices Act of 1977, as amended, and the rules and regulations thereunder (collectively, the &#147;<B>FCPA</B>&#148;) or employee from corporate funds; (iii)&nbsp;violated or is in violation of any provision
of the FCPA or any applicable non-U.S. anti-bribery statute or regulation; or (iv)&nbsp;made any unlawful bribe, rebate, payoff, influence payment, kickback or other unlawful payment to any domestic government official, such foreign official or
employee; and the Company and its subsidiaries and, to the knowledge of the Company, the Company&#146;s affiliates have conducted their respective businesses in compliance with the FCPA and have instituted and maintain policies and procedures
designed to ensure, and which are reasonably expected to continue to ensure, continued compliance therewith. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(nn) </B><B><I>Money
Laundering Laws</I></B><B>.</B> The operations of the Company and its subsidiaries are, and have been conducted at all times, in compliance with applicable financial recordkeeping and reporting requirements of the Currency and Foreign Transactions
Reporting Act of 1970, as amended, the money laundering statutes of all applicable jurisdictions, the rules and regulations thereunder and any related or similar applicable rules, regulations or guidelines, issued, administered or enforced by any
governmental agency (collectively, the &#147;<B>Money Laundering Laws</B>&#148;) and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any of its subsidiaries
with respect to the Money Laundering Laws is pending or, to the best knowledge of the Company, threatened. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(oo)
</B><B><I>OFAC</I></B><B>.</B> Neither the Company nor any of its subsidiaries nor, to the knowledge of the Company, after due inquiry, any director, officer, agent, employee, affiliate or person acting on behalf of the Company or any of its
subsidiaries is currently subject to any U.S. sanctions administered by the Office of Foreign Assets Control of the U.S. Treasury Department (&#147;<B>OFAC</B>&#148;); and the Company will not directly or indirectly use the proceeds of this
offering, or lend, contribute or otherwise make available such proceeds to any subsidiary, or any joint venture partner or other person or entity, for the purpose of financing the activities of or business with any person, or in any country or
territory, that currently is the subject to any U.S. sanctions administered by OFAC or in any other manner that will result in a violation by any person (including any person participating in the transaction whether as underwriter, advisor, investor
or otherwise) of U.S. sanctions administered by OFAC. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(pp) </B><B><I>Brokers</I></B><B>.</B> Except pursuant to this Agreement, there
is no broker, finder or other party that is entitled to receive from the Company any brokerage or finder&#146;s fee or other fee or commission as a result of any transactions contemplated by this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(qq) </B><B><I>Forward-Looking Statements.</I></B> Each financial or operational projection or other &#147;forward-looking statement&#148;
(as defined by Section&nbsp;27A of the Securities Act or Section&nbsp;21E of the Exchange Act) contained in the Registration Statement, the Time of Sale Prospectus or the Prospectus (i)&nbsp;was so included by the Company in good faith and with
reasonable basis after due consideration by the Company of the underlying assumptions, estimates and other applicable facts and circumstances and (ii)&nbsp;is accompanied by meaningful cautionary statements identifying those factors that could cause
actual results to differ materially from those in such <FONT STYLE="white-space:nowrap">forward-looking</FONT> statement. No such statement was made with the knowledge of an executive officer or director of the Company that is was false or
misleading. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(rr) </B><B><I>Reserved.</I></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(ss) </B><B><I>No Contract Terminations.</I></B> Neither the Company nor any of its subsidiaries has sent or received any communication
regarding termination of, or intent not to renew, any of the contracts or agreements referred to or described in the Time of Sale Prospectus, the Prospectus or any free writing prospectus, or referred to or described in, or filed as an exhibit to,
the Registration Statement, or any document incorporated by reference therein, and no such termination or non-renewal has been threatened by the Company or any of its subsidiaries or, to the Company&#146;s knowledge, any other party to any such
contract or agreement, which threat of termination or non-renewal has not been rescinded as of the date hereof, except, in each case, as could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(tt) </B><B><I>Dividend Restrictions</I></B><B>.</B> No subsidiary of the Company is prohibited or restricted, directly or indirectly, from
paying dividends to the Company, or from making any other distribution with respect to such subsidiary&#146;s equity securities or from repaying to the Company or any other subsidiary of the Company any amounts that may from time to time become due
under any loans or advances to such subsidiary from the Company or from transferring any property or assets to the Company or to any other subsidiary. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(uu) </B><B><I>FINRA Filing Exemption</I></B>. To enable the Underwriters to rely on FINRA Rule&nbsp;5110(b)(7)(C)(i), (i)&nbsp;the Company
was subject to the requirements of Section&nbsp;12 or 15(d) of the Exchange Act and filed all the material required to be filed pursuant to Sections 13, 14 or 15(d) for a period of at least thirty-six calendar months immediately preceding the date
of this Agreement; (ii)&nbsp;the Company filed in a timely manner all reports required to be filed pursuant to Section&nbsp;13, 14 or 15(d) of the Exchange Act during the twelve calendar months and any portion of a month immediately preceding the
date of this Agreement; (iii)&nbsp;the last reported sale price of the Company&#146;s common stock on the NYSE MKT on March 19, 2014 was $7.38 per share; (iv)&nbsp;as of such date, there were greater than 90 million shares of the Company&#146;s
common stock outstanding and held by non-affiliates of the Company; and (v)&nbsp;the Company has annual trading volume of 3&nbsp;million shares or more. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any certificate signed by any officer of the Company or any of its subsidiaries and delivered to any Underwriter or to counsel for the
Underwriters in connection with the offering, or the purchase and sale, of the Offered Shares shall be deemed a representation and warranty by the Company to each Underwriter as to the matters covered thereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company has a reasonable basis for making each of the representations set forth in this Section&nbsp;1(A). The Company acknowledges that
the Underwriters and, for purposes of the opinions to be delivered pursuant to Section&nbsp;6 hereof, counsel to the Company and counsel to the Underwriters, will rely upon the accuracy and truthfulness of the foregoing representations and hereby
consents to such reliance. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>B. Representations and Warranties of the Selling Stockholders</B>. Each Selling Stockholder represents,
warrants and covenants to each Underwriter, the Company, and their representatives and counsel, severally and not jointly, as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a) </B><B><I>The Underwriting Agreement</I></B><B>.</B> This Agreement has been duly authorized, executed and delivered by or on behalf of
such Selling Stockholder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b) </B><B><I>The Custody Agreement and Power of Attorney</I></B><B>.</B> Each of (i)&nbsp;the Stock Custody
Agreement signed by such Selling Stockholder, the Company and Computershare Shareholder Services, Inc., as custodian (the &#147;<B>Custodian</B>&#148;), relating to the deposit of the Offered Shares to be sold by such Selling Stockholder (the
&#147;<B>Custody Agreement</B>&#148;) and (ii)&nbsp;the Power of Attorney appointing certain </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
individuals named therein as such Selling Stockholder&#146;s attorneys-in-fact (each, an &#147;<B>Attorney-in-Fact</B>&#148;) to the extent set forth therein relating to the transactions
contemplated hereby and by the Prospectus (the &#147;<B>Power of Attorney</B>&#148;), of such Selling Stockholder has been duly authorized, executed and delivered by such Selling Stockholder and is a valid and binding agreement of such Selling
Stockholder, enforceable in accordance with its terms, except as rights to indemnification thereunder may be limited by applicable law and except as the enforcement thereof may be limited by bankruptcy, insolvency, reorganization, moratorium or
other similar laws relating to or affecting the rights and remedies of creditors or by general equitable principles. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c)
</B><B><I>Title to Offered Shares to be Sold</I></B><B>.</B> Such Selling Stockholder has, and on the First Closing Date (as defined in Section&nbsp;2) and each applicable Option Closing Date (as defined in Section&nbsp;2) will have, good and valid
title to all of the Offered Shares subject to sale by such Selling Stockholder pursuant to this Agreement on such date and the legal right and power to sell, transfer and deliver all of the Offered Shares which may be sold by such Selling
Stockholder pursuant to this Agreement and to comply with its other obligations hereunder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d) </B><B><I>Delivery of the Offered Shares
to be Sold</I></B><B>.</B> Delivery of the Offered Shares by such Selling Stockholder pursuant to this Agreement will pass good and valid title to such Offered Shares, free and clear of any security interest, mortgage, pledge, lien, encumbrance or
other adverse claim. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e) </B><B><I>Non-Contravention; No Further Authorizations or Approvals Required.</I></B> The execution and
delivery by such Selling Stockholder of, and the performance by such Selling Stockholder of its obligations under, this Agreement, the Custody Agreement and the Power of Attorney will not contravene or conflict with, result in a breach of, or
constitute a Default under, or require the consent of any other party to, the charter or by-laws, partnership agreement, trust agreement or other organizational documents of such Selling Stockholder or any other agreement or instrument to which such
Selling Stockholder is a party or by which such Selling Stockholder is bound or under which such Selling Stockholder is entitled to any right or benefit, any provision of applicable law or any judgment, order, decree or regulation applicable to such
Selling Stockholder of any court, regulatory body, administrative agency, governmental body or arbitrator having jurisdiction over such Selling Stockholder. No consent, approval, authorization or other order of, or registration or filing with, any
court or other governmental authority or agency, is required for the consummation by such Selling Stockholder of the transactions contemplated in this Agreement, except such as may be required under the Securities Act, applicable state securities or
blue sky laws and from the FINRA. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f) </B><B><I>No Registration, Pre-emptive, Co-Sale or Other Similar Rights</I></B><B>.</B> Such
Selling Stockholder: (i)&nbsp;does not have any registration or other similar rights to have any securities registered for sale by the Company under the Registration Statement or included in the offering contemplated by this Agreement, except for
such rights as are described in the Registration Statement, the Time of Sale Prospectus and the Prospectus; (ii)&nbsp;does not have any preemptive right, co-sale right, right of first refusal or other similar right to purchase any of the Offered
Shares that are to be sold by any of the other Selling Stockholders to the Underwriters pursuant to this Agreement, except for such rights as such Selling Stockholder has waived prior to the date hereof and are described in the Registration
Statement, the Time of Sale Prospectus and the Prospectus; and (iii)&nbsp;does not own any warrants, options or similar rights to acquire, and does not have any right or arrangement to acquire, any capital stock, right, warrants, options or other
securities from the Company, other than those described in the Registration Statement, the Time of Sale Prospectus and the Prospectus<I>.</I> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(g) </B><B><I>No Further Consents, etc</I></B><B>.</B> Except for such consents, approvals and waivers as have been obtained by such Selling
Stockholder on or prior to the date of this Agreement, no consent, approval or waiver is required under any instrument or agreement to which such Selling Stockholder is a party or by </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
which it is bound or under which it is entitled to any right or benefit, in connection with the offering, sale or purchase by the Underwriters of any of the Offered Shares which may be sold by
such Selling Stockholder under this Agreement or the consummation by such Selling Stockholder of any of the other transactions contemplated hereby. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(h) </B><B><I>Disclosure Made by Such Selling Stockholder in the Prospectus.</I></B> All information furnished to the Company or any
Underwriter by or on behalf of such Selling Stockholder in writing expressly for use in the Registration Statement, the Time of Sale Prospectus or the Prospectus is, and on the First Closing Date and each applicable Option Closing Date will be,
true, correct, and complete in all material respects, and did not, as of the Applicable Time, and on the First Closing Date and each applicable Option Closing Date will not, contain any untrue statement of a material fact or omit to state any
material fact necessary to make such information not misleading, it being understood and agreed that the only such information furnished by or on behalf of any Selling Stockholder consists of the description of such Selling Stockholder and the
number of shares beneficially owned by such Selling Stockholder and excludes the percentages that appear in the table under the caption &#147;Selling Stockholders&#148; in the Time of Sale Prospectus and the Prospectus (the &#147;<B><I>Selling
Stockholder Information</I></B>&#148;). Such Selling Stockholder confirms as accurate the information with respect to such Selling Stockholder in the Registration Statement, the Time of Sale Prospectus and the Prospectus under the caption
&#147;Selling Stockholders&#148; (both prior to and after giving effect to the sale of the Offered Shares). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i) </B><B><I>No
Requirement to Sell.</I></B> Such Selling Stockholder is not prompted to sell Shares by any information concerning the Company which is not set forth in the Registration Statement, the Time of Sale Prospectus and the Prospectus. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(j) </B><B><I>No Price Stabilization or Manipulation; Compliance with Regulation M</I></B><B>.</B> Such Selling Stockholder has not taken,
directly or indirectly, any action designed to or that might cause or result in stabilization or manipulation of the price of the Shares or any reference security, whether to facilitate the sale or resale of the Offered Shares or otherwise, and has
taken no action which would directly or indirectly violate any provision of Regulation M. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(k) </B><B><I>No Transfer Taxes or Other
Fees</I></B><B>.</B> There are no transfer taxes or other similar fees or charges under Federal law or the laws of any state, or any political subdivision thereof, required to be paid in connection with the execution and delivery of this Agreement
or the sale by such Selling Stockholder of the Offered Shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(l) </B><B><I>Distribution of Offering Materials by the Selling
Stockholders</I></B><B>.</B> Prior to the completion of the Underwriters&#146; distribution of the Offered Shares, such Selling Stockholder has not distributed and will not distribute any offering material in connection with the offering and sale of
the Offered Shares other than the Registration Statement, the Preliminary Prospectus, the free writing prospectus(es) listed on <U>Schedule&nbsp;C</U> and the Prospectus. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(m) </B><B><I>OFAC</I></B><B>. </B>Such Selling Stockholder is not currently subject to any U.S. sanctions administered by OFAC and will not
directly or indirectly use the proceeds of this offering, or lend, contribute or otherwise make available such proceeds to any subsidiary, or any joint venture partner or other person or entity, for the purpose of financing the activities of any
person currently subject to any U.S. sanctions administered by OFAC or in any other manner that will result in a violation by any person (including any person participating in the transaction whether as underwriter, advisor, investor or otherwise)
of U.S. sanctions administered by OFAC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any certificate signed by such Selling Stockholder and delivered to the Company or to counsel for
the Company or to any Underwriter or to counsel for the Underwriters or shall be deemed a representation </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and warranty by such Selling Stockholder to the Company and each Underwriter as to the matters covered thereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Such Selling Stockholder has a reasonable basis for making each of the representations set forth in this Section&nbsp;1(B). Such Selling
Stockholder acknowledges that the Underwriters and, for purposes of the opinion to be delivered pursuant to Section&nbsp;6 hereof, counsel to the Selling Stockholder and counsel to the Underwriters, will rely upon the accuracy and truthfulness of
the foregoing representations and hereby consents to such reliance. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;2. Purchase, Sale and Delivery of the Offered
Shares</B>.<B></B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a) </B><B><I>The Firm Shares</I></B><B>.</B> Upon the terms herein set forth, the Selling Stockholders agree to
sell to the several Underwriters an aggregate of 9,000,000 Firm Shares, with each Selling Stockholder selling the number of Firm Shares set forth opposite such Selling Stockholder&#146;s name on <U>Schedule A</U>. On the basis of the
representations, warranties and agreements herein contained, and upon the terms but subject to the conditions herein set forth, the Underwriters agree, severally and not jointly, to purchase from the Selling Stockholders the respective number of
Firm Shares set forth opposite their names on <U>Schedule&nbsp;B</U>. The purchase price per Firm Share to be paid by the several Underwriters to the Selling Stockholders shall be $6.697075 per share. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b) </B><B><I>The First Closing Date</I></B><B>.</B> Delivery of certificates for the Firm Shares to be purchased by the Underwriters and
payment therefor shall be made at the offices of Latham&nbsp;&amp; Watkins LLP, 12670 High Bluff Drive, San Diego, CA 92130 (or such other place as may be agreed to by the Company and the Representatives) at 9:00 a.m. New York City time, on March
26, 2014, or such other time and date not later than 1:30&nbsp;p.m. New York City time, on April 2, 2014 as the Representatives shall designate by notice to the Company (the time and date of such closing are called the &#147;<B>First Closing
Date</B>&#148;). The Company and the Selling Stockholders hereby acknowledge that circumstances under which the Representatives may provide notice to postpone the First Closing Date as originally scheduled include, but are not limited to, any
determination by the Company, the Selling Stockholders or the Representatives to recirculate to the public copies of an amended or supplemented Prospectus or a delay as contemplated by the provisions of Sections&nbsp;11 and 19. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c) </B><B><I>The Optional Shares; Option Closing Date</I></B><B>.</B> In addition, on the basis of the representations, warranties and
agreements herein contained, and upon the terms but subject to the conditions herein set forth, certain of the Selling Stockholders hereby grant an option to the several Underwriters to purchase, severally and not jointly, up to an aggregate of
1,350,000 Optional Shares from certain of the Selling Stockholders at the purchase price per share to be paid by the Underwriters for the Firm Shares, less an amount per share equal to any dividend or distribution declared by the Company and payable
on the Firm Shares but not payable on Optional Shares. The option granted hereunder may be exercised at any time and from time to time in whole or in part upon notice by the Representatives to such Selling Stockholders (with a copy to the Company),
which notice may be given at any time within 30&nbsp;days from the date of this Agreement. Such notice shall set forth (i)&nbsp;the aggregate number of Optional Shares as to which the Underwriters are exercising the option and (ii)&nbsp;the time,
date and place at which certificates for the Optional Shares will be delivered (which time and date may be simultaneous with, but not earlier than, the First Closing Date; and in the event that such time and date are simultaneous with the First
Closing Date, the term &#147;<B>First Closing Date</B>&#148; shall refer to the time and date of delivery of the Firm Shares and such Optional Shares). Any such time and date of delivery, if subsequent to the First Closing Date, is called an
&#147;<B>Option Closing Date</B>,&#148; shall be determined by the Representatives and shall not be earlier than three or later than five full business days after delivery of such notice of exercise. If any Optional Shares are to be purchased,
(a)&nbsp;each Underwriter agrees, severally and not jointly, to purchase the number of Optional Shares (subject to such adjustments to eliminate fractional shares as the Representatives may </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
determine) that bears the same proportion to the total number of Optional Shares to be purchased as the number of Firm Shares set forth on <U>Schedule B</U> opposite the name of such Underwriter
bears to the total number of Firm Shares and (b)&nbsp;each Selling Stockholder agrees, severally and not jointly, to sell the number of Optional Shares (subject to such adjustments to eliminate fractional shares as the Representatives may determine)
that bears the same proportion to the total number of Optional Shares to be sold as the number of Optional Shares set forth in <U>Schedule&nbsp;A</U> opposite the name of such Selling Stockholder bears to the total number of Optional Shares. The
Representatives may cancel the option at any time prior to its expiration by giving written notice of such cancellation to the Selling Stockholders (with a copy to the Company). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d) </B><B><I>Public Offering of the Offered Shares</I></B><B>.</B> The Representatives hereby advise the Company and the Selling
Stockholders that the Underwriters intend to offer for sale to the public, initially on the terms set forth in the Registration Statement, the Time of Sale Prospectus and the Prospectus, their respective portions of the Offered Shares as soon after
this Agreement has been executed as the Representatives, in their sole judgment, have determined is advisable and practicable. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e)
</B><B><I>Payment for the Offered Shares</I></B><B>.</B> (i)&nbsp;Payment for the Offered Shares shall be made at the First Closing Date (and, if applicable, at each Option Closing Date) by wire transfer of immediately available funds to the order
of the Custodian. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) It is understood that the Representatives have been authorized, for their own accounts and the
accounts of the several Underwriters, to accept delivery of and receipt for, and make payment of the purchase price for, the Firm Shares and any Optional Shares the Underwriters have agreed to purchase. Each of Jefferies and Stifel, individually and
not as the Representatives of the Underwriters, may (but shall not be obligated to) make payment for any Offered Shares to be purchased by any Underwriter whose funds shall not have been received by the Representatives by the First Closing Date or
the applicable Option Closing Date, as the case may be, for the account of such Underwriter, but any such payment shall not relieve such Underwriter from any of its obligations under this Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) Each Selling Stockholder hereby agrees that (i)&nbsp;it will pay all stock transfer taxes, stamp duties and other similar
taxes, if any, payable upon the sale or delivery of the Offered Shares to be sold by such Selling Stockholder to the several Underwriters, or otherwise in connection with the performance of such Selling Stockholder&#146;s obligations hereunder and
under the Custody Agreement and (ii)&nbsp;the Custodian is authorized to deduct from such payment any such amounts from the proceeds to such Selling Stockholder hereunder and to hold such amounts for the account of such Selling Stockholder with the
Custodian under the Custody Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f) </B><B><I>Delivery of the Offered Shares</I></B><B>.</B> The Selling Stockholders shall
deliver, or cause to be delivered to the Representatives for the accounts of the several Underwriters certificates for the Firm Shares to be sold by them at the First Closing Date, against release of a wire transfer of immediately available funds
for the amount of the purchase price therefor. The Selling Stockholders shall also deliver, or cause to be delivered to the Representatives for the accounts of the several Underwriters, certificates for the Optional Shares the Underwriters have
agreed to purchase from them at the First Closing Date or the applicable Option Closing Date, as the case may be, against the release of a wire transfer of immediately available funds for the amount of the purchase price therefor. The certificates
for the Offered Shares shall be in definitive form and registered in such names and denominations as the Representatives shall have requested at least two full business days prior to the First Closing Date (or the applicable Option Closing Date, as
the case may be) and shall be made available for inspection on the business day preceding the First Closing Date (or the applicable Option Closing Date, as the case may be) at a location in New York </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
City as the Representatives may designate. Time shall be of the essence, and delivery at the time and place specified in this Agreement is a further condition to the obligations of the
Underwriters. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;3. Additional Covenants.</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>A. Covenants of the Company.</B> The Company further covenants and agrees with each Underwriter as follows: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a) </B><B><I>Delivery of Registration Statement, Time of Sale Prospectus and Prospectus.</I></B> The Company shall furnish to you in New
York City, without charge, prior to 10:00 a.m. New York City time on the business day next succeeding the date of this Agreement and during the period when a prospectus relating to the Offered Shares is required by the Securities Act to be delivered
(whether physically or through compliance with Rule 172 under the Securities Act or any similar rule) in connection with sales of the Offered Shares, as many copies of the Time of Sale Prospectus, the Prospectus and any supplements and amendments
thereto or to the Registration Statement as you may reasonably request. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b) </B><B><I>Representatives&#146; Review of Proposed
Amendments and Supplements.</I></B> During the period when a prospectus relating to the Offered Shares is required by the Securities Act to be delivered (whether physically or through compliance with Rule 172 under the Securities Act or any similar
rule), the Company (i)&nbsp;will furnish to the Representatives for review, a reasonable period of time prior to the proposed time of filing of any proposed amendment or supplement to the Registration Statement, a copy of each such amendment or
supplement and (ii)&nbsp;will not amend or supplement the Registration Statement (including any amendment or supplement through incorporation of any report filed under the Exchange Act) without the Representatives&#146; prior written consent. Prior
to amending or supplementing the Time of Sale Prospectus or the Prospectus (including any amendment or supplement through incorporation of any report filed under the Exchange Act), the Company shall furnish to the Representatives for review, a
reasonable amount of time prior to the time of filing or use of the proposed amendment or supplement, a copy of each such proposed amendment or supplement. The Company shall not file or use any such proposed amendment or supplement without the
Representatives&#146; prior written consent. The Company shall file with the Commission within the applicable period specified in Rule&nbsp;424(b) under the Securities Act any prospectus required to be filed pursuant to such Rule. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c) </B><B><I>Free Writing Prospectuses.</I></B> The Company shall furnish to the Representatives for review, a reasonable amount of time
prior to the proposed time of filing or use thereof, a copy of each proposed free writing prospectus or any amendment or supplement thereto prepared by or on behalf of, used by, or referred to by the Company, and the Company shall not file, use or
refer to any proposed free writing prospectus or any amendment or supplement thereto without the Representatives&#146; prior written consent. The Company shall furnish to each Underwriter, without charge, as many copies of any free writing
prospectus prepared by or on behalf of, used by or referred to by the Company as such Underwriter may reasonably request. If at any time when a prospectus is required by the Securities Act to be delivered (whether physically or through compliance
with Rule 172 under the Securities Act or any similar rule) in connection with sales of the Offered Shares (but in any event if at any time through and including the First Closing Date) there occurred or occurs an event or development as a result of
which any free writing prospectus prepared by or on behalf of, used by, or referred to by the Company conflicted or would conflict with the information contained in the Registration Statement or included or would include an untrue statement of a
material fact or omitted or would omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances prevailing at such time, not misleading, the Company shall promptly amend or supplement such free
writing prospectus to eliminate or correct such conflict so that the statements in such free writing prospectus as so amended or supplemented will not include an untrue statement of a material fact or omit to state a material fact necessary in order
to make the statements therein, in the light of the circumstances prevailing at such time, not misleading, as the case </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
may be; <I>provided, however</I>, that prior to amending or supplementing any such free writing prospectus, the Company shall furnish to the Representatives for review, a reasonable amount of
time prior to the proposed time of filing or use thereof, a copy of such proposed amended or supplemented free writing prospectus, and the Company shall not file, use or refer to any such amended or supplemented free writing prospectus without the
Representatives&#146; prior written consent. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d) </B><B><I>Filing of Underwriter Free Writing Prospectuses.</I></B> The Company shall
not take any action that would result in an Underwriter or the Company being required to file with the Commission pursuant to Rule 433(d) under the Securities Act a free writing prospectus prepared by or on behalf of such Underwriter that such
Underwriter otherwise would not have been required to file thereunder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e) </B><B><I>Amendments and Supplements to Time of Sale
Prospectus.</I></B> If the Time of Sale Prospectus is being used to solicit offers to buy the Offered Shares at a time when the Prospectus is not yet available to prospective purchasers, and any event shall occur or condition exist as a result of
which it is necessary to amend or supplement the Time of Sale Prospectus so that the Time of Sale Prospectus does not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein,
in the light of the circumstances when delivered to a prospective purchaser, not misleading, or if any event shall occur or condition exist as a result of which the Time of Sale Prospectus conflicts with the information contained in the Registration
Statement, or if, in the opinion of counsel for the Underwriters, it is necessary to amend or supplement the Time of Sale Prospectus to comply with applicable law, the Company shall (subject to Section&nbsp;3(A)(b) and Section&nbsp;3(A)(c) hereof)
promptly prepare, file with the Commission and furnish, at its own expense, to the Underwriters and to any dealer upon request, either amendments or supplements to the Time of Sale Prospectus so that the statements in the Time of Sale Prospectus as
so amended or supplemented will not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances when delivered to a prospective purchaser, not
misleading or so that the Time of Sale Prospectus, as amended or supplemented, will no longer conflict with the information contained in the Registration Statement, or so that the Time of Sale Prospectus, as amended or supplemented, will comply with
applicable law. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f) </B><B><I>Certain Notifications and Required Actions</I></B><B>.</B> After the date of this Agreement and during
the period when a prospectus is required by the Securities Act to be delivered, the Company shall promptly advise the Representatives in writing of: (i)&nbsp;the receipt of any comments of, or requests for additional or supplemental information
from, the Commission; (ii)&nbsp;the time and date of any filing of any post-effective amendment to the Registration Statement or any amendment or supplement to the Time of Sale Prospectus, any free writing prospectus or the Prospectus;
(iii)&nbsp;the time and date that any post-effective amendment to the Registration Statement becomes effective; and (iv)&nbsp;the issuance by the Commission of any stop order suspending the effectiveness of the Registration Statement or any
post-effective amendment thereto or any amendment or supplement to the Time of Sale Prospectus or the Prospectus or of any order preventing or suspending the use of the Time of Sale Prospectus, any free writing prospectus or the Prospectus, or of
any proceedings to remove, suspend or terminate from listing or quotation the Shares from any securities exchange upon which they are listed for trading or included or designated for quotation, or of the threatening or initiation of any proceedings
for any of such purposes. If the Commission shall enter any such stop order at any time, the Company will use its best efforts to obtain the lifting of such order at the earliest possible moment. Additionally, the Company agrees that it shall comply
with all applicable provisions of Rule&nbsp;424(b), Rule 433 and Rule 430B under the Securities Act and will use its reasonable efforts to confirm that any filings made by the Company under Rule 424(b) or Rule 433 were received in a timely manner by
the Commission. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(g) </B><B><I>Amendments and Supplements to the Prospectus and Other Securities Act Matters.</I></B> If any event shall
occur or condition exist as a result of which it is necessary to amend or supplement the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Prospectus so that the Prospectus does not include an untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the
circumstances when the Prospectus is delivered (whether physically or through compliance with Rule 172 under the Securities Act or any similar rule) to a purchaser, not misleading, or if in the opinion of the Representatives or counsel for the
Underwriters it is otherwise necessary to amend or supplement the Prospectus to comply with applicable law, the Company agrees (subject to Section&nbsp;3(A)(b) and Section&nbsp;3(A)(c)) hereof to promptly prepare, file with the Commission and
furnish, at its own expense, to the Underwriters and to any dealer upon request, amendments or supplements to the Prospectus so that the statements in the Prospectus as so amended or supplemented will not include an untrue statement of a material
fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances when the Prospectus is delivered (whether physically or through compliance with Rule 172 under the Securities Act or any
similar rule) to a purchaser, not misleading or so that the Prospectus, as amended or supplemented, will comply with applicable law. Neither the Representatives&#146; consent to, nor delivery of, any such amendment or supplement shall constitute a
waiver of any of the Company&#146;s obligations under Section&nbsp;3(A)(b) or Section&nbsp;3(A)(c). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(h) </B><B><I>Blue Sky
Compliance</I></B><B>.</B> The Company shall cooperate with the Representatives and counsel for the Underwriters to qualify or register the Offered Shares for sale under (or obtain exemptions from the application of) the state securities or blue sky
laws or Canadian provincial securities laws (or other foreign laws) of those jurisdictions designated by the Representatives, shall comply with such laws and shall continue such qualifications, registrations and exemptions in effect so long as
required for the distribution of the Offered Shares. The Company shall not be required to qualify as a foreign corporation or to take any action that would subject it to general service of process in any such jurisdiction where it is not presently
qualified or where it would be subject to taxation as a foreign corporation. The Company will advise the Representatives promptly of the suspension of the qualification or registration of (or any such exemption relating to) the Offered Shares for
offering, sale or trading in any jurisdiction or any initiation or threat of any proceeding for any such purpose, and in the event of the issuance of any order suspending such qualification, registration or exemption, the Company shall use its best
efforts to obtain the withdrawal thereof at the earliest possible moment. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i)</B> <B><I>Reserved.</I></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(j) </B><B><I>Transfer Agent</I></B><B>.</B> The Company shall engage and maintain, at its expense, a registrar and transfer agent for the
Shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(k) </B><B><I>Earnings Statement</I></B><B>.</B> The Company will make generally available to its security holders and to the
Representatives as soon as practicable an earnings statement (which need not be audited) covering a period of at least twelve months beginning with the first fiscal quarter of the Company commencing after the date of this Agreement that will satisfy
the provisions of Section&nbsp;11(a) of the Securities Act and the rules and regulations of the Commission thereunder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(l)
</B><B><I>Continued Compliance with Securities Laws</I></B><B>.</B> The Company will comply with the Securities Act and the Exchange Act so as to permit the completion of the distribution of the Offered Shares as contemplated by this Agreement<B>,
</B>the Registration Statement, the Time of Sale Prospectus and the Prospectus. Without limiting the generality of the foregoing, the Company will, during the period when a prospectus relating to the Offered Shares is required by the Securities Act
to be delivered (whether physically or through compliance with Rule 172 under the Securities Act or any similar rule), file on a timely basis with the Commission and the NYSE MKT all reports and documents required to be filed under the Exchange Act.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(m) </B><B><I>Listing</I></B>. The Company will use its best efforts to maintain the listing
of the Offered Shares on the NYSE MKT. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(n) </B><B><I>Company to Provide Copy of the Prospectus in Form That May be Downloaded from the
Internet</I></B><B>.</B> If requested by the Representatives, the Company shall cause to be prepared and delivered, at its expense, within one business day from the effective date of this Agreement, to the Representatives an &#147;<B>electronic
Prospectus</B>&#148; to be used by the Underwriters in connection with the offering and sale of the Offered Shares. As used herein, the term &#147;<B>electronic Prospectus</B>&#148; means a form of Time of Sale Prospectus, and any amendment or
supplement thereto, that meets each of the following conditions: (i)&nbsp;it shall be encoded in an electronic format, satisfactory to the Representatives, that may be transmitted electronically by the Representatives and the other Underwriters to
offerees and purchasers of the Offered Shares; (ii)&nbsp;it shall disclose the same information as the paper Time of Sale Prospectus, except to the extent that graphic and image material cannot be disseminated electronically, in which case such
graphic and image material shall be replaced in the electronic Prospectus with a fair and accurate narrative description or tabular representation of such material, as appropriate; and (iii)&nbsp;it shall be in or convertible into a paper format or
an electronic format, satisfactory to the Representatives, that will allow investors to store and have continuously ready access to the Time of Sale Prospectus at any future time, without charge to investors (other than any fee charged for
subscription to the Internet as a whole and for on-line time). The Company hereby confirms that it has included or will include in the Prospectus filed pursuant to EDGAR or otherwise with the Commission and in the Registration Statement at the time
it was declared effective an undertaking that, upon receipt of a request by an investor or his or her representative, the Company shall transmit or cause to be transmitted promptly, without charge, a paper copy of the Time of Sale Prospectus. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(o) </B><B><I>Agreement Not to Offer or Sell Additional Shares</I></B><B>.</B> During the period commencing on and including the date hereof
and continuing through and including the 90th day following the date of the Prospectus (such period, as extended as described below, being referred to herein as the &#147;<B>Lock-up Period</B>&#148;), the Company will not, without the prior written
consent of Jefferies (which consent may be withheld in its sole discretion), directly or indirectly: (i)&nbsp;sell, offer to sell, contract to sell or lend any Shares or Related Securities (as defined below); (ii)&nbsp;effect any short sale, or
establish or increase any &#147;put equivalent position&#148; (as defined in Rule 16a-1(h) under the Exchange Act) or liquidate or decrease any &#147;call equivalent position&#148; (as defined in
<FONT STYLE="white-space:nowrap">Rule&nbsp;16a-1(b)</FONT> under the Exchange Act) of any Shares or Related Securities; (iii)&nbsp;pledge, hypothecate or grant any security interest in any Shares or Related Securities; (iv)&nbsp;in any other way
transfer or dispose of any Shares or Related Securities; (v)&nbsp;enter into any swap, hedge or similar arrangement or agreement that transfers, in whole or in part, the economic risk of ownership of any Shares or Related Securities, regardless of
whether any such transaction is to be settled in securities, in cash or otherwise; (vi)&nbsp;announce the offering of any Shares or Related Securities; (vii)&nbsp;file any registration statement under the Securities Act in respect of any Shares or
Related Securities (other than as contemplated by this Agreement with respect to the Offered Shares); or (viii)&nbsp;publicly announce the intention to do any of the foregoing; <I>provided, however</I>, that the Company may (A)&nbsp;effect the
transactions contemplated hereby and (B)&nbsp;issue Shares or options to purchase Shares, or issue Shares upon exercise of options, pursuant to any stock option, stock bonus or other stock plan or arrangement described in the Registration Statement,
the Time of Sale Prospectus and the Prospectus, but only if the holders of such Shares or options agree in writing with the Underwriters not to sell, offer, dispose of or otherwise transfer any such Shares or options during such Lock-up Period
without the prior written consent of Jefferies (which consent may be withheld in its sole discretion). For purposes of the foregoing, &#147;<B>Related Securities</B>&#148; shall mean any options or warrants or other rights to acquire Shares or any
securities exchangeable or exercisable for or convertible into Shares, or to acquire other securities or rights ultimately exchangeable or exercisable for, or convertible into, Shares. If (i)&nbsp;during the last 17 days of the 90-day initial
lock-up period, the Company issues an earnings release or discloses material news or a material event relating to the Company occurs, or (ii)&nbsp;prior to the expiration of such period, the Company </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
announces that it will release earnings results during the 16-day period beginning on the last day of such period, then in each case the Lock-up Period will be extended until the expiration of
the 18-day period beginning on the date of the issuance of the earnings release or the disclosure of the material news or occurrence of the material event, as applicable, unless Jefferies waive, in writing, such extension (which waiver may be
withheld in its sole discretion). The Company will provide the Representatives with prior notice of any such announcement that gives rise to an extension of the Lock-up Period. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(p) </B><B><I>Future Reports to the Representatives.</I></B> During the period of five years hereafter, the Company will furnish to the
Representatives, c/o Jefferies LLC, 520 Madison Avenue, New York, New York 10022, Attention: Global Head of Syndicate and c/o Stifel, Nicolaus&nbsp;&amp; Company, Incorporated, One Montgomery Street, Suite 3700, San Francisco, California 94104,
Attention: Syndicate Department: (i)&nbsp;as soon as practicable after the end of each fiscal year, copies of the Annual Report of the Company containing the balance sheet of the Company as of the close of such fiscal year and statements of income,
stockholders&#146; equity and cash flows for the year then ended and the opinion thereon of the Company&#146;s independent public or certified public accountants; (ii)&nbsp;as soon as practicable after the filing thereof, copies of each proxy
statement, Annual Report on Form 10-K, Quarterly Report on Form 10-Q, Current Report on Form 8-K or other report filed by the Company with the Commission or any securities exchange; and (iii)&nbsp;as soon as available, copies of any report or
communication of the Company furnished or made available generally to holders of its capital stock; <I>provided, however,</I> that the requirements of this Section&nbsp;3(A)(p) shall be satisfied to the extent that such reports, statement,
communications, financial statements or other documents are available on EDGAR. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(q) </B><B><I>Investment Limitation</I></B><B>.</B> The
Company shall not invest or otherwise use the proceeds received by the Company from its sale of the Offered Shares in such a manner as would require the Company or any of its subsidiaries to register as an investment company under the Investment
Company Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(r) </B><B><I>No Stabilization or Manipulation; Compliance with Regulation M</I></B><B>.</B> The Company will not take,
and will ensure that no affiliate of the Company will take, directly or indirectly, any action designed to or that might reasonably be expected to cause or result in stabilization or manipulation of the price of the Shares or any reference security
with respect to the Shares, whether to facilitate the sale or resale of the Offered Shares or otherwise, and the Company will, and shall cause each of its affiliates to, comply with all applicable provisions of Regulation M. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(s) </B><B><I>Enforce Lock-Up Agreements</I></B><B>.</B> During the Lock-up Period, the Company will enforce all agreements between the
Company and any of its security holders that restrict or prohibit, expressly or in operation, the offer, sale or transfer of Shares or Related Securities or any of the other actions restricted or prohibited under the terms of the form of Lock-up
Agreement. In addition, the Company will direct the transfer agent to place stop transfer restrictions upon any such securities of the Company that are bound by such &#147;lock-up&#148; agreements for the duration of the periods contemplated in such
agreements, including, without limitation, &#147;lock-up&#148; agreements entered into by the Company&#146;s officers, directors and certain stockholders, warrant holders and option holders pursuant to Section&nbsp;6(l) hereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(t) </B><B><I>Company to Provide Interim Financial Statements</I></B><B>.</B> Prior to the First Closing Date and each applicable Option
Closing Date, the Company will furnish the Underwriters, as soon as they have been prepared by or are available to the Company consistent with the Company&#146;s past practice, a copy of any unaudited interim financial statements of the Company for
any period subsequent to the period covered by the most recent financial statements appearing in the Registration Statement and the Prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(u) </B><B><I>Announcement Regarding Lock-ups</I></B><B>.</B> The Company agrees to announce
the Underwriters&#146; intention to release any director or &#147;officer&#148; (within the meaning of Rule 16a-1(f) under the Exchange Act) of the Company from any of the restrictions imposed by any Lock-Up Agreement, by issuing, through a major
news service, a press release in form and substance satisfactory to the Representatives promptly following the Company&#146;s receipt of any notification from the Representatives in which such intention is indicated, but in any case not later than
the close of the third business day prior to the date on which such release or waiver is to become effective; <I>provided, however</I>, that nothing shall prevent the Representatives, on behalf of the Underwriters, from announcing the same through a
major news service, irrespective of whether the Company has made the required announcement; and <I>provided</I>, <I>further</I>, that no such announcement shall be made of any release or waiver granted solely to permit a transfer of securities that
is not for consideration and where the transferee has agreed in writing to be bound by the terms of a Lock-Up Agreement in the form set forth as <U>Exhibit&nbsp;A</U> hereto. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>B. Covenants of the Selling Stockholders.</B> Each Selling Stockholder further covenants and agrees with each Underwriter: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a) </B><B><I>Agreement Not to Offer or Sell Additional Shares</I></B><B>.</B> During the Lock-up Period, such Selling Stockholder will not,
without the prior written consent of Jefferies (which consent may be withheld in its sole discretion), directly or indirectly: (i)&nbsp;sell, offer to sell, contract to sell or lend any Shares or Related Securities; (ii)&nbsp;effect any short sale
or establish or increase any put equivalent position or liquidate or decrease any call equivalent position of any Shares or Related Securities; (iii)&nbsp;pledge, hypothecate or grant any security interest in any Shares or Related Securities;
(iv)&nbsp;in any other way transfer or dispose of any Shares or Related Securities; (v)&nbsp;enter into any swap, hedge or similar arrangement or agreement that transfers, in whole or in part, the economic risk of ownership of any Shares or Related
Securities, regardless of whether any such transaction is to be settled in securities, in cash or otherwise; (vi)&nbsp;announce the offering of any Shares or Related Securities; (vii)&nbsp;participate in the filing of any registration statement
under the Securities Act in respect of any Shares or Related Securities (other than as contemplated by this Agreement with respect to the Offered Shares); or (viii)&nbsp;publicly announce the intention to do any of the foregoing. The foregoing shall
not apply to the Shares to be sold in this offering. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b) </B><B><I>No Stabilization or Manipulation; Compliance with Regulation
M</I></B><B>.</B> Such Selling Stockholder will not take, directly or indirectly, any action designed to or that might cause or result in stabilization or manipulation of the price of the Shares or any reference security with respect to the Shares,
whether to facilitate the sale or resale of the Offered Shares or otherwise, and such Selling Stockholder will, and shall cause each of its affiliates to, comply with all applicable provisions of Regulation M. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c) </B><B><I>Notification.</I></B> Such Selling Stockholder will advise you promptly, and if requested by you, will confirm such advice in
writing, during the period when a prospectus relating to the Offered Shares is required by the Securities Act to be delivered (whether physically or through compliance with Rule 172 under the Securities Act or any similar rule), of (i)&nbsp;any
change in information in the Registration Statement, any preliminary prospectus, any free writing prospectus, the Prospectus or any amendment or supplement thereto relating to such Selling Stockholder, or (ii)&nbsp;any new material information
relating to the Company or relating to any matter stated in the Registration Statement, the Time of Sale Prospectus or the Prospectus that comes to the attention of such Selling Stockholder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d) </B><B><I>Delivery of Forms W-8 and W-9</I></B><B>.</B> To deliver to the Representatives prior to the First Closing Date a properly
completed and executed United States Treasury Department Form W-8 (if the Selling Stockholder is a non-United States person) or Form W-9 (if the Selling Stockholder is a United States Person). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Representatives, on behalf of the several Underwriters, may, in its their discretion, waive
in writing the performance by the Company or any Selling Stockholder of any one or more of the foregoing covenants or extend the time for their performance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;4. Payment of Expenses.</B> The Company and the Selling Stockholders, jointly and severally, agree to pay all costs, fees and
expenses incurred in connection with the performance of their obligations hereunder and in connection with the transactions contemplated hereby, including without limitation (i)&nbsp;all expenses incident to the delivery of the Offered Shares
(including all printing and engraving costs), (ii)&nbsp;all fees and expenses of the registrar and transfer agent of the Offered Shares, (iii)&nbsp;all necessary transfer and other stamp taxes in connection with the sale of the Offered Shares to the
Underwriters, (iv)&nbsp;all fees and expenses of the Company&#146;s counsel, independent public or certified public accountants and other advisors, (v)&nbsp;all costs and expenses incurred in connection with the preparation, printing, filing,
shipping and distribution of the Registration Statement (including financial statements, exhibits, schedules, consents and certificates of experts), the Time of Sale Prospectus, the Prospectus, each free writing prospectus prepared by or on behalf
of, used by, or referred to by the Company, and all amendments and supplements thereto, and this Agreement, (vi)&nbsp;all filing fees, attorneys&#146; fees and expenses incurred by the Company or the Underwriters in connection with qualifying or
registering (or obtaining exemptions from the qualification or registration of) all or any part of the Offered Shares for offer and sale under the state securities or blue sky laws or the provincial securities laws of Canada, and, if requested by
the Representatives, preparing and printing a &#147;Blue Sky Survey&#148; or memorandum and a &#147;Canadian wrapper&#148;, and any supplements thereto, advising the Underwriters of such qualifications, registrations and exemptions, (vii)&nbsp;the
costs, fees and expenses incurred by the Underwriters in connection with determining their compliance with the rules and regulations of FINRA related to the Underwriters&#146; participation in the offering and distribution of the Offered Shares,
including any related filing fees and the legal fees of, and disbursements by, counsel to the Underwriters<B>,</B> (viii)&nbsp;the costs and expenses of the Company relating to investor presentations on any &#147;road show&#148; undertaken in
connection with the marketing of the offering of the Offered Shares, including, without limitation, expenses associated with the preparation or dissemination of any electronic road show, expenses associated with the production of road show slides
and graphics, fees and expenses of any consultants engaged in connection with the road show presentations with the prior approval of the Company, travel and lodging expenses of the representatives, employees and officers of the Company and any such
consultants, and the cost of any aircraft chartered in connection with the road show, (ix)&nbsp;the fees and expenses associated with maintaining the listing of the Offered Shares on the NYSE MKT, and (x)&nbsp;all other fees, costs and expenses of
the nature referred to in Item&nbsp;14 of Part&nbsp;II of the Registration Statement. Except as provided in this Section&nbsp;4 or in Section&nbsp;7, Section&nbsp;9 or Section&nbsp;10 hereof, the Underwriters shall pay their own expenses, including
the fees and disbursements of their counsel. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Selling Stockholders further agree with each Underwriter to pay (directly or by
reimbursement) all fees and expenses incident to the performance of their obligations under this Agreement that are not otherwise specifically provided for herein, including but not limited to (i)&nbsp;fees and expenses of counsel and other advisors
for such Selling Stockholders, (ii)&nbsp;fees and expenses of the Custodian and the Attorneys-in-Fact and (iii)&nbsp;expenses and taxes incident to the sale and delivery of the Offered Shares to be sold by such Selling Stockholders to the
Underwriters hereunder (which taxes, if any, may be deducted by the Custodian under the provisions of Section&nbsp;2 of this Agreement). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Section&nbsp;4 shall not affect or modify any separate, valid agreement relating to the allocation of payment of expenses between the
Company, on the one hand, and the Selling Stockholders, on the other hand. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;5. Covenant of the Underwriters.</B> Each
Underwriter severally and not jointly covenants with the Company not to take any action that would result in the Company being </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
required to file with the Commission pursuant to Rule 433(d) under the Securities Act a free writing prospectus prepared by or on behalf of such Underwriter that otherwise would not, but for such
actions, be required to be filed by the Company under Rule 433(d). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;6. Conditions of the Obligations of the
Underwriters.</B> The respective obligations of the several Underwriters hereunder to purchase and pay for the Offered Shares as provided herein on the First Closing Date and, with respect to the Optional Shares, each Option Closing Date, shall be
subject to the accuracy of the representations and warranties on the part of the Company and the Selling Stockholders set forth in Section&nbsp;1 hereof as of the date hereof and as of the First Closing Date as though then made and, with respect to
the Optional Shares, as of each Option Closing Date as though then made, to the timely performance by the Company and the Selling Stockholders of their respective covenants and other obligations hereunder, and to each of the following additional
conditions: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a) </B><B><I>Comfort Letter</I></B><B>.</B> On the date hereof, the Representatives shall have received from Rosenberg
Rich Baker Berman&nbsp;&amp; Company, independent registered public accountants for the Company, a letter dated the date hereof addressed to the Underwriters, in form and substance satisfactory to the Representatives, containing statements and
information of the type ordinarily included in accountant&#146;s &#147;comfort letters&#148; to underwriters, delivered according to Statement of Auditing Standards No.&nbsp;72 (or any successor bulletin), with respect to the audited and unaudited
financial statements and certain financial information contained in the Registration Statement, the Time of Sale Prospectus, and each free writing prospectus, if any. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b) </B><B><I>Compliance with Registration Requirements; No Stop Order; No Objection from FINRA.</I></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) The Company shall have filed the Prospectus with the Commission (including the information previously omitted from the
Registration Statement pursuant to Rule 430B under the Securities Act) in the manner and within the time period required by Rule 424(b) under the Securities Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) No stop order suspending the effectiveness of the Registration Statement or any post-effective amendment to the
Registration Statement shall be in effect, and no proceedings for such purpose shall have been instituted or threatened by the Commission. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) If a filing has been made with FINRA, FINRA shall have raised no objection to the fairness and reasonableness of the
underwriting terms and arrangements. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c) </B><B><I>No Material Adverse Change or Ratings Agency Change</I></B><B>.</B> For the period
from and after the date of this Agreement and through and including the First Closing Date and, with respect to any Optional Shares purchased after the First Closing Date, each Option Closing Date: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) in the judgment of the Representatives there shall not have occurred any Material Adverse Change; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) there shall not have occurred any downgrading, nor shall any notice have been given of any intended or potential
downgrading or of any review for a possible change that does not indicate the direction of the possible change, in the rating accorded any securities of the Company or any of its subsidiaries by any &#147;nationally recognized statistical rating
organization&#148; as that term is used in Rule&nbsp;15c3-1(c)(2)(vi)(F) under the Exchange Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d) </B><B><I>Opinion of Counsel for the Company and the Selling Stockholders</I></B><B>.</B>
On each of the First Closing Date and each Option Closing Date, the Representatives shall have received the opinion of Greenberg Traurig, LLP, counsel for the Company and the Selling Stockholders, dated as of such date, in the form attached hereto
as <U>Exhibit A</U> and to such further effect as the Representatives shall reasonably request. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e) </B><B><I>Opinion of Intellectual
Property Counsel.</I></B> On each of the First Closing Date and each Option Closing Date, the Representatives shall have received the opinion of Snell&nbsp;&amp; Wilmer L.L.P., counsel for the Company with respect to intellectual property matters,
dated as of such date, in the form attached hereto as <U>Exhibit B</U> and to such further effect as the Representatives shall reasonably request. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f)</B><B><I> Reserved.</I></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(g) </B><B><I>Opinion of Counsel for the Underwriters</I></B><B>.</B> On each of the First Closing Date and each Option Closing Date, the
Representatives shall have received the opinion of Latham&nbsp;&amp; Watkins LLP, counsel for the Underwriters in connection with the offer and sale of the Offered Shares, in form and substance satisfactory to the Underwriters, dated as of such
date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(h) </B><B><I>Officers&#146; Certificate</I></B><B>.</B> On each of the First Closing Date and each Option Closing Date, the
Representatives shall have received a certificate executed by the Chief Executive Officer or President of the Company and the Chief Financial Officer of the Company, dated as of such date, to the effect set forth in Section&nbsp;6(b)(ii) and further
to the effect that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) for the period from and including the date of this Agreement through and including such date,
there has not occurred any Material Adverse Change; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) the representations, warranties and covenants of the Company set
forth in Section&nbsp;1 of this Agreement are true and correct with the same force and effect as though expressly made on and as of such date; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) the Company has complied with all the agreements hereunder and satisfied all the conditions on its part to be performed
or satisfied hereunder at or prior to such date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(i) </B><B><I>Selling Stockholders&#146; Certificate</I></B>. On each of the First
Closing Date and each Option Closing Date, the Representatives shall receive a written certificate executed by the Attorneys-in-Fact of the Selling Stockholders, dated as of such date, to the effect that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) the representations, warranties and covenants of the Selling Stockholders set forth in Section&nbsp;1(B) of this Agreement
are true and correct with respect to each Selling Stockholder with the same force and effect as though expressly made by each such Selling Stockholder on and as of such date; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) each such Selling Stockholder has complied with all the agreements and satisfied all the conditions on its part to be
performed or satisfied at or prior to such date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(j) </B><B><I>Selling Stockholders&#146; Documents</I></B><B>.</B> On or prior to the
date hereof, the Selling Stockholders shall have furnished for review by the Representatives copies of the Powers of Attorney and Custody Agreements executed by each of the Selling Stockholders and such further information, certificates and
documents as the Representatives may reasonably request. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(k) </B><B><I>Bring-down Comfort Letters</I></B><B>.</B> On each of the First Closing Date and
each Option Closing Date, the Representatives shall have received from Rosenberg Rich Baker Berman&nbsp;&amp; Company, independent registered public accountants for the Company, a letter dated such date, in form and substance satisfactory to the
Representatives, which letter shall: (i)&nbsp;reaffirm the statements made in the letter furnished by them pursuant to Section&nbsp;6(a), except that the specified date referred to therein for the carrying out of procedures shall be no more than
three business days prior to the Closing Date, as the case may be; and (ii)&nbsp;cover certain financial information contained in the Prospectus. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(l) </B><B><I>Lock-Up Agreements.</I></B> On or prior to the date hereof, the Company shall have furnished to the Representatives an
agreement in the form of <U>Exhibit D</U> hereto from each of the persons listed on <U>Exhibit&nbsp;E</U> hereto, and each such agreement shall be in full force and effect on the each of the First Closing Date and each Option Closing Date. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(m) </B><B><I>Chief Financial Officer Certificate</I></B>. On the date of this Agreement and on each of the First Closing Date and each
Option Closing Date, the Representatives shall have received a written certificate executed by the Chief Financial Officer of the Company, in substantially the form annexed hereto as <U>Exhibit F</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(n) </B><B><I>Regulatory Officer Certificate</I></B>. On each of the First Closing Date and each Option Closing Date, the Representatives
shall have received a written certificate executed by the Chief Product Officer of the Company, in substantially the form annexed hereto as <U>Exhibit G</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(o) </B><B><I>Rule&nbsp;462(b) Registration Statement</I></B>. In the event that a Rule&nbsp;462(b) Registration Statement is filed in
connection with the offering contemplated by this Agreement, such Rule&nbsp;462(b) Registration Statement shall have been filed with the Commission on the date of this Agreement and shall have become effective automatically upon such filing. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(p) </B><B><I>Additional Documents</I></B>. On or before each of the First Closing Date and each Option Closing Date, the Representatives
and counsel for the Underwriters shall have received such information, documents and opinions as they may reasonably request for the purposes of enabling them to pass upon the sale of the Offered Shares as contemplated herein, or in order to
evidence the accuracy of any of the representations and warranties, or the satisfaction of any of the conditions or agreements, herein contained; and all proceedings taken by the Company in connection with the sale of the Offered Shares as
contemplated herein and in connection with the other transactions contemplated by this Agreement shall be satisfactory in form and substance to the Representatives and counsel for the Underwriters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any condition specified in this Section&nbsp;6 is not satisfied when and as required to be satisfied and is not waived in writing by the
Representatives, this Agreement may be terminated by the Representatives by notice from Jefferies and Stifel to the Company and the Selling Stockholders at any time on or prior to the First Closing Date and, with respect to the Optional Shares, at
any time on or prior to the applicable Option Closing Date, which termination shall be without liability on the part of any party to any other party, except that Section&nbsp;4, Section&nbsp;7, Section&nbsp;9 and Section&nbsp;10 shall at all times
be effective and shall survive such termination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;7. Reimbursement of Underwriters&#146; Expenses</B>. If this Agreement
is terminated by the Representatives pursuant to Section&nbsp;6, Section&nbsp;11, Section&nbsp;12 or Section&nbsp;19, or if the sale to the Underwriters of the Offered Shares on the First Closing Date is not consummated because of any refusal,
inability or failure on the part of the Company or the Selling Stockholders to perform any agreement herein or to comply with any provision hereof, the Company agrees to reimburse the Representatives and the other Underwriters (or such Underwriters
as have terminated this Agreement with respect to themselves), severally, upon demand for all out-of-pocket expenses that shall have been </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reasonably incurred by the Representatives and the Underwriters in connection with the proposed purchase and the offering and sale of the Offered Shares, including, but not limited to, fees and
disbursements of counsel, printing expenses, travel expenses, postage, facsimile and telephone charges; <I>provided, however</I>, if this Agreement is terminated pursuant to Section&nbsp;11 by reason of the default of one or more Underwriters, the
Company shall not be obligated under this Section&nbsp;7 to reimburse any defaulting Underwriter on account of its expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;8. Effectiveness of this Agreement</B>. This Agreement shall become effective upon&nbsp;the execution and delivery hereof by
the parties hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;9. Indemnification</B>.<B></B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(a) </B><B><I>Indemnification of the Underwriters</I></B><B>.</B> The Company agrees to indemnify and hold harmless each Underwriter, its
affiliates, directors, officers, employees and agents, and each person, if any, who controls any Underwriter within the meaning of the Securities Act or the Exchange Act against any loss, claim, damage, liability or expense, as incurred, to which
such Underwriter or such affiliate, director, officer, employee, agent or controlling person may become subject, under the Securities Act, the Exchange Act, other federal or state statutory law or regulation, or the laws or regulations of foreign
jurisdictions where Offered Shares have been offered or sold or at common law or otherwise (including in settlement of any litigation, if such settlement is effected with the written consent of the Company), insofar as such loss, claim, damage,
liability or expense (or actions in respect thereof as contemplated below) arises out of or is based upon (i)&nbsp;any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement, or any amendment thereto,
or the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading; or (ii)&nbsp;any untrue statement or alleged untrue statement of a material fact included
in the Time of Sale Prospectus, any free writing prospectus that the Company has used, referred to or filed, or is required to file, pursuant to Rule 433(d) of the Securities Act, or the Prospectus (or any amendment or supplement to the foregoing),
or the omission or alleged omission to state therein a material fact necessary in order to make the statements, in the light of the circumstances under which they were made, not misleading; (iii)&nbsp;any breach of the representations, warranties
and other statements of the Company set forth in this Agreement (or in any other certificate or document delivered by the Company or its officers pursuant to this Agreement) amounting to or resulting from any breach of applicable law; or
(iv)&nbsp;any act or failure to act or any alleged act or failure to act by any Underwriter in connection with, or relating in any manner to, the Shares or the offering contemplated hereby, and which is included as part of or referred to in any
loss, claim, damage, liability or action arising out of or based upon any matter covered by clause (i), (ii)&nbsp;or (iii)&nbsp;above; and to reimburse each Underwriter and each such affiliate, director, officer, employee, agent and controlling
person for any and all expenses (including the fees and disbursements of counsel) as such expenses are reasonably incurred by such Underwriter or such affiliate, director, officer, employee, agent or controlling person in connection with
investigating, defending, settling, compromising or paying any such loss, claim, damage, liability, expense or action; <I>provided, however</I>, that the foregoing indemnity agreement shall not apply to any loss, claim, damage, liability or expense
to the extent, but only to the extent, arising out of or based upon any untrue statement or alleged untrue statement or omission or alleged omission made in reliance upon and in conformity with information relating to any Underwriter furnished to
the Company by the Representatives in writing expressly for use in the Registration Statement, the Time of Sale Prospectus, any such free writing prospectus, or the Prospectus (or any amendment or supplement thereto), it being understood and agreed
that the only such information consists of the information described in Section&nbsp;9(c) below. The indemnity agreement set forth in this Section&nbsp;9(a) shall be in addition to any liabilities that the Company may otherwise have. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(b) </B><B><I>Indemnification by the Selling Stockholders of the Underwriters</I></B>. Each Selling Stockholder, severally and not jointly,
agrees to indemnify and hold harmless each Underwriter, its </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
affiliates, directors, officers, employees and agents, and each person, if any, who controls any Underwriter within the meaning of the Securities Act or the Exchange Act against any loss, claim,
damage, liability or expense, as incurred, to which such Underwriter or such affiliate, director, officer, employee, agent or controlling person may become subject, under the Securities Act, the Exchange Act, other federal or state statutory law or
regulation, or the laws or regulations of foreign jurisdictions where Offered Shares have been offered or sold or at common law or otherwise (including in settlement of any litigation, if such settlement is effected in accordance with
Section&nbsp;9(e)), insofar as such loss, claim, damage, liability or expense (or actions in respect thereof as contemplated below) arises out of or is based upon (i)&nbsp;any untrue statement or alleged untrue statement of a material fact contained
in the Registration Statement, or any amendment thereto, or the omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading; or (ii)&nbsp;any untrue statement
or alleged untrue statement of a material fact included in any preliminary prospectus, the Time of Sale Prospectus, any free writing prospectus that the Company has used, referred to or filed, or is required to file, pursuant to Rule 433(d) of the
Securities Act, or the Prospectus (or any amendment or supplement to the foregoing), or the omission or alleged omission to state therein a material fact necessary in order to make the statements, in the light of the circumstances under which they
were made, not misleading; in each case to the extent, but only to the extent, that such untrue statement or alleged untrue statement or omission or alleged omission was made in the Registration Statement, any preliminary prospectus, the Time of
Sale Prospectus, any such free writing prospectus that the Company has used, referred to or filed, or is required to file, pursuant to Rule 433(d) of the Securities Act, or the Prospectus (or such amendment or supplement thereto), in reliance upon
and in conformity with the Selling Stockholder Information expressly for use therein; and, subject to the limitations set forth above in this subsection (b); and to reimburse each Underwriter and each such affiliate, director, officer, employee,
agent and controlling person for any and all reasonable and documented expenses (including such fees and disbursements of counsel chosen by Jefferies) as such expenses are incurred by such Underwriter or such affiliate, director, officer, employee,
agent or controlling person in connection with investigating, defending, settling, compromising or paying any such loss, claim, damage, liability, expense or action. No Selling Stockholder shall be required to indemnify or reimburse any amount
which, in the aggregate together with any other amounts paid pursuant to this Section&nbsp;9(b), exceeds the product of the number of Offered Shares sold by such Selling Stockholder and the public offering price of the Offered Shares (less the
related underwriting discounts and commissions) set forth on the front cover page of the Prospectus. The indemnity agreement set forth in this Section&nbsp;9(b) shall be in addition to any liabilities that the Selling Stockholders may otherwise
have. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(c) </B><B><I>Indemnification of the Company, its Directors and Officers and the Selling Stockholders</I></B>. Each Underwriter
agrees, severally and not jointly, to indemnify and hold harmless the Company, each of its directors, each of its officers, the Selling Stockholders and each person, if any, who controls the Company and any Selling Stockholder within the meaning of
the Securities Act or the Exchange Act, against any loss, claim, damage, liability or expense, as incurred, to which the Company, or any such director, officer, Selling Stockholder or controlling person may become subject, under the Securities Act,
the Exchange Act, or other federal or state statutory law or regulation, or at common law or otherwise (including in settlement of any litigation, if such settlement is effected with the written consent of such Underwriter), insofar as such loss,
claim, damage, liability or expense (or actions in respect thereof as contemplated below) arises out of or is based upon (i)&nbsp;any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement, or any
amendment thereto, or any omission or alleged omission to state therein a material fact required to be stated therein or necessary to make the statements therein not misleading or (ii)&nbsp;any untrue statement or alleged untrue statement of a
material fact included in the Time of Sale Prospectus, any free writing prospectus that the Company has used, referred to or filed, or is required to file, pursuant to Rule 433 of the Securities Act or the Prospectus (or any such amendment or
supplement), or the omission or alleged omission to state therein a material fact necessary in order to make the statements, in the light of the circumstances under which they were made, not misleading, in each case to the extent, but only to the
extent, that such untrue statement or alleged untrue </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
statement or omission or alleged omission was made in the Registration Statement, the Time of Sale Prospectus, such free writing prospectus or the Prospectus (or any such amendment or
supplement), in reliance upon and in conformity with information relating to such Underwriter furnished to the Company by the Representatives in writing expressly for use therein; and to reimburse the Company, or any such director, officer, Selling
Stockholder or controlling person for any and all expenses (including the fees and disbursements of counsel) as such expenses are incurred by the Company, or any such director, officer, Selling Stockholder or controlling person in connection with
investigating, defending, settling, compromising or paying any such loss, claim, damage, liability, expense or action. The Company and each of the Selling Stockholders hereby acknowledges that the only information that the Representatives has
furnished to the Company expressly for use in the Registration Statement, the Time of Sale Prospectus, any free writing prospectus that the Company has filed, or is required to file, pursuant to Rule&nbsp;433(d) of the Securities Act or the
Prospectus (or any amendment or supplement to the foregoing) are the statements set forth in the first sentence in the third paragraph, the first and third sentences of the first paragraph under the title &#147;Commissions and Expenses&#148; and the
statements in the first and fourth paragraphs under the title &#147;Stabilization,&#148; in each case under the caption &#147;Underwriting&#148; in the Preliminary Prospectus Supplement and the Final Prospectus Supplement. The indemnity agreement
set forth in this Section&nbsp;9(c) shall be in addition to any liabilities that each Underwriter may otherwise have. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(d)
</B><B><I>Notifications and Other Indemnification Procedures</I></B><B>.</B> Promptly after receipt by an indemnified party under this Section&nbsp;9 of notice of the commencement of any action, such indemnified party will, if a claim in respect
thereof is to be made against an indemnifying party under this Section&nbsp;9, notify the indemnifying party in writing of the commencement thereof, but the omission so to notify the indemnifying party will not relieve the indemnifying party from
any liability which it may have to any indemnified party to the extent the indemnifying party is not materially prejudiced as a proximate result of such failure and shall not in any event relieve the indemnifying party from any liability that it may
have otherwise than on account of this indemnity agreement. In case any such action is brought against any indemnified party and such indemnified party seeks or intends to seek indemnity from an indemnifying party, the indemnifying party will be
entitled to participate in, and, to the extent that it shall elect, jointly with all other indemnifying parties similarly notified, by written notice delivered to the indemnified party promptly after receiving the aforesaid notice from such
indemnified party, to assume the defense thereof with counsel reasonably satisfactory to such indemnified party; <I>provided, however</I>, that if the defendants in any such action include both the indemnified party and the indemnifying party and
the indemnified party shall have reasonably concluded that a conflict may arise between the positions of the indemnifying party and the indemnified party in conducting the defense of any such action or that there may be legal defenses available to
it and/or other indemnified parties which are different from or additional to those available to the indemnifying party, the indemnified party or parties shall have the right to select separate counsel to assume such legal defenses and to otherwise
participate in the defense of such action on behalf of such indemnified party or parties. Upon receipt of notice from the indemnifying party to such indemnified party of such indemnifying party&#146;s election so to assume the defense of such action
and approval by the indemnified party of counsel, the indemnifying party will not be liable to such indemnified party under this Section&nbsp;9 for any legal or other expenses subsequently incurred by such indemnified party in connection with the
defense thereof unless (i)&nbsp;the indemnified party shall have employed separate counsel in accordance with the proviso to the preceding sentence (it being understood, however, that the indemnifying party shall not be liable for the fees and
expenses of more than one separate counsel (together with local counsel), representing the indemnified parties who are parties to such action), which counsel (together with any local counsel) for the indemnified parties shall be selected by
Jefferies (in the case of counsel for the indemnified parties referred to in Section&nbsp;9(a) above), by the Selling Stockholders (in the case of counsel for the indemnified parties referred to in Section&nbsp;9(b) above) or by the Company (in the
case of counsel for the indemnified parties referred to in Section&nbsp;9(c) above)) or (ii)&nbsp;the indemnifying party shall not have employed counsel satisfactory to the indemnified party to represent the indemnified party within a reasonable
time after notice of commencement of the action or (iii)&nbsp;the indemnifying party </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
has authorized in writing the employment of counsel for the indemnified party at the expense of the indemnifying party, in each of which cases the fees and expenses of counsel shall be at the
expense of the indemnifying party and shall be paid as they are incurred. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(e) </B><B><I>Settlements</I></B><B>.</B> The indemnifying
party under this Section&nbsp;9 shall not be liable for any settlement of any proceeding effected without its written consent, but if settled with such consent or if there be a final judgment for the plaintiff, the indemnifying party agrees to
indemnify the indemnified party against any loss, claim, damage, liability or expense by reason of such settlement or judgment. Notwithstanding the foregoing sentence, if at any time an indemnified party shall have requested an indemnifying party to
reimburse the indemnified party for fees and expenses of counsel as contemplated by Section&nbsp;9(d) hereof, the indemnifying party shall be liable for any settlement of any proceeding effected without its written consent if (i)&nbsp;such
settlement is entered into more than 45&nbsp;days after receipt by such indemnifying party of the aforesaid request and (ii)&nbsp;such indemnifying party shall not have reimbursed the indemnified party in accordance with such request prior to the
date of such settlement. No indemnifying party shall, without the prior written consent of the indemnified party, effect any settlement, compromise or consent to the entry of judgment in any pending or threatened action, suit or proceeding in
respect of which any indemnified party is or could have been a party and indemnity was or could have been sought hereunder by such indemnified party, unless such settlement, compromise or consent includes an unconditional release of such indemnified
party from all liability on claims that are the subject matter of such action, suit or proceeding and does not include an admission of fault or culpability or a failure to act by or on behalf of such indemnified party. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>(f) </B><B><I>Risk Allocation</I></B>. The representations, warranties, covenants and agreements made herein, together with the
indemnification provisions herein, are intended among other things to allocate the economic cost and the risks inherent in the transactions contemplated hereby between the parties and, accordingly, a party shall be entitled to the indemnification or
other remedies provided in this Agreement by reason of any breach of any such representation, warranty, covenant or agreement by another party notwithstanding whether any director, officer, employee, agent, consultant, advisor or other
representative (including legal counsel, accountants and financial advisors) of the party seeking to enforce a remedy knew or had reason to know of such breach. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;10. Contribution</B>. If the indemnification provided for in Section&nbsp;9 is for any reason held to be unavailable to or
otherwise insufficient to hold harmless an indemnified party in respect of any losses, claims, damages, liabilities or expenses referred to therein, then each indemnifying party shall contribute to the aggregate amount paid or payable by such
indemnified party, as incurred, as a result of any losses, claims, damages, liabilities or expenses referred to therein (i)&nbsp;in such proportion as is appropriate to reflect the relative benefits received by the Company and the Selling
Stockholders, on the one hand, and the Underwriters, on the other hand, from the offering of the Offered Shares pursuant to this Agreement or (ii)&nbsp;if the allocation provided by clause&nbsp;(i) above is not permitted by applicable law, in such
proportion as is appropriate to reflect not only the relative benefits referred to in clause&nbsp;(i) above but also the relative fault of the Company and the Selling Stockholders, on the one hand, and the Underwriters, on the other hand, in
connection with the statements or omissions which resulted in such losses, claims, damages, liabilities or expenses, as well as any other relevant equitable considerations. The relative benefits received by the Company and the Selling Stockholders,
on the one hand, and the Underwriters, on the other hand, in connection with the offering of the Offered Shares pursuant to this Agreement shall be deemed to be in the same respective proportions as the total proceeds from the offering of the
Offered Shares pursuant to this Agreement (before deducting expenses) received by the Company and the Selling Stockholders, and the total underwriting discounts and commissions received by the Underwriters, in each case as set forth on the front
cover page of the Prospectus, bear to the aggregate public offering price of the Offered Shares as set forth on such cover. The relative fault of the Company and the Selling Stockholders, on the one hand, and the Underwriters, on the other hand,
shall be determined by reference to, among other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
things, whether any such untrue or alleged untrue statement of a material fact or omission or alleged omission to state a material fact relates to information supplied by the Company or the
Selling Stockholders, on the one hand, or the Underwriters, on the other hand, and the parties&#146; relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The amount paid or payable by a party as a result of the losses, claims, damages, liabilities and expenses referred to above shall be deemed
to include, subject to the limitations set forth in Section&nbsp;9(d), any legal or other fees or expenses reasonably incurred by such party in connection with investigating or defending any action or claim. The provisions set forth in
Section&nbsp;9(d) with respect to notice of commencement of any action shall apply if a claim for contribution is to be made under this Section&nbsp;10; <I>provided, however,</I> that no additional notice shall be required with respect to any action
for which notice has been given under Section&nbsp;9(d) for purposes of indemnification. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company, the Selling Stockholders and the
Underwriters agree that it would not be just and equitable if contribution pursuant to this Section&nbsp;10 were determined by pro rata allocation (even if the Underwriters were treated as one entity for such purpose) or by any other method of
allocation which does not take account of the equitable considerations referred to in this Section&nbsp;10. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the
provisions of this Section&nbsp;10, no Underwriter shall be required to contribute any amount in excess of the underwriting discounts and commissions received by such Underwriter in connection with the Offered Shares underwritten by it and
distributed to the public. No person guilty of fraudulent misrepresentation (within the meaning of Section&nbsp;11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation.
The Underwriters&#146; obligations to contribute pursuant to this Section&nbsp;10 are several, and not joint, in proportion to their respective underwriting commitments as set forth opposite their respective names on&nbsp;<U>Schedule B</U>. For
purposes of this Section&nbsp;10, each affiliate, director, officer, employee and agent of an Underwriter and each person, if any, who controls an Underwriter within the meaning of the Securities Act or the Exchange Act shall have the same rights to
contribution as such Underwriter, and each director of the Company, each officer of the Company who signed the Registration Statement, and each person, if any, who controls the Company within the meaning of the Securities Act and the Exchange Act
shall have the same rights to contribution as the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;11. Default of One or More of the Several
Underwriters</B><I>.</I> If, on the First Closing Date or any Option Closing Date any one or more of the several Underwriters shall fail or refuse to purchase Offered Shares that it or they have agreed to purchase hereunder on such date, and the
aggregate number of Offered Shares which such defaulting Underwriter or Underwriters agreed but failed or refused to purchase does not exceed 10% of the aggregate number of the Offered Shares to be purchased on such date by the Underwriters, the
Representatives may make arrangements satisfactory to the Company and the Selling Stockholders for the purchase of such Offered Shares by other persons, including any of the Underwriters, but if no such arrangements are made by such date, the other
Underwriters shall be obligated, severally and not jointly, in the proportions that the number of Firm Shares set forth opposite their respective names on <U>Schedule B</U> bears to the aggregate number of Firm Shares set forth opposite the names of
all such non-defaulting Underwriters, or in such other proportions as may be specified by the Representatives with the consent of the non-defaulting Underwriters, to purchase the Offered Shares which such defaulting Underwriter or Underwriters
agreed but failed or refused to purchase on such date. If, on the First Closing Date or any Option Closing Date any one or more of the Underwriters shall fail or refuse to purchase Offered Shares and the aggregate number of Offered Shares with
respect to which such default occurs exceeds 10% of the aggregate number of Offered Shares to be purchased on such date by the Underwriters, and arrangements satisfactory to the Representatives and the Company for the purchase of such Offered Shares
are not made within 48 hours after such default, this Agreement shall terminate without liability of any party to any other party except that the provisions of Section&nbsp;4, Section&nbsp;7, Section&nbsp;9
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
and Section&nbsp;10 shall at all times be effective and shall survive such termination. In any such case either the Representatives or the Company shall have the right to postpone the First
Closing Date or the applicable Option Closing Date, as the case may be, but in no event for longer than seven days in order that the required changes, if any, to the Registration Statement and the Prospectus or any other documents or arrangements
may be effected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As used in this Agreement, the term &#147;<B>Underwriter</B>&#148; shall be deemed to include any person substituted for
a defaulting Underwriter under this Section&nbsp;11. Any action taken under this Section&nbsp;11 shall not relieve any defaulting Underwriter from liability in respect of any default of such Underwriter under this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;12. Termination of this Agreement</B><I>.</I> Prior to the purchase of the Firm Shares by the Underwriters on the First
Closing Date, this Agreement may be terminated by Jefferies and Stifel by written notice given to the Company and the Selling Stockholders if at any time: (i)&nbsp;trading or quotation in any of the Company&#146;s securities shall have been
suspended or limited by the Commission or by the NYSE MKT or trading in securities generally on either the NASDAQ or the NYSE shall have been suspended or limited, or minimum or maximum prices shall have been generally established on any of such
stock exchanges; (ii)&nbsp;a general banking moratorium shall have been declared by any of federal, New York or Florida authorities; (iii)&nbsp;there shall have occurred any outbreak or escalation of national or international hostilities or any
crisis or calamity, or any change in the United States or international financial markets, or any substantial change or development involving a prospective substantial change in United States&#146; or international political, financial or economic
conditions, as in the judgment of Jefferies and Stifel is material and adverse and makes it impracticable to market the Offered Shares in the manner and on the terms described in the Time of Sale Prospectus or the Prospectus or to enforce contracts
for the sale of securities; (iv)&nbsp;in the judgment of Jefferies and Stifel there shall have occurred any Material Adverse Change; or (v)&nbsp;the Company shall have sustained a loss by strike, fire, flood, earthquake, accident or other calamity
of such character as in the judgment of Jefferies and Stifel may interfere materially with the conduct of the business and operations of the Company regardless of whether or not such loss shall have been insured. Any termination pursuant to this
Section&nbsp;12 shall be without liability on the part of (a)&nbsp;the Company or the Selling Stockholders to any Underwriter, except that the Company and the Selling Stockholders shall be obligated to reimburse the expenses of the Representatives
and the Underwriters pursuant to Section&nbsp;4 or Section&nbsp;7 hereof or (b)&nbsp;any Underwriter to the Company or the Selling Stockholders; <I>provided, however,</I> that the provisions of Section&nbsp;9 and Section&nbsp;10 shall at all times
be effective and shall survive such termination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;13. No Advisory or Fiduciary Relationship. </B>The Company and the
Selling Stockholders acknowledge and agree that (a)&nbsp;the purchase and sale of the Offered Shares pursuant to this Agreement, including the determination of the public offering price of the Offered Shares and any related discounts and
commissions, is an arm&#146;s-length commercial transaction between the Company and the Selling Stockholders, on the one hand, and the several Underwriters, on the other hand, (b)&nbsp;in connection with the offering contemplated hereby and the
process leading to such transaction, each Underwriter is and has been acting solely as a principal and is not the agent or fiduciary of the Company or the Selling Stockholders, or the Company&#146;s other stockholders, or its creditors, employees or
any other party, (c)&nbsp;no Underwriter has assumed or will assume an advisory or fiduciary responsibility in favor of the Company or the Selling Stockholders with respect to the offering contemplated hereby or the process leading thereto
(irrespective of whether such Underwriter has advised or is currently advising the Company or the Selling Stockholders on other matters) and no Underwriter has any obligation to the Company or the Selling Stockholders with respect to the offering
contemplated hereby except the obligations expressly set forth in this Agreement, (d)&nbsp;the Underwriters and their respective affiliates may be engaged in a broad range of transactions that involve interests that differ from those of the Company
and the Selling Stockholders, and (e)&nbsp;the Underwriters have not provided any legal, accounting, regulatory or tax advice with respect to the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
offering contemplated hereby and the Company and the Selling Stockholders have consulted their own legal, accounting, regulatory and tax advisors to the extent they deemed appropriate. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;14. Representations and Indemnities to Survive Delivery</B><I>.</I> The respective indemnities, agreements, representations,
warranties and other statements of the Company, of its officers, of the Selling Stockholders and of the several Underwriters set forth in or made pursuant to this Agreement will remain in full force and effect, regardless of any investigation made
by or on behalf of any Underwriter or the Company or any of its or their partners, officers or directors or any controlling person, or the Selling Stockholders, as the case may be, and, anything herein to the contrary notwithstanding, will survive
delivery of and payment for the Offered Shares sold hereunder and any termination of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;15. Notices</B>. All
communications hereunder shall be in writing and shall be mailed, hand delivered or telecopied and confirmed to the parties hereto as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="31%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="67%"></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; font-size:10pt; font-family:Times New Roman">If to the Representatives:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jefferies LLC</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">520 Madison Avenue</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10022</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Facsimile: (646)&nbsp;619-4437</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attention: General Counsel</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stifel, Nicolaus&nbsp;&amp; Company, Incorporated</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">One Montgomery
Street, Suite 3700</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Francisco, California 94104</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Facsimile:
(415)&nbsp;364-2695</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Attention: General Counsel</P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; font-size:10pt; font-family:Times New Roman">with a copy to:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Latham&nbsp;&amp; Watkins LLP</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">12670 High Bluff
Drive</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">San Diego, CA 92130</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Facsimile: (858)&nbsp;523-5450</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Attn: Cheston J. Larson, Esq.</P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; font-size:10pt; font-family:Times New Roman">If to the Company:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TherapeuticsMD, Inc.</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6800 Broken Sound Parkway,
Third Floor</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boca Raton, FL 33487</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Facsimile:
(561)&nbsp;431-3389</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Attention: Robert G. Finizio</P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; font-size:10pt; font-family:Times New Roman">with a copy to:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Greenberg Traurig, LLP</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2375 E. Camelback Rd.,
Suite 700</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Phoenix, AZ 85016</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Facsimile:
(602)&nbsp;445-8614</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Attn: Robert S. Kant, Esq.</P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; font-size:10pt; font-family:Times New Roman">If to the Selling Stockholders:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Robert G. Finizio</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o TherapeuticsMD, Inc.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6800 Broken Sound Parkway, Third Floor</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boca Raton, FL 33487</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Facsimile: (561)&nbsp;431-3389</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="31%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="67%"></TD></TR>

<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Richard Segal</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">707 Westchester Avenue</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">White Plains, NY 10640</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Facsimile:
(914)&nbsp;681-5182</P></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.00em; font-size:10pt; font-family:Times New Roman">with a copy to:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Greenberg Traurig, LLP</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2375 E. Camelback Rd.,
Suite 700</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Phoenix, AZ 85016</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Facsimile:
(602)&nbsp;445-8614</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Attn: Robert S. Kant, Esq.</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any party hereto may change the address for receipt of communications by giving written notice to the others. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;16. Successors</B><I>.</I> This Agreement will inure to the benefit of and be binding upon the parties hereto, including any
substitute Underwriters pursuant to Section&nbsp;11 hereof, and to the benefit of the affiliates, directors, officers, employees, agents and controlling persons referred to in Section&nbsp;9 and Section&nbsp;10, and in each case their respective
successors, and no other person will have any right or obligation hereunder. The term &#147;<B>successors</B>&#148; shall not include any purchaser of the Offered Shares as such from any of the Underwriters merely by reason of such purchase. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;17. Partial Unenforceability</B>. The invalidity or unenforceability of any section, paragraph or provision of this Agreement
shall not affect the validity or enforceability of any other section, paragraph or provision hereof. If any section, paragraph or provision of this Agreement is for any reason determined to be invalid or unenforceable, there shall be deemed to be
made such minor changes (and only such minor changes) as are necessary to make it valid and enforceable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;18. Governing
Law Provisions</B><I>.</I> This Agreement shall be governed by and construed in accordance with the internal laws of the State of New York applicable to agreements made and to be performed in such state. Any legal suit, action or proceeding arising
out of or based upon this Agreement or the transactions contemplated hereby (&#147;<B>Related Proceedings</B>&#148;) may be instituted in the federal courts of the United States of America located in the Borough of Manhattan in the City of New York
or the courts of the State of New York in each case located in the Borough of Manhattan in the City of New York (collectively, the &#147;<B>Specified Courts</B>&#148;), and each party irrevocably submits to the exclusive jurisdiction (except for
proceedings instituted in regard to the enforcement of a judgment of any such court (a &#147;<B>Related Judgment</B>&#148;), as to which such jurisdiction is non-exclusive) of such courts in any such suit, action or proceeding. Service of any
process, summons, notice or document by mail to such party&#146;s address set forth above shall be effective service of process for any suit, action or other proceeding brought in any such court. The parties irrevocably and unconditionally waive any
objection to the laying of venue of any suit, action or other proceeding in the Specified Courts and irrevocably and unconditionally waive and agree not to plead or claim in any such court that any such suit, action or other proceeding brought in
any such court has been brought in an inconvenient forum. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;19. Failure of One or More of the Selling Stockholders to Sell
and Deliver Offered Shares.</B> If one or more of the Selling Stockholders shall fail to sell and deliver to the Underwriters the Offered Shares to be sold and delivered by such Selling Stockholders at the First Closing Date pursuant to this
Agreement, then the Underwriters may at their option, by written notice from the Representatives to the Company and the Selling Stockholders, either (i)&nbsp;terminate this Agreement without any liability on the part of any Underwriter or, except as
provided in Section&nbsp;4, Section&nbsp;7, Section&nbsp;9 and Section&nbsp;10 hereof, the Company or the other Selling Stockholders, or (ii)&nbsp;purchase the shares which other Selling Stockholders have agreed to sell and deliver in accordance
with the terms hereof. If one or more of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Selling Stockholders shall fail to sell and deliver to the Underwriters the Offered Shares to be sold and delivered by such Selling Stockholders pursuant to this Agreement at the First
Closing Date or the applicable Option Closing Date, then the Underwriters shall have the right, by written notice from the Representatives to the Company and the Selling Stockholders, to postpone the First Closing Date or the applicable Option
Closing Date, as the case may be, but in no event for longer than seven days in order that the required changes, if any, to the Registration Statement and the Prospectus or any other documents or arrangements may be effected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman"><B>Section&nbsp;20. General Provisions.</B> This Agreement constitutes the entire agreement of the parties to this Agreement and supersedes
all prior written or oral and all contemporaneous oral agreements, understandings and negotiations with respect to the subject matter hereof. This Agreement may be executed in two or more counterparts, each one of which shall be an original, with
the same effect as if the signatures thereto and hereto were upon the same instrument. This Agreement may not be amended or modified unless in writing by all of the parties hereto, and no condition herein (express or implied) may be waived unless
waived in writing by each party whom the condition is meant to benefit. The section headings herein are for the convenience of the parties only and shall not affect the construction or interpretation of this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each of the parties hereto acknowledges that it is a sophisticated business person who was adequately represented by counsel during
negotiations regarding the provisions hereof, including, without limitation, the indemnification provisions of Section&nbsp;9 and the contribution provisions of Section&nbsp;10, and is fully informed regarding said provisions. Each of the parties
hereto further acknowledges that the provisions of Section&nbsp;9 and&nbsp;Section 10 hereof fairly allocate the risks in light of the ability of the parties to investigate the Company, its affairs and its business in order to assure that adequate
disclosure has been made in the Registration Statement, the Time of Sale Prospectus, each free writing prospectus and the Prospectus (and any amendments and supplements to the foregoing), as contemplated by the Securities Act and the Exchange Act.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the foregoing is in accordance with your understanding of our agreement, kindly sign and
return to the Company and the Custodian the enclosed copies hereof, whereupon this instrument, along with all counterparts hereof, shall become a binding agreement in accordance with its terms. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="89%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Very truly yours,</TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>THERAPEUTICSMD, INC.</B></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><I>/s/ Daniel Cartwright</I></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Name: Daniel Cartwright</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Title: CFO</TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ON&nbsp;BEHALF&nbsp;OF&nbsp;THE&nbsp;SELLING&nbsp;STOCKHOLDERS</B></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><I>/s/ Robert G. Finizio</I></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"><I>As Attorney-in-fact</I></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Name: Robert G. Finizio</TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><I>/s/ Richard Segal</I></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"><I>As Attorney-in-fact</I></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Name: Richard Segal</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I></I>[<I>Signature Page
to Underwriting Agreement</I>]<I> </I></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing Underwriting Agreement is hereby confirmed and accepted by the Representatives in
New York, New York as of the date first above written. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>JEFFERIES LLC </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>STIFEL, NICOLAUS &amp; COMPANY, INCORPORATED </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Acting
individually and as Representatives </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">of the several Underwriters named in </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">the attached <U>Schedule B</U>. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="93%"></TD></TR>


<TR>
<TD HEIGHT="8" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><B>JEFFERIES LLC</B></P></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><I>/s/ Sage Kelly</I></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Name: Sage Kelly</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Title: Head of Healthcare IB, Managing Director</TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>STIFEL,&nbsp;NICOLAUS&nbsp;&amp;&nbsp;COMPANY,&nbsp;INCORPORATED</B></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><I>/s/ Seth Rubin</I></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Name: Seth Rubin</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">Title: Managing Director</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I></I>[<I>Signature Page
to Underwriting Agreement</I>]<I> </I></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Schedule A </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Selling Stockholders</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Firm&nbsp;Shares</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>to be
Sold</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Maximum&nbsp;Number<BR>of&nbsp;Optional&nbsp;Shares</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>to be Sold</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert G. Finizio</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">982,053</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">754,680</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John C.K. Milligan Revocable Trust U/A 08/10/2009, as amended 11/22/2011</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">353,412</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">271,588</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BF Investment Enterprises, Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">421,268</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">323,732</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Nicholas Segal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gregory Segal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Fourth Generation Private Equity Partners</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,600,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patricia Lieberman</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">400,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Reich Family L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gregory G. Mario</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">189,163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mario Family Partners LP</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">407,127</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">DJA Spring Investments L.L.C.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">400,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SGH Holdings, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">200,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Anthony Aquino</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bradley Douglas</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">241,715</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Seth Becker</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,348</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Steven S. Williamson</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">102,285</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joes Christopher Work</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,344</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mitchell R. Work</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Daniel Kandler</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,441,945</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Donald J. Duberstein</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">James Nuckols</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">193,340</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gerald B. Cramer Revocable Trust</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total:</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,350,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Schedule B </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="89%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><B>Underwriters</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Firm&nbsp;Shares</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>to&nbsp;be&nbsp;Purchased</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jefferies LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,191,630</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stifel, Nicolaus&nbsp;&amp; Company, Incorporated</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,191,630</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cowen and Company, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,744,493</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mizuho Securities USA Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">872,247</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Schedule C </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Free Writing Prospectuses Included in the Time of Sale Prospectus </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">None. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Schedule D </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Pricing Information </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Number of
Shares being offered: 9,000,000 shares </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Price per Share: $7.10 </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit D </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Form of Lock-up Agreement </U></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2014 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jefferies LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">As Representative of the several Underwriters </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Jefferies LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">520 Madison Avenue </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10022 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">RE: TherapeuticsMD, Inc. (the
&#147;<B>Company</B>&#148;) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies&nbsp;&amp; Gentlemen: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned is an officer, director and/or owner of shares of common stock, par value $0.001 per share, of the Company (&#147;<B>Shares</B>&#148;) or of
securities convertible into or exchangeable or exercisable for Shares. The Company proposes to conduct a public offering of Shares (the &#147;<B>Offering</B>&#148;) for which Jefferies LLC (&#147;<B>Jefferies</B>&#148;) will act as the
representative of the underwriters. The undersigned recognizes that the Offering will benefit each of the Company and the undersigned. The undersigned acknowledges that the underwriters are relying on the representations and agreements of the
undersigned contained in this letter agreement in conducting the Offering and, at a subsequent date, in entering into an underwriting agreement (the &#147;<B>Underwriting Agreement</B>&#148;) and other underwriting arrangements with the Company with
respect to the Offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Annex A sets forth definitions for capitalized terms used in this letter agreement that are not defined in the body of this
agreement. Those definitions are a part of this agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In consideration of the foregoing, and for other good and valuable consideration, the receipt
and sufficiency of which are hereby acknowledged, the undersigned hereby agrees that, during the Lock-up Period, the undersigned will not (and will cause any Family Member not to), without the prior written consent of Jefferies, which may withhold
its consent in its sole discretion: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Sell or Offer to Sell any Shares or Related Securities currently or hereafter owned either of record or beneficially (as defined in Rule 13d-3 under the Exchange Act) by the undersigned or such Family Member,
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">enter into any Swap, </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">make any demand for, or exercise any right with respect to, the registration under the Securities Act of the offer and sale of any Shares or Related Securities, or cause to be filed a registration statement, prospectus
or prospectus supplement (or an amendment or supplement thereto) with respect to any such registration, or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">publicly announce any intention to do any of the foregoing. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing will not apply to the registration
of the offer and sale of the Shares, and the sale of the Shares to the underwriters, in each case as contemplated by the Underwriting Agreement. In addition, the foregoing restrictions shall not apply to the transfer of Shares or Related Securities
by gift, or by will or intestate succession to a Family Member or to a trust whose beneficiaries consist exclusively of one or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
more of the undersigned and/or a Family Member; <I>provided, however</I>, that in any such case, it shall be a condition to such transfer that: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">each transferee executes and delivers to Jefferies an agreement in form and substance satisfactory to Jefferies stating that such transferee is receiving and holding such Shares and/or Related Securities subject to the
provisions of this letter agreement and agrees not to Sell or Offer to Sell such Shares and/or Related Securities, engage in any Swap or engage in any other activities restricted under this letter agreement except in accordance with this letter
agreement (as if such transferee had been an original signatory hereto), and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">prior to the expiration of the Lock-up Period, no public disclosure or filing under the Exchange Act by any party to the transfer (donor, donee, transferor or transferee) shall be required, or made voluntarily,
reporting a reduction in beneficial ownership of Shares in connection with such transfer. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned acknowledges and agrees that
written notice by Jefferies to the Company of any extension of the 90-day initial lock-up period as contemplated herein will be deemed to have been given to, and received by, the undersigned. The undersigned further agrees that, prior to engaging in
any transaction or taking any other action that is subject to the terms of this letter agreement during the period from the date of this letter agreement through the close of trading on the date that is the 34th day following the expiration of the
90-day initial lock-up period, the undersigned will give notice thereof to the Company and will not consummate any such transaction or take any such action unless the undersigned has received written confirmation from the Company that the Lock-Up
Period has expired. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned further agrees that the foregoing provisions shall be equally applicable to any Company-directed Shares the
undersigned may purchase or otherwise receive in the Offering (including pursuant to a directed share program). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, (i)&nbsp;Jefferies agrees
that, at least three business days before the effective date of any release or waiver of the foregoing restrictions in connection with a transfer of Shares, Jefferies will notify the Company of the impending release or waiver, and (ii)&nbsp;the
Company (in accordance with the provisions of the Underwriting Agreement) will announce the impending release or waiver by press release through a major news service at least two business days before the effective date of the release or waiver. Any
release or waiver granted by Jefferies hereunder to any such officer or director shall only be effective two business days after the publication date of such press release. The provisions of this paragraph will not apply if both (a)&nbsp;the release
or waiver is effected solely to permit a transfer not for consideration and (b)&nbsp;the transferee has agreed in writing to be bound by the same terms described in this letter agreement that are applicable to the transferor to the extent and for
the duration that such terms remain in effect at the time of the transfer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned also agrees and consents to the entry of stop transfer
instructions with the Company&#146;s transfer agent and registrar against the transfer of Shares or Related Securities held by the undersigned and the undersigned&#146;s Family Members, if any, except in compliance with the foregoing restrictions.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With respect to the Offering only, the undersigned waives any registration rights relating to registration under the Securities Act of the offer and sale
of any Shares and/or any Related Securities owned either of record or beneficially by the undersigned, including any rights to receive notice of the Offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned confirms that the undersigned has not, and has no knowledge that any Family Member has, directly or indirectly, taken any action designed to
or that might reasonably be expected to cause or result in the stabilization or manipulation of the price of any security of the Company to facilitate the sale </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of the Shares. The undersigned will not, and will cause any Family Member not to take, directly or indirectly, any such action. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Whether or not the Offering occurs as currently contemplated or at all depends on market conditions and other factors. The Offering will only be made pursuant
to the Underwriting Agreement, the terms of which are subject to negotiation between the Company and the underwriters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned hereby represents
and warrants that the undersigned has full power, capacity and authority to enter into this letter agreement. This letter agreement is irrevocable and will be binding on the undersigned and the successors, heirs, personal representatives and assigns
of the undersigned. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This letter agreement shall be governed by, and construed in accordance with, the laws of the State of New York. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-size:8pt">&nbsp;</FONT> <P STYLE="font-size:3pt">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signature</TD></TR>
<TR>
<TD HEIGHT="8"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT STYLE="font-size:8pt">&nbsp;</FONT> <P STYLE="font-size:3pt">&nbsp;</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Printed Name of Person Signing</TD></TR>
<TR>
<TD HEIGHT="16"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>(Indicate capacity of person signing if signing as custodian or trustee, or on behalf of an entity)</I></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certain Defined Terms<U> </U></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Used in Lock-up Agreement </U> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For
purposes of the letter agreement to which this Annex A is attached and of which it is made a part: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&#147;<B>Call Equivalent Position</B>&#148; shall have the meaning set forth in Rule 16a-1(b) under the Exchange Act. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&#147;<B>Exchange Act</B>&#148; shall mean the Securities Exchange Act of 1934, as amended. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&#147;<B>Family Member</B>&#148; shall mean the spouse of the undersigned, an immediate family member of the undersigned or an immediate family member of the undersigned&#146;s spouse, in each case living in the
undersigned&#146;s household or whose principal residence is the undersigned&#146;s household (regardless of whether such spouse or family member may at the time be living elsewhere due to educational activities, health care treatment, military
service, temporary internship or employment or otherwise). &#147;<B>Immediate family member</B>&#148; as used above shall have the meaning set forth in Rule 16a-1(e) under the Exchange Act. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&#147;<B>Lock-up Period</B>&#148; shall mean the period beginning on the date hereof and continuing through the close of trading on the date that is 90 days after the date of the Prospectus (as defined in the
Underwriting Agreement); <I>provided</I>, that if (i)&nbsp;during the last 17 days of the 90-day initial lock-up period, the Company issues an earnings release or discloses material news or a material event relating to the Company occurs or
(ii)&nbsp;prior to the expiration of such period, the Company announces that it will release earnings results during the 16-day period beginning on the last day of such period, then, in each case, the Lock-up Period will be extended until the
expiration of the 18-day period beginning on the date of the issuance of the earnings release or the disclosure of the material news or occurrence of the material event, as applicable, unless Jefferies waives, in writing, such extension. If the
initial lock-up period is extended pursuant to the provisions above, &#147;Lock-up Period&#148; shall mean the period described in the first clause of this paragraph, as so extended. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&#147;<B>Put Equivalent Position</B>&#148; shall have the meaning set forth in Rule 16a-1(h) under the Exchange Act. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&#147;<B>Related Securities</B>&#148; shall mean any options or warrants or other rights to acquire Shares or any securities exchangeable or exercisable for or convertible into Shares, or to acquire other securities or
rights ultimately exchangeable or exercisable for or convertible into Shares. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&#147;<B>Securities Act</B>&#148; shall mean the Securities Act of 1933, as amended. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&#147;<B>Sell or Offer to Sell</B>&#148; shall mean to: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">sell, offer to sell, contract to sell or lend, </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">effect any short sale or establish or increase a Put Equivalent Position or liquidate or decrease any Call Equivalent Position </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">pledge, hypothecate or grant any security interest in, or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="14%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">in any other way transfer or dispose of, </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">in each case whether effected
directly or indirectly. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&#147;<B>Swap</B>&#148; shall mean any swap, hedge or similar arrangement or agreement that transfers, in whole or in part, the economic risk of ownership of Shares or Related Securities, regardless of whether any such
transaction is to be settled in securities, in cash or otherwise. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Capitalized terms not defined in this Annex A shall have the meanings
given to them in the body of this lock-up agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">D-5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit E </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Directors, Officers and Affiliated Entities </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>Signing Lock-up Agreement&nbsp;</U> </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">Robert Finizio </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">Brian Bernick </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">BF Investment Enterprises, Ltd. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">John Milligan </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top">Equity Trust Company DBA Sterling Trust (John C.K. Milligan IRA) </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">6.</TD>
<TD ALIGN="left" VALIGN="top">John C.K. Milligan Revocable Trust dtd 08/10/2009 </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">7.</TD>
<TD ALIGN="left" VALIGN="top">Tommy Thompson </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">8.</TD>
<TD ALIGN="left" VALIGN="top">Thompson Family Investments </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">9.</TD>
<TD ALIGN="left" VALIGN="top">Cooper Collins </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">10.</TD>
<TD ALIGN="left" VALIGN="top">Nicholas Segal </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">11.</TD>
<TD ALIGN="left" VALIGN="top">Fourth Generation Equity Partners </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">12.</TD>
<TD ALIGN="left" VALIGN="top">Seavest Capital Ventures LLC </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">13.</TD>
<TD ALIGN="left" VALIGN="top">Robert LaPenta, Jr. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">14.</TD>
<TD ALIGN="left" VALIGN="top">Jules Musing </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">15.</TD>
<TD ALIGN="left" VALIGN="top">Dan Cartwright </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">16.</TD>
<TD ALIGN="left" VALIGN="top">Mitchell Krassan </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">17.</TD>
<TD ALIGN="left" VALIGN="top">Christian Bloomgren </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">18.</TD>
<TD ALIGN="left" VALIGN="top">Julia Amadio </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">19.</TD>
<TD ALIGN="left" VALIGN="top">Jason Spitz </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">20.</TD>
<TD ALIGN="left" VALIGN="top">Marlan Walker </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">21.</TD>
<TD ALIGN="left" VALIGN="top">Randall S. Stanicky </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">22.</TD>
<TD ALIGN="left" VALIGN="top">Sebastian Mirkin </TD></TR></TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>d693672dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="87%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="12%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ROWSPAN="10"> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g6936721.jpg" ALT="LOGO">
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March&nbsp;20, 2014</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TherapeuticsMD, Inc.</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6800 Broken Sound Parkway NW</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Third Floor</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boca Raton, FL 33487</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman"><B>Re:&nbsp;&nbsp;Registration Statement on Form S-3</B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen:</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As legal counsel to TherapeuticsMD, Inc., a Nevada corporation (the &#147;Company&#148;),
we have assisted in the preparation of the Company&#146;s Registration Statement on Form S-3 (File No.&nbsp;333-193558) (the &#147;Registration Statement&#148;), filed with the Securities and Exchange Commission (the &#147;Commission&#148;) on
January&nbsp;24, 2014 pursuant to the Securities Act of 1933, as amended (the &#147;Securities Act&#148;), and declared effective by the Commission on February&nbsp;3, 2014, the preliminary prospectus supplement dated March&nbsp;18, 2014 (the
&#147;Preliminary Prospectus Supplement&#148;), and the final prospectus supplement dated March&nbsp;20, 2014 (the &#147;Final Prospectus Supplement,&#148; together with the Preliminary Prospectus Supplement, the &#147;Prospectus Supplement&#148;),
filed with the Commission under Rule 424(b) of the Securities Act, relating to the proposed offering (the &#147;Offering&#148;) of up to 10,350,000 shares of the Company&#146;s common stock, par value&nbsp;$0.001 per share (the &#147;Common
Stock&#148;), which includes an option granted to the Underwriters (as defined below) to purchase 1,350,000 shares of the Company&#146;s Common Stock (the &#147;Shares&#148;), all of which are being offered by the Selling Stockholders (as defined
below). The facts, as we understand them, are set forth in the Registration Statement.</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With respect to the opinions set forth below, we have examined originals, certified copies, or copies otherwise identified to our satisfaction as being true
copies, only of the following:</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">A.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Amended and Restated Articles of Incorporation of the Company, as amended and
restated to date;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">B.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Bylaws of the Company, as amended to date;</P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">C.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Registration
Statement;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">D.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Prospectus Supplement;</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">GREENBERG TRAURIG,
LLP&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:'WINGDINGS 2'">&#151;</FONT>&nbsp;&nbsp;ATTORNEYS AT LAW&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:'WINGDINGS 2'">&#151;</FONT>&nbsp;&nbsp;WWW.GTLAW.COM</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">2375 East Camelback Road, Suite 700&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:'WINGDINGS 2'">&#151;</FONT>&nbsp;&nbsp;Phoenix, Arizona 85016&nbsp;&nbsp;<FONT
STYLE="FONT-FAMILY:'WINGDINGS 2'">&#151;</FONT>&nbsp;&nbsp;Tel 602.445.8000&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:'WINGDINGS 2'">&#151;</FONT>&nbsp;&nbsp;Fax 602.445.8100</P></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ROWSPAN="10" ALIGN="right">


<IMG SRC="g6936722.jpg" ALT="LOGO">
</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TherapeuticsMD, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">March&nbsp;20, 2014 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 2 </P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">E.</TD>
<TD ALIGN="left" VALIGN="top">The Underwriting Agreement, dated March&nbsp;20, 2014 (the &#147;Underwriting Agreement&#148;), by and among Jefferies LLC and Stifel, Nicolaus&nbsp;&amp; Company, Incorporated, as representatives of the underwriters
named therein (collectively, the &#147;Underwriters&#148;), the Company, and the selling stockholders named in Schedule A thereto; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">F.</TD>
<TD ALIGN="left" VALIGN="top">The resolutions of the Board of Directors of the Company and the Pricing Committee relating to the approval of the filing of the Registration Statement and transactions in connection therewith, including the Offering;
and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">G.</TD>
<TD ALIGN="left" VALIGN="top">Such other documents, records and other instruments as we have deemed appropriate for purposes of the opinion set forth herein. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In rendering the opinions set forth below, we have assumed the genuineness of all signatures, the legal capacity of natural persons, the authenticity of all
documents submitted to us as originals, the conformity to original documents of all documents submitted to us as duplicates or certified or conformed copies, and the authenticity of originals or such latter documents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based solely upon and subject to the foregoing, and subject to the assumptions, limitations, and qualifications stated herein, we are of the opinion that the
Shares have been duly authorized and are validly issued, fully paid, and nonassessable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We express no opinion as to the applicability or effect of any
laws, orders, or judgments of any state or other jurisdiction other than the federal securities laws of the United States of America and the substantive laws of the state of Nevada, including interpretations of such laws and reported judicial
decisions relating thereto. Further, our opinion is based solely upon existing laws, rules, and regulations, and we undertake no obligation to advise you of any changes that may be brought to our attention after the date hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We understand that this opinion is to be used in connection with the Registration Statement. We hereby consent to the filing of this opinion letter as Exhibit
5.1 to the Company&#146;s Current Report on Form 8-K to be filed on March&nbsp;20, 2014 and to the reference to this firm under the caption &#147;Legal Matters&#148; in the Prospectus Supplement constituting a part of the Registration Statement. In
giving this consent, we do not admit that we are experts within the meaning of Section&nbsp;11 of the Act or within the category of persons whose consent is required by Section&nbsp;7 of the Act. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Very truly yours,</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">/s/ Greenberg Traurig, LLP</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">GREENBERG TRAURIG, LLP </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>4
<FILENAME>d693672dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g693672ex99_1logo.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>FOR IMMEDIATE RELEASE</B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THERAPEUTICSMD ANNOUNCES LAUNCH OF SECONDARY OFFERING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Boca Raton, FL, March&nbsp;18, 2014 &#150; </B>TherapeuticsMD, Inc. (NYSE MKT: TXMD) (the &#147;Company&#148;) today announced the launch of an
underwritten secondary public offering of 9,000,000 shares of its common stock. All shares will be offered by the selling stockholders, including certain members of management of the Company and certain of their affiliates. The Company will not sell
any shares or receive any proceeds from the offering. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. In addition, certain of the selling stockholders intend to grant
the underwriters a 30-day option to purchase up to an additional 1,350,000 shares of common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jefferies LLC and Stifel are acting as joint
book-running managers for the offering, and Cowen&nbsp;and&nbsp;Company, LLC and Mizuho Securities USA Inc. are acting as co-managers for the offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A
shelf registration statement on Form S-3 relating to the public offering of the shares of common stock described above was filed by the Company with the Securities and Exchange Commission (&#147;SEC&#148;) and has been declared effective by the SEC.
A preliminary prospectus supplement related to the offering will be filed with the SEC and will be available on the SEC&#146;s website located at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus relating
to this offering, when available, may be obtained from Jefferies&nbsp;LLC, Attention: Equity Syndicate Prospectus Department, 520&nbsp;Madison Avenue, 12th&nbsp;Floor, New York, NY 10022, by telephone at (877)&nbsp;547-6340, or by e-mail at
Prospectus_Department@Jefferies.com; and from Stifel, Nicolaus&nbsp;&amp; Company, Incorporated, Attention:&nbsp;Syndicate, One Montgomery Street, 36th Floor, San Francisco, CA 94104, by telephone at (415)&nbsp;364-2720, or by e-mail at
syndprospectus@stifel.com. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall
there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About TherapeuticsMD, Inc. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TherapeuticsMD, Inc. is a
women&#146;s healthcare company focused on developing and commercializing products targeted exclusively for women. We are developing advanced hormone therapy pharmaceutical products based on novel technologies that enable delivery of bioidentical
hormones through a variety of dosage forms and administration routes. We also manufacture and distribute branded and generic prescription prenatal vitamins, as well as over-the-counter vitamins and cosmetics, under our vitaMedMD<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and BocaGreenMD<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> brands. More information is available at the following websites: www.therapeuticsmd.com, www.vitamedmd.com,
www.vitamedmdrx.com, and www.bocagreenmd.com. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">vitaMedMD<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, BocaGreenMD<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, and TherapeuticsMD<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> are registered trademarks of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Except for the historical information contained herein, the matters set forth in this press release, including statements regarding the Company&#146;s
expectations with respect to the proposed offering by the selling stockholders are forward-looking statements within the meaning of the &#147;safe harbor&#148; provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking
statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with market conditions, the satisfaction of customary closing conditions related to the offering,
risks and uncertainties associated with Company&#146;s business and finances in general, and other risks detailed in the Company&#146;s annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> filed on March&nbsp;5, 2014 and other filings
with the SEC. These forward-looking statements are based on current information that may change and you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. All
forward-looking statements are qualified in their entirety by this cautionary statement, and the Company undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press
release. </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="33%"></TD>
<TD VALIGN="bottom"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Contacts:</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Daniel A. Cartwright</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Lisa M. Wilson</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Chief Financial Officer</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">In-Site Communications, Inc.</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">TherapeuticsMD, Inc.</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">Healthcare Investor Relations</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(561) 961-1900</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="top">(917) 543-9932</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">### </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>5
<FILENAME>d693672dex992.htm
<DESCRIPTION>EX-99.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.2 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:1pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g693672ex99_1logo.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>FOR IMMEDIATE RELEASE</B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>THERAPEUTICSMD ANNOUNCES PRICING OF SECONDARY OFFERING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Boca Raton, FL, March&nbsp;20, 2014 &#150; </B>TherapeuticsMD, Inc. (NYSE MKT: TXMD) (the &#147;Company&#148;), a women&#146;s health care product company,
announced today the pricing of a previously announced underwritten secondary public offering of 9,000,000 shares of its common stock, offered at a price of $7.10 per share. All shares are offered by the selling stockholders, including certain
members of management of the Company and certain of their and the Company&#146;s affiliates. The Company will not sell any shares or receive any proceeds from the offering. The offering is expected to close on or about March&nbsp;26, 2014, subject
to the satisfaction of customary closing conditions. In addition, certain of the selling stockholders have granted the underwriters a 30-day option to purchase up to an aggregate of 1,350,000 additional shares of common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jefferies LLC and Stifel are acting as joint book-running managers for the offering, and Cowen&nbsp;and&nbsp;Company, LLC and Mizuho Securities USA Inc. are
acting as co-managers for the offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A shelf registration statement on Form S-3 relating to the public offering of the shares of common stock
described above was filed by the Company with the Securities and Exchange Commission (&#147;SEC&#148;) and has been declared effective by the SEC. A preliminary prospectus supplement related to the offering has been filed with the SEC and a final
prospectus supplement related to the offering will be filed with the SEC and will be available on the SEC&#146;s website located at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to this offering,
when available, may be obtained from Jefferies&nbsp;LLC, Attention: Equity Syndicate Prospectus Department, 520&nbsp;Madison Avenue, 12th Floor, New York, NY 10022, by telephone at (877)&nbsp;547-6340, or by e-mail at
Prospectus_Department@Jefferies.com; and from Stifel, Nicolaus&nbsp;&amp; Company, Incorporated, Attention:&nbsp;Syndicate, One Montgomery Street, 36th Floor, San Francisco, CA 94104, by telephone at (415)&nbsp;364-2720, or by e-mail at
syndprospectus@stifel.com. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall
there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About TherapeuticsMD, Inc. </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TherapeuticsMD, Inc. is a
women&#146;s healthcare company focused on developing and commercializing products targeted exclusively for women. We are developing advanced hormone therapy pharmaceutical products based on novel technologies that enable delivery of bioidentical
hormones through a variety of dosage forms and administration routes. We also manufacture and distribute branded and generic prescription prenatal vitamins, as well as over-the-counter vitamins and cosmetics, under our vitaMedMD<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and BocaGreenMD<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> brands. More information is available at the following websites: www.therapeuticsmd.com, www.vitamedmd.com,
www.vitamedmdrx.com, and www.bocagreenmd.com. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">vitaMedMD<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, BocaGreenMD<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, and TherapeuticsMD<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> are registered trademarks of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Except for the historical information contained herein, the matters set forth in this press release, including statements regarding the Company&#146;s
expectations with respect to the closing of the offering by the selling stockholders are forward-looking statements within the meaning of the &#147;safe harbor&#148; provisions of the Private Securities Litigation Reform Act of 1995. These
forward-looking statements are subject to risks and uncertainties </I></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>
that may cause actual results to differ materially, including the risks and uncertainties associated with market conditions, the satisfaction of customary closing conditions related to the
offering, risks and uncertainties associated with Company&#146;s business and finances in general, and other risks detailed in the Company&#146;s annual report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> filed on March&nbsp;5, 2014 and
other filings with the SEC. These forward-looking statements are based on current information that may change and you are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press
release. All forward-looking statements are qualified in their entirety by this cautionary statement, and the Company undertakes no obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of
this press release. </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="44%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Contacts:</B></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Daniel A. Cartwright</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">Lisa M. Wilson</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Chief Financial Officer</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">In-Site Communications, Inc.</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">TherapeuticsMD, Inc.</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">Healthcare Investor Relations</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">(561) 961-1900</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:8pt">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom">(917) 543-9932</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">### </P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g6936721.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g6936721.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`*`#W`P$1``(1`0,1`?_$`*@``0`"`@(#`0``````
M```````("0<*!@L#!`4"`0$``@,!`0$!````````````!08$!P@#`@$)$```
M!@("`0(#!`@%!0`````"`P0%!@<!"``)$Q$2(105TQ87&#$B5)15E;<*06$C
M.'@D)789.1$``@$#!`$"!`,&!0,%`````0(#$00%`"$2!C$B$T%1%`=A<3*1
M0E*S%1:!<B-T-J%C-_"Q8C1$_]H`#`,!``(1`Q$`/P#5S^MO7\8=?YBL^VY_
M0?VX_P"$?LUP1[LO\1_;I];>OXPZ_P`Q6?;<>W'_``C]FGNR_P`1_;I];>OX
MPZ_S%9]MQ[<?\(_9I[LO\1_;I];>OXPZ_P`Q6?;<>W'_``C]FGNR_P`1_;J6
M>@[P[F;UZ6%F.SF,L>V6NP!@&O5B`,`K=B.!`&$1V0B"+&?3.,_#..0?9XXQ
MUK(D**_0S_#_`+3:F^M22'L5@"QI];!\?^ZFNW1YPIKMS3C33C33C33C33C3
M3C33C33C33C33C33C33C33C33C33C33C33C33C33C33C33C33C33C33C33C3
M74H]?>AEB]@-UK*UBDA8ZX@$%C"ZQKRNJ7^T$.J&L6?.<N<D=A&JD!"QR4^P
M9:!&)0G"<,!AIII*5.H/*[D[5V>UZOCQ=S(TUW*XCAB7]<LA\*/-!\S0T\`%
MB`>*^K=9N.RWQ@1EBM(T+RRM^F-%\DG8?D*BOS`#,MB\I5_VX=1K3*S21;?K
M:)2UF";'S8&(RB,0IB=%Q(_`K>(1''5XA92QI\F!&)OF&GQF`]/0P\.<&"J,
M"_=G(+]:7QEFK;B%E=R!\`[`-0_.C?X#QJX3M]KL<_T/"^NF78RK[:BO@\0U
M#M\.0K^)\ZAB\1?J7BVW+(219NWUH:./58CD3DLCL7A<7V(AUFN7U("&OU8)
M$C;XF]MT=$E3C6N!1`"SL*<@($;@OS#L4<W>9L$Q:&PA[$LW$!F=H&C%/6.)
M+@MO12:BF]*T%>D@Z/!FE"RWDN#:*IXJBRJ_J])Y^@@'CZEV(K3YFU&I],.A
MBY-6MG=NHJZ]FB6L=3EE=HK*;'IUHM+,7(ZS7M,P1[,0:TK&M;',"=:I#E7E
M2M1Y*+]<AP//PY2K_L7W+Q^:L\%,N'-Y>B0QD"?B/;7DW(E@1MXH#4_+5RL^
MO_;N^Q%SFH3E!:6ICY@_3\C[C\%XT4CSYJPH-]0OB'_K"_.9UX?D!_.1]ZOS
MHT3^(_YH/PT^B_=O\3(9]&^Z?W"_ZGZM]6]WS'S'^GX/3V_K<L-Q_>7]`RO]
MS_T_V/Z?-P^G]RO+VWKRY[4IXIJOP_V?_7,;_;OUWO\`UT/+WO9I3W8Z4]O?
MYUK^&NR8N:X:YU^JN>W5;DF10ZMJTC;A*Y?(W#WY);FEN+]P\%$%!&H7."P\
M0$Z5*2$9ZI4:624$1@PASR/C["[RE[%C[%#)=S.%51\2?_8#R2=@`2=AKJF^
MO;;'6DE]>-PMHEY,?P^0'DDG8`;DD`;G5!=?;E]T'8@2"U-'Z)UXU)U2=U!Y
MM:6;M]F4R"RK482QX*32E!#HB)8!I8G4`?*1_P!O&G$`7^@X*PA]_-F76`Z!
MU8_1=BN;J]S2C_4CMN(CC;^$LU*D?'U5^:+XUKZWS?=>Q@7>"@M[7$D^EYR>
M;C^(4#;'_)Q_AD:F]@FG,N[74-MNU8;W5;J^]UJ1!G.01O9+7.629O3.4I0/
M+$@20A_K29A&^D.+HVN:E8%846D1%@1#!C)@Q8"&L9Z#I36*WG6YKQ;OW`K0
M3JI(4AB75T]-`0!0EB:UVU8<+-VY;LVN?BM6MN#$30L:5!4*I5O42P)->"J.
M/QKJSSE.U:M.--.--.--.--.--5T=N4KE,%ZS]UY?")+((;+8]0DR<X_*8H\
MN,=D;$Y)R"<D.#,^-"E&YMBXC.?U#B#0&!_PSCEIZ1!#<]ML(+A%D@:X4,K`
M,I&^Q!J"/P.J_P!JEE@Z]=30LR2K'4%201ZAX(W&L_:5N[O(=.-3'^0.CD^/
MKYK11+N]/;RN5.;N\.SE5T66N+HZN2TT]8X.+@L.&<>><,9IIHQ"$+(LYSR.
M[#''%G[Z*)0L2WDP`````D8``#8`#8`;#63U^227`V4LK%I6M(222223&I))
M.Y).Y)\ZDSR'U+Z<::<::<::_(\BP$608P(>`YR'&<^F,B],^W&<_P"&,YXT
M_+SK7`V+W_[P=7ZDLR^K4T%U`:ZHJQK5R*2O+=L.Z/CJ1'R7`E"0K(96]?E:
MM4F95%9R46'W?K9^'PYMC%=8^W>8OXL999.^:\F;BH,(`K0GR5H/'SUK;)=@
M[OB[*2_N;"V$$:@M1P?)`VI-4[GSQ&V]!K(FN^Y'=Y>C-1]G%Z'ZCHJ/MU+6
M\T,E:789=B1(:KG.&9X4R%-'53CE1];1Q-R$I+1&!\GG#@H6/7UQS$RV`^WN
M,EN;+^I7IR,!D3B8?29$J.-0M*%A2M:4WKK)Q6;[GDH;>\^BMQ8SHC\N0KP<
M`@T]ZO@_PDCY5VU?[S66M@:<::<::<::<::BQN58NSE642^3#42BF'8NZTC]
M$D3164CFB."MJUB<Y`A129WR\KCDJ<PYE9S3#@DY/(SGTR9ZF>/PFS6`M,/>
MY)8,Y<M:8\JQ,BJ7((!*B@!\GXT/RVK416:N<G:6#38B`7%Z&`"$@;$[G<J#
M3_,*>=Z4,FVXU:>WH3W%&6WN!R-,:O0%*L+BD*TP@`U2,M;@E/A86F/R(`3<
M%@P9@/N]N/7TQ#N%#$(:I78TI4?`T^'Y:DT+%07%'IN/-#\17XZ]SGSKZUUN
M.HOS,;_M]^T.55]DTJ<R?8NC():*ULSG#JFID*JMOE4ZPPGT/)8G%?)W=,=Z
MY\9A*E0$7ZN1\ZVSW&;[I8>"[H;5+69XP?'NT>M/Q`52/C4#7+6!YP_;3*3V
MM1<M<Q*Q7]7MAEXU_`NS+^51JHS5>C*VV`L%VAMH[/53J>P-T272-)8=P()"
MXQMY=DCLRMQ$/0$QLHQ6![7)'0Y86(W("<$(3<9S[\@#F]YS)WF*M%N+*SFO
M93(%*1E0P!#'D>1`H"`/G4C5%P&+M,O>-;WES':QB,MR?E0D%1Q]*MN:D_+8
M[ZD/O=UYXTJA&MEFL>Q]7;+5UM$RS]_KZ958RR-I9LM=?.$<:UZH9LA&(:TI
M>ND.2RLEX#D`DIF!8^(<YB>L=K/8KB[M);2:TNK-HU=9"I-9`Q'Z?%`O_4:E
M>T]57KL5K<17$=Q!="0JRUI_ILJGRJ_%B/\``ZFYH7_\-^[#_P`AU%_J4T<K
MG9__`"/U[_+=?RCJR=;_`/'F:_S6O\\ZJZT$_P!]NE7_`"TUT_J[$.77M'_&
M<C_L9_Y3:HW6?^1V'^]@_FIK>V_N8'9Q!I;0L,7*E#?5UE[KT3$+G7EG&)TF
M(%@J5OIB1U.`+``-HW9G3J<Y'\,')"\_IQCG-'VBC0]@NKA0#>PX^5HA\>=4
M7;\:$C\B==*?=&1QA;:%B1:2WJ+*?_B$D85/PHRA@?@0#J^J3N*>JZHD+M"8
M*X2=+7%>.SC$:S@2-(!TD*>'QM0I8(+#$&,DH0.#L6W%-[<3ZA*P886'X!YK
M2%#>WR)<RA&FE`:1R:+S;U.Y\T%2S'SYUL&9Q963/;QEUBB)6-`*MQ7TH@\5
M-`JCQXU3Y5_<^^2C9O7G6&X>O;;?6&2[*/TA8J_D5V(HHQ,ZHV+1]1('U22F
M*<!N#D2VE`(*.P0`0BQJBLY^&>7J\Z!'#A[K,V.3LKN&T52ZQ$L1R-!^`KO2
MOR.JA;]U,F6M\3=V-S;RW+,$,@*@\:5(Y*M0*BOYZKKB&K%N=A':'VRT-.MH
MM@:QU&KRRJ6>9I"*FL!?'Y!-92[UMX89#D#XYA>DD4KYJ3IW5R<T"-'@MR7F
M)!&XSDD(@6N?,V/5^FX3)6UG;39R6*4(\B`JBAQS8@4+.?0%).PY?,@UF'%W
MO8>VY:PGNIXL1$T99$-"Q(;@*GD.(]?(%37T_$*5CO>MX:W/&Y<PZ_=FME-F
M:@Z\^OJO*UIJ'594R>Z9'.=FK,)BR!3()->5BU#%'M]-;V/!HBA)SQ(@*S<`
M-2!*$-5G$KC<9ETP$?:,/:6<_:,I*\K22&)4MX^1XK"DK@5.QJ*TW#5].HK)
M97%?UQ^NY>YN8>OX^-45$61S.W&C&4QH1YY5!`&RF/B>6I!==MN5C6_:%6=,
M=:UD[)VOHM<]2V.XWM5%NQV^%$4UQG,):C7.*V!$9)=S`V.;6V3!>!(UF%`4
M*/(H5C`:(>1(@IXOM5A>W73ILAVZ*T@[);SH(9(FAY3HY`9&6)B"5%6\#8`@
M#U5D>M9&SB[1%9=6DN9L%-$WNQNL@6$JK$.#(JFA(5:[FK$,35`L.H?N'ICV
M"VU>UW=I&QVS*2#-ML2Z$:T:A4]'ME&ZIH+6,:4%HVF<2J04;%E*64V!(A^N
M3\C7EJ$YR<P1N!$FIDZ:?GZ_V'J]C;8_IMI:&Y,*O/=2M`97D;RBK*P*H/AZ
M2*$`;ABT'%V'`=@N[B[[7<W/T_NE8;=$F]M4`!#$QH:M\#0@D@DU4JJS@Z[K
MSE08SVOT-1UH[!W=HG5FN3[8>K=SW6RV4Q32L9+(ZTE)LFIE!*["9X]+7(AA
M7@RI;<B"$28I!\P7[,J1"%7.TXV$3X3(Y*&UM^R37:I<11-&R2*LB\92J%E%
M1LWS+4/Z=6#KV2E>UR]GCYKB?!1VSO!)(KJR$H24JP4^20H`%!'R`JQ)]?K1
MZFJNWWZ^-=-B-O[^VLM*U9S`%Q<">4%\S>,H:5BK#('Z-19HA32D7G-[@\I,
MM67%:Y.A2TY<O4"\F,EA#@7YVSNUWUKL]SB\%:V4-E&XY@Q*QE9E5F+GR`:\
M0%(HHU[]>ZE;Y[!Q7^9N+F:[<R<#R`$05V4!!0C]WEO45/CXGCM;W)<L_P"@
M_M8J>]+!>+<ENHLNV>U@:K*DJH]=(IA#J[!&SV!4_.*PP]Q<5J3ZL>G`<I--
M/^4+)`,8Q`R+/M>V%A:_<K"WV.B6""^B@N#&HHJL_*H`&P!H"0*"M3\=8V/O
MKV[Z-E+*]D:6:SF>`2&I9@OMFI)))H6-*GQ0?#4A==>A_6Z[-1=>K4EM_;CE
M[!S:A:FFC3=S9L!*43Q7[@]UZP.S`Q0J*E#^ZC5"X46I)1H$`2,&A1I@A^8"
M//DQ&9;[DY;'YZ[LX+:P_I<=U*AA,*T<*[!F=OU%WH2Q\<C7CK.Q'0\;?8&T
MNI;B[_J#VT;"7F.2<D#!5J/TI7BHKR"@`,/AC6+=I6T.K769V'M-R2E!;>W7
M7S?1^I,2M]R185I[&631Y9V"K;+E211@0')Z8D;HK6*0J,#&N"WD!5Y,/-4&
M#RYNFX;-=OQ;X]#!A,I;?4M$-N'%2TD:D>`WI`I^GD>-``!CQ]KRN'ZMD!?M
M[N5L)_963SR!;@)"#Y*\78`U+!5YU8L3`5HQU0R2EQS6XM]-_I=V"O,6')UF
MTJ&/;KMBN'W`I;Q.2=-"HLVP)+%"*_89`(M,6D&3DP]$5G)9Z;(P>&SR+W>+
M(?3V&-QB=75^(MRUH0\0-*NQ?ES9=Z^*^0V]:TEUTV6Q]^\O[YNQ,A/O^W<^
MF0BM%_T_T`[`D\J?I9=J2)VUV6W>M;J5ZAK2?'^9U7ME8>Z-10TQ_<0/D-,F
MKF0;:$;KV:32-H1-)CK&YPG;6E[7(5!/R;A@T1F"?$8`.(O!XCKMEW?.V<:Q
MSX2+'R/04;@#[;2*C&M"A+("#5:4K4'4CFLKGKSJ.%NF:2#+27ZK5MBU!*$9
M@!0APJL=J$FH%"-2XW`TUL7JVT%W:V<UPV!VENW;"TXA731;=VV7-!2]^C4>
M.L%$"S;-K:)-S8G##EZ%CD2U0'(#U@VE*04:2:7A+DS,#@<]:=R[-C\/EK6S
MM\)"[F.*->(9@A]M'8D\JD#:@#DD$'E34_F\/=]6Z]>Y/&W%S/EI%0/(Y!(!
M<<V7B`R[&G(NQ0>H,""35YNIK#UU0"B]5'/0';NW;KV:OZZJ;A*Z'0?;*<RV
M=;)Q&<+BB+(/L6)Q^4&.]<N04ZGR#5A(;/IZ@8TYI0S,^XJXX#+]JN<C>Q]G
ML8;?#VUO*P9[=52!E_1[;,*2#\*M4#D"!YJV8Q_6X+*UDZ[>//EIID!5)0SS
M`@U]Q1O'5J*:A15N)!)J-C7N*B33`>FS;:"L`G`3%"]<VF),HG9R6/+J)ICC
MA$V=N$YN[B:>X.KAE&C!YE)Y@SCS/48Q9$+.>:IZ).]UWVRN9:>[)=,QH`!5
M@Q-`-@*G8#8>-;)[?`EMTZXMHJ^W'#&HJ23170"I.Y-!N3N=1*V=GDVK'^VD
MCD[KJ92JOIG'M']25#',80_ND7E3(:I44P@5GL[\RJD;HW'J&]6<2,1)H!"*
M-$#/ZHLXS.XFVMKO[NR6]W&DMNV1NN2NH9303$54@@[@'<>1J#O9[BV^U\$U
MH[1W`LK3BRDJ15H1Y!!%02#0^"=9NZ_-%+Z<%M,;U;1[J[&V)=,TI1,L!2+;
M,3&?7&MVNQ8"C2,C&W001:DU_D<(9G`(C716?D2Y[\JTP`S?:9R.[1V3&(+C
MKF&Q]I%CX[@CW2M9Y"CU8E]N*N1LH&R>D$#;6?UO`Y!UM\[EKZYDOG@!]L-2
M)`Z'B.-35E5A4UH6`8@G<T@[G+="M6X+:LUI+NYVZGO8M6J1>_QE>/8>36LP
M3BQF0_)RF`R2+1.(.%;(6-Y/`:D&D5+\)T0LX"?DPH`R1[#Z^O9<U=0VV0Z]
M8Q=7EHK#V5C9$(V=2SAR1L:A:GX4-#JD9Q\#AK22ZM<W>R9N,EE;F75W!W3D
MJ$4K4`&0@&@:H!!L8W-VRNJ>49T%7.SSN6UT_;+[2ZH.%OM\!D;S$FF7HYS#
MFEVE<8>T#,N2E.L1<G-2:+Z<J\R?QYP$01>GKRJX#!X^URG9L<\:2Q6=G<B(
MNH8KP9@K`D&C``>H4-=3^:S-]=8KK^061XI;JYMC($8J&Y^WR!`(JIJ?2:BA
MU.'OML.?U5U6;,SJKYQ+JXF[+FJ?HTQ@LB=HI*&GY^XX"W+OIK\QJT+FA^=;
MU9I!OC-#Y"31`%ZA%G&:Y]L[6UO>YVEM>1I+;L):JZAE-(G(JI!!H0"/QU8?
MN#<W%IU6XGM9'CF#PT96*L*S1@T(((J"0=_!U7EV!3O<>1[P=15%ZR[`3:I9
M!L-K=9K),)"4\/+LP-B1?!V04NM9VA0W1,PS*>0F(C<ES":Y!,\+SX#/>#./
M=BT]7ML#%U[.Y'+VL<\5K=(56BAB0YXQAZ$JCMQ5POE*BAU6^PW&:ES6&L<7
M</#+<6Y#&K$4*'FQ4$!F5.3*3^\`00=]?3[)M?)]UI=2=Y?A9M_MQ8MC2K8.
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MF+@C,K-Q'"CD;AE^=31E&M;+KB[`E&C\RLJ.SVN45ZZL;'0_-;;+40Z*@I"I
ME%!%KTZ%_CJP[.$[?-(R2[J\)1F9`6>0I-*R809DA4GV_P!MZL.QP0S6LIML
MU:2>Y;S`5XMM56'Q1J"OY`T(JIU!U+M/]O3RP748GQ%RG":([<EWH0?@RU/$
M_B1L3R$JU^E_37;;N;-Z=[7G37JOUZ@Q>JJ'9#7&</\`:<'1&FX,RRHI-&'1
MKCLW,1@'DLD:?YDS.`XR,XX7J8*#3L7?[",6V0PBW5T!02P7"+&Y^95P62OD
MUI^0U/2==Z-D9#=6&6:VMR:F.6!V=:[TY(>#4K3T^/QUC[M&V7U-L.IM&=3=
M0YG8ULP'2BOK,AKA=,^B!<$)L9QL"01M[^9CL:/\#TF0MYS(?D0U:5+ZA/+`
M#!OL&</+Z5A\Y:7N2S>=CB@N<A+&PB1N?`1JR^IAZ234>"?!.U:#"[OF,+>6
MMAB<+))-!91R@R,O$,9&5O2I/(`4/ZM]QYI4^+4/9:CJVZH.TW7B;3Y$PW+L
M`\ZX*J?@YS5(%2R:D0><MKM*3$CFWM"MB;<-#<0,T6%RI+DS`?0O`Q>F.,_A
M\E=]WPV5MXBUA;+<>Z]5'#G&0NQ(8U.VP/XZ_<%E\=:]*RF-GDXWLYM^"\6/
M+A+R;<`J*#?<BOPU"[03_?;I5_RTUT_J[$.6/M'_`!G(_P"QG_E-JL]9_P"1
MV'^]@_FIKM1=R-2ZIW@USLC6FY$:HV'6$UE$@=6S)`'Z)R)L4E.<:F$=4*"C
MB2'J.O"8I07@81%'@",DT(R33`"XJP.;O>NY6++V!'OQ'P?TLIV96_!AM\QL
M1N!KLK-8BUSF-DQMY7VI!L1Y5ANK#\0?\"*@[$C50%53;N>Z\8FVT?/-78[V
M;T[`D:>.UA>=/VNQ5A=8H@W%%)(\U69!I^4M$]N[4W%`($I29.%[08\JQ6/U
M.S>[VWZ!VF=LC;7CXB_E/*2&6,R1<SNQC=*!03O0D?@J^-4ZSF[KUR)<?-:I
MD[*/TI*DG!PH`XAU(9F/PV4T%*NYWUQMCK'L8W_["-*MJKRT^CNDE%Z6N]G/
MJ!KG=QL=CVK8ZFQ8NE8E*%.RPM'E$U92*6],,O*HM&6`K)^<G'C\9>/62\ZI
MUCJ^0PN-OWR.1R"Q@E(C'''[;$^6.]03X)/C8;G7A'9]D[#V2RR^0LUL;*Q+
MT#2!V?F%\4`/E0*%5IN>1V&IDZ*ZW7E478)VQ7#8D''':LV,L>@)#3$G&\QY
MPQ-$,.KY_8I,I*;FMV6N[.!L7JB2L@7ITHS,B]Q>!!QG.('LF6QU]U?"6%K)
MSO;2*=95HPX%G4KN0`:@'])/XZF\#C;^T[)EKVYCXV=PT)C:JGEQ$G+8$D4Y
M#R!YU@V^]<-U]+MY+7WWT-JZ/;.5OM#'H8W[8:H.,V;JZF9\PKU!EHCEJ5/)
MWW`F`US$S",+4HU&##!'*%.0DG8/+&BD<9ENO=@ZY!UGLLS6=W9NYMKD(73B
MYJT<BC>E:4.PH%W'$AL#(8S.83/3=@P$2W5O=*HG@+<&Y+L'1CML*G8$U9_2
MW(%)LZC;0;D[#6"]EW-H-*-0*=98:I4H9/:%MP>7SV76`8[LY")@:81"\&"9
MHXD91KU![@L-SYC0$EE@#[A^E>SF'P&+M%-ADTOL@T@!6.)E14H:L7;RQ/$!
M1XW)U/8G*9O(7;+>V!M+`1D\FD#,SU%%"<5(%.1+'Y"GG5;==U-OYU$63=<2
MUIUAQO5H?<MJR6YX)#8-849K^\]=Y;.S2U$IA^&V89PW3*$B5)B_D\IA"$``
M`FF#3FF'`,MEW?=8[S:6\^7O/Z;V2WA6)V=&>&=4_2U5W5]R37YT`(`(K5M9
M]@ZA=30XRV%]@II2ZJ'"20DBA%*$E0`J@!36G(LI+`V"PJPMP=KM7-LD]SZ?
MJ=6GB5UE/(11=:/UJ1"?V!,LO]:O[<:Z2]5'1)(S#C%\D7$)4:,T[R%@",P\
MS`<ASBL3VN"PF:L6L+X7D:3(\T@C9$3C(IHH-6:B@DD?@!J?2?-9?$7J7EG]
M,[PND2%PS,2C"I/I"U-*`@$;UVWU]3J-H^TM;.N'5.CKKBID(M.NX"YL\RBI
MSFS/)K,Y*)I*'4E,-SC[@ZLRO(T#@29[DZ@T&/?Z>OKC.,>7=\A9Y7M5YD,>
M_N6<LBE6H14!%!V8`^0?(UD=5L[G'X&"TO%*7"<ZJ2#3E([#P2/!!\ZKFIOK
MRV87==O;?K0_PQHKZTML=I]NYK3XI5)6<YCDD0LH,5%`Y&X.L54R8;*A>`M9
MI?B4%`5I\A]3208SZYMN1[3B!VC!Y:*1I;.RL;9)>*FJLG/FH#!:D5!V-#\#
MJK8SKN47`9?'R1B.ZNKZ:2/DPHRM[?$U4M2O$C>A^8&OL57M;VR4QKU6NL$=
MZB)6XW=5]80NHHY9CAL74"O79:*%QIMB#9/7EZ3.R)]"WG$M@%A[2#):C/J(
ML*H/K@6/.]PO2<AE9LQ+G$&.FF>5HQ!()QS8N8P*$5WH'I3X\=?=CD^W6&)A
MQ46))OH8TB5C,IC(0!!(3L/`Y%.8/PY:Y'4?2\L>>N/9_6C:"S$DIV8W<G;_
M`'_>EQ1U*8J:XU>K@ZMDDAQD8)4`;3W2.01Z9D^3`Y`DRNP>L"7@@HTH)?E?
M?<!8^UV>7PT)3$8^(00Q'8M"`5?EYHSJ33SQHI-2#7TL^DL_6[K&920/D[V0
MS2.-U66H90/%5#"K#;ER<"@(IX:OVX[A-<84QT+=O6*][56+!FI%$8]L-1M_
M5Q'ZTME`SIRFMGE<K334DI\A#NXIDX#7$2@D&3#Q#,PF("+V87F$Z)EKALGC
M\NME:RL6:"6%V>(G<JO$T<#]T"M!MR.OVTRW<<9;BPO,8;JXB4*LJ2JJRT%`
M353Q/S+<:G?BOC7/NR/7G;7;"H.M!Q;Z@:16O6NZNLM\[#PN*S./*6*KV..-
MKRIL'+;(I"YLP)<WQ!Q<<)<&(L&J%WM\I).0Y],8_4LK@\)?9A&G;Z&;'7$,
M#LC<I"Q'"JJ#Q+`5WH!X)U]=JQF9S-GB72`?5PW\,TRJRTC`5N="2.04FFU2
M?(&LR=R]\ME3:4S&LVUTM1/<NV3@EUCUZ9:3"U8LB26S8Y)Y#.V-JMZ,);6E
MA.2)3BG=6(99I:`X8$XP*3"1AC^@8U[[L,=XXA^@L@;B<RUX+&GDD#<L/*CQ
M45(*@C4EW;(+9X-[53+]9=D0Q+'3DSOX%3X4_I8U!HW%2&(U2?K:*YNEB(PF
MR]QNHG7DN!0R/QZ+S#>'3HZ,2ZU8$UN!:)D<9#;#(_&.4J6+EIJO!;LY-RYK
M;5)QH@%>[!@"A;!R_P#3_N!/+:8'.77U,C,RVESR6-R*L!&0`H`IZ58.P&Y\
M$ZI.+^OZ7%#/F<1"T,:A3<P\6D2M%]0+.2S5]1!C0G8$U`U>SVB1.3;1=6^R
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MM>$1/B:5*@[!C76MXK;,GKS]8L\.8\FR%7F8!8V%22WN<:,[`>`Q"DCB2`!J
M3UM:F[H7;U1=:$FKK7]XAFVO7I/J5LDO7.T76/M;M81-"-:J%N:1"K(=QMZ(
M^6!:$SJ@2K#TJDQ&,96/0X1'DB++.8#']VR\=W<K)A,K%*GOQ@D1^^>0KM4\
M:E20".5#XK3/N\)FKWJ&+-M`RY7&R1M[3T!D$(H"-Q3D55@#0\:@;TKPWLFV
M`[#NR71^TM:ZAZH=FZF<WI/"WJTGRZET090@(BTTCS^7$:8:_J"-SLU[='Q`
MF$)=XD29,V$J3!E^_(/9[]2QG5NI=BAR]]FK2=%YB,1!F_4C+RE.XC`!.U22
MQ&_S_.S7W8>SX1\79XNXB8O&9#)Z0.+JW^G507%0"2!7B#Z=ZB;EG:[WRX]G
M?3W;S35,J<JRI'7"[(=<4U(+0X9:ZD$DJ7#*SMDA,$MPH`K7NP/ERPDEFAR9
MGXYQCX\KUGE<:G4,]8O,@N[FZB:)=ZN%E!)7;X#?\M3-UC,@W9<+>)$QMK>!
MED;X(3"Z[_XD#\R/QIECO=HJX=C>NJ?U;15>2&T;$<K)I5V;XA%RDAKNK;8_
M93`[/2PD"Y6B3Y);FU*8<9ZF8S@`<^GKS"^VN2L,3VN*]R4JPVBQ2@LW@%D(
M'BODZR_N!CKW*=9EL["-I;DLI"CR:&O_`*_Z[:ASWT.4JOV+ZP]<=#M$AM+9
M:T9;%[N=M?4;:SI8%+Z8K(Q4G?#;LL5QD,775K"37PL84ZEM6`6+%2,9.!E9
M\8\SWVT2#&37G:\FR0XB&-HA.2>:RR4H(D"L)'H14,*`$'?<:A?N`TV0AM>N
M8]6FRDCI(8@!Q*+7>1BZ%!4-0@[\2*@\3J.E$6/3^JD:L_22V^FN.Z6[&[;5
M+:5(5::C?BYGKKN#/GB#O3:PT.OV00O`Y?$6JR7=<E;O":[GEI?G0G&JTYN"
MS.2F2L[[-2P]@L,\V0Q-C/'-)Z>$UL@8%IA!QXL8P"U>`)XT"L*C6#8WEKBX
MY<-?8CZ/)W4+Q1GD72<D$)%[Q;DON,0`%E8*6!9U-#K1,^26_L2S]U/^SYTS
MS3YC]NN8^#_+3Y);^Q+/W4_[/CFGS'[=.#_+3Y);^Q+/W4_[/CFGS'[=.#_+
M3Y);^Q+/W4_[/CFGS'[=.#_+4M-!4:P.]FE8A)%00AVSUUR(0DQX0AQBW8CG
M.<YR#&,8QC].>0?:&7^VLCN/_HS_`!_[3:G.M(P[%8$C_P#;!_-37;M\X3UV
M[IQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIIQIJ`G8AH\#>*HX@P1JR72D
M[PI2SXO>FN]SL[<4\**]MF%_-?1UKDS'')PO$=<DZLQ.M3X,`+TR`T/OR5@L
M=GZKV,]<OI)98EN,=<0M#/$33G&_D`_!A38_F-JU%>['@AG;-(XY6@OH)1+%
M(-^+KX)'Q'QI\&"M0TH:[+<TR[H=S*S7:R[4;0:65AK_`#(A/';CEFMM=6:Y
M7/9L+)5)CW)G2$V!\I#XCF3%)L`5#2>+QX&(/C,($,@=JLL_]OL#=C+X6SR$
MV4CJ8UG>,11L00#Z*LW&NU:_F#0BMW&&[SF(6QV6NK&+',0&:%7,K*#6A#@+
MO3?CQ%?@5)75[=<0&.557D#J^')ST<1K>&1>!19(I4"5J4T<A[(ACS(G4*AX
MP-2>2VMQ01F9QC(Q8SG/Z>:VN[J:]NI;VX(,\TC.Q\>IB6.WYG5]M+:*RM8[
M.`$011JBCSZ5`4;_`)#7,^8^LC3C33C33C33C33C33C350^\^D6RDGV<IW?_
M`$4GU91C:&IJZ?:7E-?7BA>U%1753;X\'23[L.[K&"S9#%WYH?E!IZ94G!G!
MV1EX$83@C'EO/7.Q8F'#S]8[)%,^&GE$JO"1[L4H`7D`WI8$``@^-]C7:G9[
M!9*7*1=AP,D29:*/VV64'VY(ZD\21N*%B=J5/'U+QWBO86KW<%M].*EL_9K\
MG%41[425'['T;0M/OT_DXKGV?@<<?1TZEM6P9(@+%$*U)DJT!+B-MR-3\@I/
M#@D1N2E">:M,ST7!6T]GA_KYI;Y/8FFE"+[5N[+[OMHOZI.()7D*<@IK2JM$
F7>'[AFKF&ZRILXX;-Q/#''R)>=`2G,DFB<J`D,/26%*D,O\`_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g6936722.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g6936722.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@"WP!=`P$1``(1`0,1`?_$`'<```$%`0$!`0$`````
M```````$!08'"`,"`0D*`0$`````````````````````$``!!0`!`P,#!`("
M`@$#!0$$`0(#!08'`!$2$Q0(%;5W(2(6.#$C,A=1)$$S-!AA@4)2)281`0``
M``````````````````#_V@`,`P$``A$#$0`_`/[=OB>YS_C+P*][G/>[BC$*
MY[W*YSE6@"[JYSE57*O_`)7H*/Y<YAUU3R7NTIB-B#C*/$:7C9+<041,.%R(
M9@;??!7K[E"_>#ZNOLX*JF&B]!T*2&O:K_/]J!"N=>73YXL39XGDRNFC#X6U
MNAE+I^:1<B.[9U!&(<.8P"O#N:SDK0!1GR*R@+6"$OUO3<]B3(Y`-GR_R%=G
M\L14>BW>-J-PP/-<6:XNJ"'SM+=839Y+,6-AD)7D$26-EHW7%T8<*3!&UPU0
MC&JYJ*J@_LY'Y9TT6LNJ>_GS>D!YGIN`M-FK"6:2CRUALL/QI0V>@S@TP\R%
MEY':DNO*=ZJD5C7GR,D<B3M=&&_@1$`!#!0@HM`Q1Q$*.G<4<2@\+(4(,*?^
M\DJ9&>4DB_J]ZJJ_YZ!5T!T!T!T!T!T&>_B;_6/@3\3X?[`%T%\OKP)8I8)`
MA)()YE(GA>-"^*8A7(]9Y8W,5DDRO:B^2HKNZ=^_0,L.,QXWM?;Y3-#^Q*4X
M'T:*KB]F:[TO(L7P%;[<IWH,[R,[/7P;^OZ)T#RZNKWQ0P/`#?"/(LT$+A8'
M102JKU66&-6*R.15D=^YJ(O[E_\`/0>U#$<Y[E%&5TI$1<CE@B5TA4#8F0$O
M56]WD0L@8C'K^YJ,:B+^B=`IZ`Z`Z`Z`Z`Z`Z#/?Q-_K'P)^)\/]@"Z!CY!^
M0O\`$.2-#@P8\R7]&XQT.AC0NX8R\?O0<]>;2HH9:.*=IKJ";(9HLHDIC.['
MNB8B]W+T$!__`"<WUG'D@\]AJLVXL^&_YGK(X8[VZDS.VAV63R]W5!T50UUS
MH*O*5YUM9D"#I]2,A&'C@\73>702FNY6Y7T)?$JYRVX>/J-QHM+F;FPAJMF5
M)Z^5$TUV6<"'+>59>>,*J:)@TU381RE5=@^1LDL[6(C@K.O^4F_*X^#VQ)>&
M#==7.(K8HI^*>:!@<O%JC+!"922R9XDY#<*.&D+%HU2-95]=R^@YO<'NH^1'
M+-[0%ZRIJ>.B:+*<;'<GWON`]A62[W,A:[<58MIAI326SY@;0YC&H<$VT%+=
MZI3&/=Z7^Y0<=C\J+*MDYH#R%7D]!9X3^*)B*Q]RZ2QT,DNJS>/W8^@K@B'&
MTDU/>:2$<+NQOKO=Y+W:BIT%R<<<N3\A<B\EYP(`%,CD:7CJQS=]#-.\V^GU
M@5^5>>YA=_Z\(M4170C1>'=RS,G1R_M:B!>/0'0'0'09[^)O]8^!/Q/A_L`7
M02:^X+XVTOUZ6WHU(LM'>R:&RO6DRQ:!#)::#.2#B7,:M/#JW9^!`E%C>V!1
MG/8K?WN[@UR_'7B][K":&MM@#+`ZQMOJ-;H+@&P`N;'^$R+<59D!;9J\\,OC
MZLG@6-49',R5WBJ3S(\)-G^)LCG&YQPC+8P[-7]]JH+>UMS+"VL])IJRPJ+N
MXO"Y7HMD48#9RL1KFI%"U&-B8QL;&M".9C@/(Y:.G$'O=];56<L*6RS=)H=E
M:W%1GB,^I*53*@0AW_K#C#E.A]-7.:Z%&L7]$3H$1_QNXXL+4BP677`A6"G1
MW.:JM?=UN6OJ^RT5KJS*2YIA"(H3:&>_O3IG!^38'-,FB<U87K'T#J[@'BY4
MIGLS_H&4MF3;)9CDRCVML8;I0-B8N@L(E83>0DZ6K'+=&0Y[/5A;V1$3MT$B
MP?%6+XV];^(UT]>TBL%J)6RGF&HH0=_JM-`WN7+*[U&6NS.7S[^7I.9'_P`(
MF(@6+T!T!T!T&>_B;_6/@3\3X?[`%T$^MN3L_5;9_':#7%CK/X18[L6NKA('
M1G@`%N"CIQ#2RPPOY%9RQR.&&EDC1\4,DCGL8Q7=!&N/^<:7D`VKKX\EN<H5
M=/V;:F/6UU(+[[^`6E?2:AT:TVAO$B:!<6#1T]7P65\;U8BL1'N!+I/D5QKD
MX>1BKDJWA#XKO\3G]<9#4S$CP3;L^KJZZQ!=$]SK"HJSK-8[&=B?^HX0E'-5
M8510\7_/M-37(M+7X;D362E[,O`1F9BMS<P#-.'1-T[PI);?54TWHRT"2%,F
M;&Z%S(7IY(_P:X)]F>1<WK=-NLG3RER6O'EE65=\LXKH0Y9[6N:?#+5$J]S;
M`6"5LPDSVHB1&BS1+^L:]!.N@.@.@.@.@.@SW\3?ZQ\"?B?#_8`N@XD\%GD\
MGNY93;7,6BBW-5=AT["C_P"(,R`&6DQD]`3GE+46>XGI[.QG8?\`M6,PI'>"
ML8B*"1.(]_G9\)98G18Y]IE#^8%.;JJ6[G`.K.5-J-KT:$VHN`B!K"G0-D'E
M(Z2*7R<[Q;^B($5$^+IPIU=;2[ZQMS;:U#N.2`+[WUKG+LF'EFBY;(@S%(0:
MHV:!?:B6(K8?]S5&L5\_)6=G!)\%\?B\.)1UK=:ZW`SG-=SR74N-!D]]#EB<
M/<XC/8V<E2WJ43G*VP'A::]/*>`1OFSU'*[H%_&?!9W'>L@V*[>ZO[*ZIM0-
MO`[4P\FG/NM%J?YI'892LF+D@S(5??6-IXCIZJ/A.[*[RC15#1/0'0'0'0'0
M'09[^)O]8^!/Q/A_L`707D3<U`1$HIEK6B%0UI-S,,2<+`1%4!O9&7:RPRRL
MDCK19)&MDG5$B8YR(YR*J=`@MM=E*$(JRO-/GJ6N!%`.-/MKJMK@@PK2>46L
M,**,)A@'%L28'QP2/<C)GL<UBJJ*G0,\_*'&@MH/1D\AX8>Z,'&+$IY];016
MA0AHB'AE#U\E@TN<<L%4FB>UBMDB7S:JM_7H)%!H*$KP]M=U!'J6/TAGH60<
MOG;>T^H?3&>G,[RL?8?[_13_`&>C^_Q\?UZ!WZ`Z`Z`Z`Z`Z`Z#/?Q-_K'P)
M^)\/]@"Z"G^2^->7M=R7L-I6T](E%85-KPS7#DH3'K)L1H,/:@%7#26VBTK<
MJG)5_!8$Q/@4YPU4CV]_V,Z!!9Y[6Z=(]B7QKR7GTSM-P_G@_8P8LG;TNCQ`
MO*;K;3T^4MI[_/[//5\VX&!?#+XN)BG(*#[O&A=(#\/QGJSZ#+$V''=)5W<'
MQWYKRY(E14T=9$!H]!9X9V1K&!P'GP4]E9UE9-(X88J<,&9)88YEC1BO"&XO
MAKDC+[O%WHN9GCH;_FF32<A"3'A(ZEESO%MK09?>!BH4]DL5L.1]$/9'WG58
M`)/#PCE<H?H/T!T!T!T!T!T!T&>_B;_6/@3\3X?[`%T&A.@.@.@.@.@.@.@.
M@.@.@.@SW\3?ZQ\"?B?#_8`N@S-R%R-R#G^=MPF9ORCC:[:,H*')LY+?83'1
M3?'FLTE;0C\%OKTB(K"]B0PN>\A,:5#Y2*C%CCD105VNK<.&%5X;G6TTM)I,
MAB]#KKS1<@6`XXVE-V-$-74D>\J0;,OB.?E:LGM!6L@AA%"FKXF00C+(]S@>
MJ$NVT5IQ!HJ37\KGDRY7F:=<T=R*414Z&_XIT%4#G@3I,X6S/["J]V3,(EDQ
M/_\`<#]*<GRD>J($)N=;L)L_A1.*^;;ZYUG(5'Q_:[>SLKR#1BXS:'\L<4UM
M7+-2*Q[<37:,N^MZ8ZBC:/%('#*R.!DXLDBAJSX[[ZSY&H]_>VJ68I(G*6DH
M'T5L]7E90NCJ\^#=99%\&-=!2Z)AD;'M3PF;_M8JL>U>@T%T!T!T!T!T!T&>
M_B;_`%CX$_$^'^P!=!>#:2E;:/O&U%6V[DB0>2X;7B):20(UK$A?8)%[MT2,
M8U/%7]NR(G;].@Y-SF>8+9@LH:9H5U,01<AMJP6BVQ!:(A4]F.D"0GS$HB)(
MZ5'N>B?JJ]`N@`!%8)$,$(/&!![4".`:&%@0OA''[81D;&M&@\(6)X,\6]FH
MG;]$Z!,/24HDALPM15C2V1L=E8RC@"0R'V,3F/B/-?'$UQ1L3XVJV5ZND:K4
M5%_3H%\4$$'JK##%"L\KIYEBC9'ZT[T:U\TO@B>I*Y&(BN7NJHB=!UZ`Z`Z`
MZ`Z`Z#/?Q-_K'P)^)\/]@"Z!6;N^1S=-M)LN!BW8OCN_#S%Z)>26\&GN3)<O
M3::TN*FR@GCJ*L.F@THC(A)QB)+%T,Z).,CHE<%1UGRQEMXLH4)G2H1CLAQA
MH],ZXRNUSD@Y&SN_I]W#FTT=?4MO0@0XI'C3CJ1$^3P\GJUR=PE5AR[RAF>,
M+'D74!<7PLT>9S%CQV*ES84@=7J]O9`U&=RVUL;<V06QJX"KT)Y5P*X!B,9.
MB#,1(WN!HL_D=:V-+'L,M8\;T6/IL1Q]K[^TW)-S*'<6&_0^<3,U-Q0D>USD
M%>-52-FMB(;&%")FM]OX12/4)=3<N;,ZVS.C+`RJ\9;;D6_XWHQ`V6R[2N(J
M2])55FFLK"4MU,>%=VV5F:\"(2&4(<J*12)G,ECZ#2G0'0'0'0'0'09[^)O]
M8^!/Q/A_L`702V\X9Q6AU$^JL&WJ3G3UQUQ2":*V#RU]<4H\8E'?7><@)96V
M-U30#PM@G>SOW&'5Z/<-`L8=G<.X-[LR]]84]<C3Y.BI$=9G.9#68JPCLZ"`
MABSJTQ8"XD61TB.6=O[7^2+VZ!@J/CQQE4E5Y+P+B\CI2`US]=I]#;Z.IS]7
M6B68M7FZBMMBBA!\[6+:OEA&<U_C-",Y7+[49(@YV7QVXVL8)PXH=)25I\5L
M!=U6:U=[GJW14%U>76B+R]V)4F"QE9V*ST1ZCP-]-18#)H(7,@D?&H2"NX;Q
M55K&:T1EVDHUI97]9G9=!;38VETMS`6+<:6FRLA*U%?=64%B2DDC(_%KRIY&
M-9)/,]X6IT!T!T!T!T!T&>_B;_6/@3\3X?[`%T$A*YLSX6Z,Q)>>V4`X&GI,
M45MUJ`I<1#KM%24U[2T$U@/:S6XY-A!H`X(YI06!J80R'UO-S44%5!S3BM*1
M$-526DKYN2[[BF-TH'I1OTN>H[G1%$L>Z;_90EU5'-(*6WNPCNSQ3L[N@/#^
M3,S'FMSJY''QU/'IVGKK]7"?^RXK)1++9LKATE535F[>(Z(K73/5&HB*J=!$
MG\\Y-\V5CK*79W\>FRU!M22*.A8:F3S&F/\`I=5:Z@13HK.)KK".>.>(*`Z<
M1!9GSLCC9YJ%W=`=`=`=`=`=`=!GOXF_UCX$_$^'^P!=`V:+B/D:UU6REK=9
MD*W%Z?<Y7DN,>6@MR]4W3XG.8P//5A!WUF&H90-U&&".(<P9291_4'16J])F
M!"ZWXS:W`$YH_C;?1VA%#-E+*43E-^@TH9-UG,ENL7*6)-76@!=8&;4;;R0>
M-58R4./_`"U7)T#U)PIR?;AZC(7FPR8.%V6Z@W5T3E`=-5;B*=]O3:*QJ*NV
MEN)@0A9[2J6*.=(EF:(_LJ*_NY0:#OC1J6BT='6;*C+J*"ZM"\[IM%361G*&
M&%L=65JY;#*;BOM*^P(NBUL90B(35DKYH1A7OB<C9X2`V1T!T!T!T!T!T!T&
M>_B;_6/@3\3X?[`%T%O+M<<FAER*ZW,IK(!U+GS"WU5_(814&::I,M+[KZE&
M.@;TE\UB1OI*CN_BO?H$E#R'Q_JI'Q9?<X[22QSPBOCH=-2W$C"B("RH!GLK
MS2'-GG%KYY&,7]SHX)'(BHQRH#\3=TP<Y`Q=O6"DB#@E%#DGBP3C"V9<P%:2
M1%+*V2$>P.'DA@>Y$;+,QS&JKD5$#Q%?4<TSAX;FIEG:<75N@BL0Y)FV5>/[
ML^N=&R97H<$)_MFA[>I''^YR(GZ]`QV?(O'U*REEN-WC:F/20,)SLEGIZ0!E
M\-+Z'ID4KRCHFVD$GNHO%\'J-7U&]E_<G<.XV\PQNBGR`>SRA>L%6=I.7&T5
M1/HAW#1MF);/21&/LHE'A<CWHZ)/!JHJ]DZ"5]`=`=`=`=!GOXF_UCX$_$^'
M^P!=!5&SQ^ANMUR%1`<8W4UM=\O8/?4')\H%#!05&<SV"XX!O%'OWVC;U]G9
M)F[&E0*(=5>AB^:H.Z5Z!!^.*W:Y')\1D66%YHO2N/-'CR+VE.X_XQI3Z\:+
MB3D7(DMS'\3DHW:,`&[M1XIY39YYXXI&/8KO*3N#O?<;<M;+7[G?DY:L#IN3
MJ;7X46G+:7#O:"DJ<T,;QI9Z#RLYZ"&O!WN1E,@A'12!Y-*Y7KV23Q"/A<3\
MR0K?G!92.LN=UQ[-K5(()&47,<X<\V5/D^1G&("8A+XN.\G5>ZFD@<J21/<P
M=SWKX]`W6'Q]YB/KC<>,)24`V*X[Y(R-*E+14-GC]?FM#IJ#49_!9\C;,N[;
M),&H32:2`WTW.#E!;,Y)8V,8\+;X-H-%GN2=)'8T'*-+5VFEU]M5"6V+X[_A
MPM79Q#%U4I6W&B+W\UNX9B1R1RF/C4M7QJBQM8O0;2Z`Z`Z`Z`Z#/?Q-_K'P
M)^)\/]@"Z#0G0'0'0'0'0'0'0'0'0'0'09[^)O\`6/@3\3X?[`%T%*;76R5O
M)?(9-9R?H(>0:SES"9;,\90[20FLL<5:\=<<G:GMQS(5*/$,#77%O;K:1CQR
MPD"^?K>#'L<%8X;5<BFX+B>SQ>X9;;:QU6%M[2N'Y_M^8EV@M?Q+R/K;?(Z.
MNOJH`?CW^9$TZP-B'65D9OI2>?81$<$PQ/*>KUH&/!K-5J9H_D+9$RX@\R>6
M"USU5B.6MI/R.R&,B-)J8P?BME?`V)>SH3(U[?N[]!7F6T^SON,\9)5ZD_1:
MS7Z;C`:T!H?E=JK:]MX;(/1V-F+9-;3,=P\XHD9BRPA>Y]1T:AN<UL:.4-O?
M'.RN[3BJIFT=D<;>#W6OK[$"XM2+Z^RLH&KN!8L5H;XL8,N^N\@-&P`@Z2)J
MFN@]9KI&/9+(%Y=`=`=`=`=`=!GOXF_UCX$_$^'^P!=!>:5%2EA);)5UR6LT
M/MYK-`ADL)1_%K?0D-]+W+X?%B)XJY6]D3]/TZ!/7YW/U+WR55%35DDCV2R/
MKZP(-[Y(VS,9(]PT$:N>QA$B(J_JB/<G_P`KW!P:&(QT3F"C,<.Z=T#FP1-=
M"XIRN)=$J-18W$.<JO5.WFJ_KWZ!O"SF>K9I2*ZAI@")GMDFG"JP19I9&.>]
MCY98((WR/8^1RHJJJHKE7_Y7H'6.&&%9%ABBB6:5TTRQQM8LLSD:UTLGBB><
MKFL1%<O=51$Z#IT!T!T!T!T!T&>_B;_6/@3\3X?[`%T$+T//NCS^_P"7JV7^
M/S9SBH`HUN=CQV[=H=`V#C;.["%W_8S2%X[I7DW6A:.@TL4A+1XE>K%5S5Z!
MDY#YVY1XP/K<GKI^-`[ZW*SUC#JZ[+<@W^:KZ"RK-K+;@DY.GM"-4=:U5ME8
M(82XIV0$CFK-)`/Z$C5![QW*_,>ON.&9(F<;U^:Y(H=1?FK/G=G]5-J<?<5@
MR7F=>9?UR@UN]H+@:RK(C@UG`BF:PA)W=^P6F7RO%24?.>DT$(0E3Q!<V`D<
MC2%@]^`!QSD-IYF3%2)!"7.?HI!V]E;'X-C[_JKEZ"L<M\A;R_S#K5]=DB+.
MLX;Y$V5[]!MI+FC9O.-]"N7N*BJM!298C<U/9C3/AE1RS/@6-WE^O01.U^1'
M*-%F=!R`=48$S),M-[EJ*L$'T8^AK]!E\5?::FL+@N2S+!NJ>TL,[(.1"-`'
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M9J<@1$L$CU8.-/04@\+XX_%KE:KO^3E50AN?X2QF?L0+KW&IOKVKM`+("]U.
MKN]#;C15%/I*.HIV&6)<KUI*T#6V'@.[NDDY+IYEDF7U.@?:+B_'YPN@+J`2
M1G9=VR3/P>_+D#JA]W9BV]\"(*^588Z_W@<:"P=O3#B:D4*,C1&H$:M>"L7=
M:6[T5B;KIX-+=4NAT&2=JK5<-<V]#!GAP"[#*.E=5D(Z'+`MFC5OI3I"J2-<
MCWHX$MY\>>-+J4V5@5Q0,M"+9;87*7UGF@;2KT-;GZO1YPP*IG'&_C]_#F`Y
M"H(VQJXALDS'LDFF<\$Y/QRXW--T9)W\J-#T:ZJ5^?(V%^[,4IVTICL_H;;.
M9]AK*VFMBZ>S*@C(C9Z@S29?16-9'*H2+/\`#V;HBP3R[C9ZXRL;<Q`$;G66
MNJ>,+?@!5ML"U+.21D@)@X$:NB>CF^?=W^7+W"*!?&GC>O+BG&)V[08&4ZP9
M]VZTK\Y$?G*,+.9NY6G<?[4BXSM36","GF21T$HD$R)ZT+)&@LM/CGQB<RD^
MEA7.-*SP5.!5V.%O;#*6,4-!!9"54DY55+"XPL4.Y,A]:9'R.B+E:JJCUZ!X
MR_#5#D=+-IZG2\ANF,*DL+&G/W%U89NTLYZ@:F)M+"C)F>&0>3"(R:2143R*
M3U>WDJKT%N]!GOXF_P!8^!/Q/A_L`703ZPY3RM9/=0&2'1NH=WF>.[%_MF>G
M'?:NNS5I62L>Z9J.JXQ-4*L\Z]DB5)/T7P[J$-K/D-C+!]=[BFVE(/H79^;&
M&WE#&"+N*C1ZO/XX*_S:M/GF6M'M-572$1FL#.B#+CG]NL;N_0*;GGK*5-T=
MGQZ+:Z&TJ#M!!=C9RBBL9:BLRT.7FOM%/`^P&)-J`?Y@"Q(PHRCYGO>D0TB,
M<J`@D^0M"+<[2FL<-R56/Q,]:$4:31TTX=Y:Z$\6MR5-FHZ[1G6-G9Z\@V/V
M+'#Q-\7=YW0=E[!V"^1."ET-%C[473YC7WI&P!9FM#3QP6%;:XNDI-,?4V<X
M!MC5-+M,[?P&UKX"9QCH4>D<JO8K.@MW-7X&KSE!J:KU_I>DI*J_K?=1>@3[
M"X!@L0_<0^3_`$9_;DM\V]U\7=T[KT#WT!T!T!T!T&>_B;_6/@3\3X?[`%T#
M/J?C/E=9J=-LK('-3:6^Y+Q6P&T4U#&_0UN:S6;QV=LLN/<)*AD:V@^?+\)&
M.:R-IJHK'=E5P,I'`O(5L!FQKS:Y.8GBNHJ*SBLL/-6L333*+2XK1!W/(`[[
MWM/,9#@@PIQZYT$;6D%3L=Y.AB@!OTOQVW.EJIW%Z/!NT>BT&GTMT?)FK=K\
M1H+^&CKZK4\67P5L%J:B]R]30Q1>,I+![.94ED2%&)&H63H.&[.T-VEP%I1X
M+JXN>+]/F##ZR0V&OO\`C%@\@KKX8<P'ZG7WDXZQDL@<-(R"9_IN;(C'($#N
M/C??[,S1Z;7ZRI"VFHI='#[_`"U4;$'D-$K..&\?7.7=9'S%S29`GC_W)#R%
M:MA,;(SQB@_U=!HW!9V?'X;%Y(HN$\G+Y/.YT@X>!PHYL])3AUDQ<`KY)GC0
MD2#*]L:O>K&JB*J]N_02SH#H#H#H#H,]_$W^L?`GXGP_V`+H+[A-#(D,B@+&
MGEKIVC6$4,\4L@)+QAS6CF,8]SAIW!EQ3(QZ-<L4C'=O%R*H1XS=8FN%HCK#
M8Y4$+4RCP9DPS0U`HNCF+8R06&B(G+9#;RDQR-=&T=9%>CD5._=.@>Y[6K&<
M>PFR`'?5`QV=HV<P>)U;6RH6L5@>V21JA@R(!/XRR>,:^A)V7]CNP14#D_C6
MUGN!:OD/#61.>$,/OQP-90&3T8%?+Z!YMQ"/8225@@,_[)I)D8R)_P"CE1>@
M=:_99"WJ@;VJU6;LZ2T.AK*RYK[RL-JK&R(*]C!7@V`Q4HA9TYO^ED,;W2.E
M_8B*[].@[0:K+E7YN4%TE"3J:X6,ZPS4%Q7S7X`4R1+$8;3QD.L1194G8K9'
MQM8[S;V7]4Z!^Z`Z`Z`Z`Z#/?Q-_K'P)^)\/]@"Z"#ZA>11+#Y!XS*875)=\
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MS$4+0PE!KX^80KE..;_/5=I<Z38:>+4B8VWI*`K2Y9L?US#[6NG'V`VDM[%H
MX-G2%--"A:A+XGQQ0B/F#8W0'0'0'0'09[^)O]8^!/Q/A_L`70:$Z`Z`Z`Z`
MZ`Z`Z`Z`Z`Z`Z#/?Q-_K'P)^)\/]@"Z""[+E(JH&^1]*+N10=12;+.PTU>EE
M6E:3*8<SC[B@S6:6DST[IRW"YVOMK6V:]1Y8$GCD>Y'(CF]!5ESLM;0\BT%7
MQ#R'HN0<1FM"'I2A"-)+NI-8^'CK:V6ZXNATIDYY5M.M$)77-<QY$KPK<J!G
MDT:1(F!$,)R>;?5]9LAN7M)8;Z<K@=<#BB-M+$)N*39I127,!?'A<_IV$=O4
MVI<I!ZBH2`D*S>K&@SNP*M)L]//B<Y-BN:]2G(V_S<B\FQ+>I;_]9:2;68\!
MUF-E9DD&PRY76VCZ%M:R$:,\:61DS)IHEF:&D>#>0^0]UIM[]4K0H:Z@W9V3
MV@1UB:PW':F@XXXT]:GR@+A)(++-6^@+L#XB'S,\QB89FH[U51H:EZ`Z`Z`Z
M`Z`Z#/?Q-_K'P)^)\/\`8`N@O#Z'2+9K=K3U:W*Q^BMO]/$^IK$L?HK$I_H^
M[]/T?V>/GV\?T_QT'L&GJ*R`<:MJZZO&$?/(*."",)`-(2KW$R#Q#Q1QPO(=
M(Y7JU$5ZN7OW[KT'.*AHX3HK.&FJ8K*`?VD%A%7!QG0B]G)[:(ML*3QC]G*G
M@CD;V5?TZ#W'35$4QY,556Q$6D@\UG/&"*R:QF$1$%E/E;$CRY!D1/3=(KE9
MV_3MT"YD,4;I7QQ1QOGD26=[&-:Z:5L<<*22N:B+)(D,36(J]U\6HG^$3H.G
M0'0'0'0'0'09[^)O]8^!/Q/A_L`70.-]RS94M5S&<RF".*X_V><Q>:#]U,)%
M<V6KS7'9E,ZX+5A'L1_Y'NTBGEBC?Z8D7FC'/144*ZU7,'+..GL\Q;@8R2[I
M"<Y:W6[J<KNKW(5&,T]1L9:RQM,7265CK1"4U&,GK)IVF2B#0SPF2N:USH&A
M(^4>?HN...N/-G,[&3&;`BD-.B?JQ%SZ9D2DEUN[L<S?2*#%?RA9NO(2J\6M
M]\5*.G@B2*B!`[GY5V.;M]S7WF5"CARG(-_6TTHQDKWZ[CV@PF@OCKBM61[8
MXM#7:JA0`N)?*"$<P2=?T(:B`GUO/_(V+?/G;FUXB(V?UG`BF`9VDY#U!N/%
MU\%N28/;XJE*(TVFB&8&,T.R!?!&2Z=ZRB#MB_>$\$YIT\6-Y9NC!:.QLN..
M):_D`$F&AU65$N;(ZEVUM[8W,Z29^FI0HW9J%GHS*A79[U7MW9V"&S\Y<G#X
MT'1,DRA0\]\6)<Z\GAWF[.YW(UPF=;9BMNLO;2NV!`US:2-@^MPHE771]UF1
M\G9BAKF@LG7-%2V[_8>=K4UUD_Z58QW%7Y'!PDN^FVT,<,-H!WE_TDL8UL\?
M9Z(B.[=`[=`=`=!GOXF_UCX$_$^'^P!=!)+3A+'W6@UMY9&ZP@3<Q*W4Y/\`
ME-M#CK0G^/5>99:?0H)HX@[<>KI1/2*@?%-#..R9CFR-1W0-W_X_X[VB_P#^
MWO\`^1K:QVR[W^;W?\[66*LFI(@ET'K>:T\=.1)`@7I^V1SW3^'NE6=0DB\.
M\<2#YD`G+@'U6/R9N*SM/:-6UJZZBL4IV&,8)8J4R4^:&B'C4MZN)]-KD\_]
MC_(([%\=N*&#Y<<G/S6B8^[N[^FFM[,^Q(0S29(G$7XY\Q,[W6=9;YTI8B!I
M_.&21D<JM]2-CD!KE^->#F8US[SDEUB'+4)17LG(>DFO<N!1R%2UM/GK*<N6
M4&N8ILB3>223E-5J3R2(QGB"DOX\9`^8Z8[3<EE_6<HN-TT4^]NG0:VE]I?@
MQII8D>UMD;`)I"61SKXR-1(_U_UM[`I=P-02@BCD[;EDNPKS2"ZS2D<C7[M/
M60G!1`6=4%<,E9.RHM1X&+..Y'M6:-DS?&:..1H6]24U7G*:ISU(''7TU%6@
MT]2!"KW1!5M:+$&")&Z5\DKF#C0M8BN<YRHGZJJ_KT#GT!T!T&>_B;_6/@3\
M3X?[`%T#AIOD-Q]DDY82W;H$DX<-Q8&IA&J?7E-GWPE45GOXZQ"6_5F2.MF1
M3+_K]&6.1%_:WR4/('/=.95WNEGPW(E7C*`L\<K:6%9G'4)`]3JEREM:BPU^
MI/OTJJN>*8TB68&%8Z\>696_M1B@/^0^#='*\`;1W#ID;_'HJJM&)?LW$:\K
M$5O\4>^PB@L![B["E<*1*^`5X,:F.E:+_MZ#R=S_`$((S9'8GDLBP#K+6[UE
M"-FA'W.%I*:S+J"[;20/N(Q2A9RZ\A0FU,UG-90CRRAQSQL5W02+5\O4&:6E
MCKZ?3[HN\H#-<,#A*X2Y*AR%>T)Q6FF:58UL4@"K8PL'A@?,<;(_Q&@F<UZ-
M",V/R"I1[:IJJC"<CZOZSK#\0+84%5G&@1Z*MJ"-`2&5]>U5&:.UM`',8CU@
M\?2B<U>TO:-0=:[GSC<Y/*>TFIHA*PRPT,]]#%5#Y`D343XUM#J)R"/2K=`;
MH@#8!QFK(LR5Y$C7>FUKGA<D<C)6,EB>R2.1C9(Y(W(]DC'HCF/8]JJUS'-7
MNBI^BIT'OH#H#H,]_$W^L?`GXGP_V`+H(ER!\:"=OIMC?LUL%</KR;<HVL=4
M2$,FE_Z^R>3R#BYD/B65<I>4IMDSQ:GJ*:UG[5C\W`U9;XWZ3.B[BE'FXIIA
M=P1HQ+?:YC%V5?R999S5[:?07E?:W9%N2$18$T)Q`D9"1HD!2QDM8OII&H.4
M'QPNJ?Z*[.Z^M'=QY74M5Q7%9TQIP]139;3'VV9SVB5EM"1:UP&8M9J%9HY(
MB5&9$2KG3M=YA(#N+>7I9K"\$Y%RJ:G:9R7([@@[(&$5%53QVM_8YV;"ACW0
M9,962'TYH[&6,I#;%TC)IG1*STG`\W7%.GIR,I8<3Z2ESI]!@&<6SNUE,9H8
M%S`[J^6FN`F`V=2O\BSI`3W1LF\Q3&D/;(C/%CD#M2\/&U5E2V$^D;8/JN7K
M_DZ>6<!(RK"*[X_N\4H$SH)8AHSO<6R%R3,C;$[Q5C8F(J*@2W,\<56?T/*-
MV\6I*;R7K*C3ECMJH(W-6JQ>4R[(;![O4;8S*7G9"FR*UOBI'^/)'.<%D=`=
M`=`=!GOXF_UCX$_$^'^P!=!=!.GS8;;EY>AHQ69UXL>@<3;`0-HI#H("@F7+
MI2&I5O+&*BDB2?P62.1KF]T<BJ'=E[222@P1W%5)/9S6(U;"RP$=+8$5#I66
MT`,;9E>7-5O@>A#(T<Z!6.1Z-[+T"!=ED$!`M%U6;2LM4.6KL5O*Q`;)*P<L
MNR4`OW7MS$KQ`)Y9_3<[THX9'.[(QRH$DZ`Z`Z`Z`Z`Z`Z`Z#/?Q-_K'P)^)
M\/\`8`N@SOS#PQR+I-+SG#1Y24_.<L6-:=;S-*K(_J#N*^.L,?A&L@G,BDF^
MO[)2@'>2)XMKOW]HU8YP*H^->:8M1FM4!FZR&OXGU>CMZL"S1TFEO(-YS%K[
MS=28T@*ZAJ19+3C<P,95L&.]1\CV-1BHJJ%53_'SEC^#9G+KB"9!,#F-HF6%
M893*_P"L<P<0;Q-F.D2V",'=3[5(`&*J^+OJZJQ5C21S0_59J=FM1?\`*-1%
M_P#V3H/O0'0'0'0'0'0'09[^)O\`6/@3\3X?[`%T&A.@.@.@.@.@.@.@.@.@
M.@.@SW\3?ZQ\"?B?#_8`N@S/S+R7R'0:'Y$9FGV%^!)>VF??@B1241<4'QUQ
MQ@]KR='3/6)S067%->0.5%5?_9+D>W]7=!9'&_-H-!<<G3\B[T9(*?/'7E-3
MW5X#"<3!4<L_(<`]*&N)FB)-F;39D`7QA:]?`6%G^43H*DS_`"AS9&_`UUB1
MO`]IF=UH-UJ<5JZL,&ZW>`ON.[36V&2&`&*.9,#27KKNOSLC9&O0BB#9+V:L
MB*&D.`=GRAL<5QE?R#9[0871Y^OMG[0^_LDUMA7V%,:?"?)2OJ&C>X?;*/"C
M'3HJ#.<]>SV^'0:?Z`Z`Z`Z`Z`Z`Z#/?Q-_K'P)^)\/]@"Z"^9``95D=*$)*
MZ;U/5=(-"]9?5AB'E]17,57^K!`QCN_?R8QJ+^B(G0-Q67S1Q,!AN=HC"Q4>
M@Q152`02.DDTA$B03RCOEA1\\SWKXJG=[U5?U55Z!T<((XEACA1W%QL].,IT
M,:DLC_V?ZV3JWU6L_P!S_P!$7M^Y?_*]![A@A&B9`/#%!!$WQCAAC9%%&U/\
M-9&Q&L8U/_")T'7H#H#H#H#H#H#H,]_$W^L?`GXGP_V`+H(=H_D5>Y[D/=X8
MK.U$,=/ML!0XBTF)+\-36753A"]V/.Q',:/H<D1MAI6,:[TY@BHI/%?2G[!$
M<I\E-K+B*'>:5<R?67(PJF"!\:<I<>NI["TXYU6OI@A+'=FD":V*POJ,>M:0
M`WTNY+7=^\D?07=PIRAHN2H+/Z]35=09FZ;*U>F@K9"Y8P^3%;<LY`H8'E2.
M<M91DC"-&\D]96S.615_;V"IL_\`('<Z7E$C&QIG*6JKKMU=+$WC7D_8F6T$
M?)G(N-=Y:O-G,RN+E=58J%Z2VC5B;/.^14]%OCT$1PGR=Y1V=):&5-1F-2=!
MCLAISUSO'G*(*\>RZ?1U0$HUQ2VQDMER8P?-D6-D/_'Y(GFMI9F,1$GA>@2:
MJ^0FVO-=F,X%<810S:*FLS[:DXPY?VX]R38;_99*>!CZ,H5G&)(X.7B4@6_]
M20`V>6*225@LCU"X^-.2-EM-3ILS=9@2C7CKW.?W!R,L$&L=F44/89YF1>3X
MLGH#,+,-;SOD662+ZL*/Y>K"3V"\^@.@.@.@SW\3?ZQ\"?B?#_8`N@F6AX9X
M\U)J6%[2/--9OZGDV`A3SXI!=C39H#(!V(JPD1^C"_.UT8TPZ?Z)F^2O8KE[
M]!'JSX]X,'-1X\X[;:;-"GXFQK*G6;707X]+/Q];"7.:93N,+=*"/"4#"R>-
MKO`J!B12H]BJBA*HN)L0/1;O.BUI0E=R/H+K5ZE1;2Q@,(T5\P-IUL`<PE"J
MHILE?#)"H[HTAEC1[$1>_<(O6<`8VCN*^\I+OD.H.%AKX[+V&]T4(VIF`N[K
M1..UPRENAO["RM]$=*7+,BN(]PYKOVHU$!Q.X+X\.K:&M0&U`3,Y6MQ]'855
M];UML!4T=E4W.>D;9B%QES6.=M::*<(B1SY('23M3O&3.R0&D/X]8NKL0K>F
MO>1J2R@AACM3*GD#2!RZN6._M],\W7>!BLOS2+>_,>]\R?\`TR'1-1L2-8T+
M;J\]54UCI+4"&2(W66HMU=R/GFE:18!T-/FX)8HY'N8,QM31#,5D:-:KF*Y4
M\G.50>^@.@.@.@SW\3?ZQ\"?B?#_`&`+H'\SG?``Z+;92>>U2\P&BPN;T`;:
MU_=".10*X_-6($CI&1GU$B6/HSS,7O!/#(QS>Z-\@:J/Y`4=I54M[;8GD+&T
MFD"FL<]:ZFMSD8EN'!C[K=/F@2CU-Z0-_P#\Y0SRHTED#U=XL[=^_B#I3<Z8
MW09.TV-0'I3:RFX_S7(]B+%3*ML/2Z82X/@KOION?6DT=6)1SN,";WEB7P8W
MS>]&]!P+YYR:E/`S-/JM\>ZP)`KA<57UMBVYCK:.EO[VUJK"PN*JIFIL^-H@
M("B)"(F*<4P6'U2.\:`S"_)3%GV`<=?GMT;FR3,56E;N&DKV92GM=^VL;G*N
MX:1=0:80UYMR**2U*U[0R9D9,YGC(K`GF$Y5S'(\G;+1VI8\6>SM^=82A,BK
MJV33@0VU;G#2D(>Q-3'4$1%$AQ^HX2&:)9G,66)'A970'0'0'0'09[^)O]8^
M!/Q/A_L`70,.W^.<VLUTFR#U3*6U?RE2[.9T58Z=+''A9/#4ECB;+_VX_627
M0842V%)3LHL\:-1BMDF\P@F;^*ML#QQ!Q^4O%F4>!:<<E,T'&^1M:@[0!Y=9
MJ?6,U$=A;D-+-U&-L3P8Y8W)[>0^1[DD3]JAH/BOC#_K9_(+WV<5JFSW][K`
M&1A>S;1T=DD#JW+L;ZTS9QZB52',>B,:J3JB,3MT$`HN$=+Q]GN/(N-[K)`:
M+!UFWSJPW6?.?E;;/[O0A:2QB]C4V85A76%?:U`<\4L<KFRHR:-[4]9LD012
MG^)--1V@FMALJJRW]'I<7I*+5V=%YJZ6EKXA-:%:5GO917B:><VS(%2/L^J(
M*AEA>Z09CG!9/"?"<?"0`5#G;`%N9ERE&/?4PX)`\9?(-5#$':;D&20TA8)=
M<&B+8PR>:OG&AE:Y'.F\POOH#H#H#H#H,]_$W^L?`GXGP_V`+H+F+U.8`O*[
M,G:.A"TEO#(14YXNWKQKRT'A]3U9ZZIF(8>;#%Z+_)T4;FM\%[K^B]`WTO(&
M#TC[6/.[;(W[Z)CI;ME+I*:T?31L=,Q\EJT$V=:]C'#R(JS>"(K'?_U7L#I_
M),[Z:R_7J7TFTS-&Z3ZH#Z;<](CUCOE?Z_BE-(D;E:5W]!?%>SOTZ!%/M\8+
M<%9XG79@>_!K9+DVCGOZJ*X#J(8$)FM2JR0MIH];$,OJ.G>Q(FL_<KNWZ]`9
MS;XO8"F&Y'79C4A5[VQ'EYR_JKL4&1\7KLC,(K"RHAGNA_>B/5JJW]?\=`D;
MR-QZ_/SZUF[QK\J*4H).F;J*1V?&.;)'"H<]RARUT)22RM:L;I$?Y.1.W=4Z
M!Z9H:"2%Y#+RG>/'!6DR3LL@G0L&N51M00^5)E8V"U5409ZKXSK_`,%=T#=8
M;C%5%:RZM=AEJRGD0ET=M8:"I"K7H&;%6F*PXDN(5R"V,[().S_V3/:QW9RH
MG0>:K>8:]KBKBDV>4N*D+TO>VE5HJBPKA/7E?!![HT0R88?UIXG,9YN3R>U4
M3]47H)7T!T&>_B;_`%CX$_$^'^P!=!7^XQND*TO(F?'X_L[BZY#Y`X[UF1Y/
M'@I'5.4J<N)B('_5K4@^"XICL2;FSS`QHH9$-><WT%628KTPIJKX1YBHL[35
ML07U>QV7%$?'%:I-%E*2LXI&T.IS9'(=1MGYB.MN=75GY4%OL#/=$$PD!3L_
M24Q)N@:]%P?S.RCU!5;DAB-CA^&[_B/."4Q<(.9W6#O=1M$(QM(MI8REC05F
M-N*:>O\`>N18[.ECC5_IR2*H3'=X3DN0&[Q-)QNZVM"M)S9H[K6%YK.V-?I:
MG=4FQCS=U3;0G3`6^?UU54W(V?0)P1#Y&-6-4:"C9N@L/.Y78:3@;DC&0!\A
MIH;"@CK@A.2,MQU@9K7O401D9\!^`#`K9*VT8/()*29Y/B4E>[UC3]`]&B%F
MZ/-<F!<!Z"JRV;O9TM<O]+S4>TO#I\;-GZK:ICQK):^9,9Y.J!U]U(9(*9+-
M"SV\,:R!7]/QSR!2BZ',+QW=#0<J6?']M0,`?1$4/&U+1\OZC7$Y/4%0VJ1U
MCLCC[07T6",)&F>BC".>L:=P383A/D'-V-;5$Y%2,39\=<\W;Q32:XI^7Y'W
M.@H93<[[&4B6-:[92!,N171^4<)SCDD5GJ1)T%K"\+S2'_'"=]$37!4F4IZK
ME&I!4`:JL7XZB%T>(%TXD:JARYGD6!2A%@[]B))$>KHI'(H:ZZ`Z#/?Q-_K'
MP)^)\/\`8`N@T)T!T!T!T!T!T!T!T!T!T!T&>_B;_6/@3\3X?[`%T%7[[6F"
M;/>EOY`NJ?D7,;WCFEXNXW'TD@%9I\Q=#8Y\B.Q3)(A]C#KK6VN12CY829*Y
M@2K#(,X.1ZA0^+W7(&<'RU[K-?H\I3WU1Q;?R6^MY;M=C6<@`VO.O&U5>WU7
M'>@`5G'$6=H+&>"WKX271R!WT#?%T8[I6A=.\YKM9.60[3(V.BL^*:&CCQ=W
MILVZIL.-G:KD"ILK`$^TOQK59DNJ"V@RXP3X(98HV7I*/>U7?H%'U')FQ(3C
MG"<H<FZFEBK<KPA+K-DW3EX1NJSFR)U-C1[&72`D57L[*Y&`966SXIHUDL:Z
M9OZ1RQHX)R)N4/K=)'KN:M3G\UE<KM;#A/6CZ_Z45R(E1N]I5#Z,BQ&6&+DX
MW/UM13"C"3(6/9P&-)E@)<8R3H-\Y$RYL<IF+#1!I7Z`[/4IEZ`C%C0&Y)K1
MI[,-(W.<Z-!C7O9XJJJGCV[]!(>@.@.@.@.@SW\3?ZQ\"?B?#_8`N@OB2NKY
MC1K*8$.6Q#CFA#/D%@>:)$0B(1$,4YBSP1SHB(]K7(CNWZ]^@YDU-48.T,NL
MKRA&1K$P4D(:<=D3O'RB;!+&Z)L;O!O=J)V7LG_CH`>HJA!/IXM97C`>2/\`
M9#A#0B>;58YKO;1Q-A\D=&U47Q[HK4_\)T'DNFJ#X/;'55::,L<,*CE@BDP+
M".[S@B]*:)\?IPO7NQO;LU?U3MT'N:JJR6@M(K0)VU<T)-8V8,>5M<0.Q8QY
MP4?&Y!)H&+XL?'XN:GZ(J=`OZ`Z`Z`Z`Z`Z#/?Q-_K'P)^)\/]@"Z"#VWR"T
M-3S7H,.^7($9K-:BMI[>FCI-<FOK,M/QK3[FVY#L=3&01C@Z2E)LGQR#S#PO
M?##XMF]=\4<@.G"WR$.Y4+R`4H>7;/<"<D$7RYVX;=BUDN=DX[N<B**<*40,
M\@W'<C"26+'*KH3FOC;XHU4Z"-\<?);4[6?@:L-SE`+;<AW.Y#Y`C#GL%AS5
M=2YRZO\`'DTS9I7222ZH:$29/<.<U($(\4[M:J!5\?R[Y%D;!"HF.C(N[A@H
M!*\;<NRIG1&;R?)RPI4QD(;RQ/,&U)5)S<B0!2,[D,2.>%5"X"/DJN<TG'>=
MT9>7.2\QMSHM87%7W>&O?>E0Z8O##YGC[8G/U;(;2/"VL!C"FODBG4545K)N
M@7KS/R/E(>-[[D.DS)&7Y+L:MHK,!3;;2:C.QV>+U^I6CEH*J&^L=1.&^G":
MZV$@''5CY_,.%K8Y5!=2<R[+=Y_CEN-`SU3I.1+#DTB([5U.A6II,SQUHC:7
MUS,TIU#H9;ZS]:OC<)*0&HSY9WO_`%A2!X-1W-7)U=5:+9V%%AA<OQ[HL]B=
MO1#$W5I?G7U@-G(]#<YF^;*#6Q4]%:ZF%HXA`#R+"`:5RRC/?&SH&/7_`"8U
M^7&XC/AQ]7<#[/&87:ZX0*6P6RK:FY',L=C-G84D>A\V?I0)BAAY$60KT5B[
M^;VJ@.`?*_-.OT-%!A"N(74&H9S1/0NMJ?6GSEC\5;F')ULBW-;JA`7#:P2Q
M&)2=@KFC)Y*C)D<U$!='\CM#_!B^3Y>-;C^*_P`JK\*#1QQ%_P`O34>TL\_:
MQ%CNA6!0%YF]GDQYF,2)'I,>^11%8Y`EWQ-_K'P)^)\/]@"Z"S++CO,6M9O*
M@L<Q0.2B7$Z^**Q-A6P?+G:7*$1PR13->#`50T`\$C(58CT1RK^Y[E4(3;_'
M_C^QTL.MJUTF*O(H$&?/@-+9XX8J!4%;-$8!2RC@D(9&`,V971^4K184<JI&
MWL"[.<$\:Y2TJ[JCI2!;*G_C*!$/MK,A6_Q'*:'%4GJ1SE212K!GM07%)W3_
M`'O<R23R?&QS0B2_%SC7PC1+'D-LU>?)89DMO(NK0G%2$7"7IL&,=]06//C6
M)T<:$-A;WEABCB<OIM1O02@7@?CR(0V&Q#M=+96%GG[8K3:FX-OM8XK+$5Y5
M'''H3WR6,`8<U:Q5@C>V&1))4>UR2R>0?,UP-Q_E;BGO0(]";89LABY9]WJ+
MNYCRU5!4W=*+F:&$\R:,+-B@:`EK!NSNZ^DKW.]O`D8+[+AG&6%%448[M!1+
MGKN^T%#=YW16E/I*BQU!UJ?H?:70TZ%^TMY+HADP[U?`K'-[-1T43F`UC?'[
MC4$^L(KP;D&JK7T)3\D-I+QN.M[7+CAC9Z]T&>D-D"N[RLBKAE]P1YO(D&AE
M(]:6&)[`^YS@+CS,GUMB'%H3BJ(NJDSKKO3W5PS.5E$'=@TV;I6'%RH)FZV#
M1%(P5?)'*YGFYZ0PI&#[C.'\!Q_!F!,G3OJ@\=#N!LX&P\Z<:M%Y#T0^ITHL
M41!$J/&EMA8U'8[R02%J11>,:>/0.O\`UWEOXU_$O9D_1/Y/_,/0]^9ZWUW^
M<_\`8WN/=>M[CT?Y5_N]+R]/T_\`5V]/]O05G\3?ZQ\"?B?#_8`N@6:;Y!Y7
M):'14MQF]RRMS%A]%L]D/35Y&330OQ8N['H(BH[GZNM@72G0LC>\)@JE2MA6
M9'.3N#IH^=<-EY6PV7UE[G9ZJTR*)7L(;]-N:#D'2!HJ^Y9V)^F\:67FS_\`
MC(L+>Z^IW:$@TG*&5RD6"FMI#FMY&T-/F\\T<-T[V&W@DI89-FUKT4"LC5C(
MI2'=V1S3Q,7]7IT%=6'R5Q]3_))K7+\@UU;12;P6MNB*&O=4[.SXX+LP]-39
M0J"[F?+;,?2EO&A/8`I40TKXU<V-ZM"?9KDR"^MJR@LLAL\7=W`.DLZ^LUH=
M)$1/6Y:;+C6)OJ4-_?B1Q2$:P=D*.D21ZQR]VM1J*X()3?)3&6IM>&3G=W01
MWME%796PO:2O@KM8U=S3<>DGTDX%U8/:%7WVA"=-[M@L_M2&RLC>B.1H2$_G
M;"UT^P')6Y]3$U6TM[?TZY)4F@PDF>AMQZQ&$*XXXJ?3B1AQ(B.(D<K4[*B(
MH69G;ZOU-!2:6I?))5W]57W->Z:/TIO9V0L18Z3PJJK"0V.5$D8J]V/16K^J
M=`\]`=`=!GOXF_UCX$_$^'^P!=`GO/CIE[^ZY;UA\`!.OWZ6+,U>%,LITR+#
MN+:7CEDC*Q]E]+F.@4`F9"8H82?0*6+S[?JH0>Q^)5#`A,&(_BN(".R^?ICP
MJ3,1`P&VU-A^9<?+=$Q@SBLFF*_[0'?^Y%>D8#F*Y5D:K`4WOQ]WG(]<!!R/
MO0Z<S+XVQS603BU=%GP&6=A-2E?6])'96AI%S"*5F0'1A^;8OV2=W?O_`$!L
MT'QUY&V68T..T^PPKZ!YW*^CSD%?F+Q)R]5R@_7><^ME*OY(9J*D&VQ\*"AQ
MQ/)1T;G2,]-6R`^YSAODC'GY2XR0O!F5(HOYK76%'G\MJZ_.&U&RGP1<]@-#
M#=L(BT<$V,6-7R><$D4K/VHYG=0^`_$W#"XR//D5U%97-CK:"[U]S:`&6L&C
MI*KD\3D0_.?3[2P,AKP+51&12PP^`SYF,D?&Y&-:@-DOQ0&C-("HK\3(8X[0
MW5C/39&MEH#J^GLM=@MM%6T!P)4<-23]:P<233,B[/B(D\6HJ]^@T!Q;AB.-
M\FS'ON2KVOK+B_GHC;&2<BVCH[6X,MPJ^V.(EEDL3:U3WP>O^WU(HV*K4=W[
MA8O0'0'09[^)O]8^!/Q/A_L`706L1R!@A+\G*E;?(C:@(20\S-D:2FAOQ`80
M?JDQI-/(:VQ@$BK?_8=(^-&-@_V*OA^O0.%EJLO3!FV%QI*"J`K0`[2Q.LKB
MN!#`K+&:4:OL322B(H10#B!Y(X9GN;'*]CFM5514Z!A-Y3XQK5I&V/(V#`=I
MAH#,XTW7Y\5=`(3,T88JD2>PC6U&((>D;'P>HU[U1J*JKVZ!_74YE((2ET5$
M@Q+SF#D+;U_H$/K#6UEDR&7W'IROK[)[1YT:JK%.J1O[.7MT"@6]I#7AQA7%
M67)8PG$5[!;`0AYP]61")9SAMBF>I,-<43'%.YGDV&21K7JBN1%!UZ`Z`Z`Z
M`Z`Z#/?Q-_K'P)^)\/\`8`N@J[=<$:K87G.>@(.F;6DW1FAP^1&HLTTG37\'
M`^;QU;8OUTSY+P4!UTA`S@_(5CWC=GO6"61L@,K>)^0\IK<[K;E-CR_29BFX
M@.LJFV'P27!$E!5\T5!E;0UU+696KLR<-;;"NMXXR6NGE=Y*/-)/'%'T$=J,
M3O\`/\GQ:[^(<HYO.:A#;*OH,5FN)-'%1AV/)=]??0-A_*76LF><6,>MH0VF
MD1T,EF0SU5EA:J!&V\"<JT\(-1691\V;MP>5-04*EG7NGR^[TO*N4/L`H89B
MT:ZHVU(`ES'Z3G)`="8LGBXF-O0:,XBPVIS/*V\V5SEWA47):W-AF1?=1SR\
M8C5]\^0Z@)@4\J$7_M<PQ=02@34CBM'D0$*Y8QWJ&J>@.@.@.@.@.@SW\3?Z
MQ\"?B?#_`&`+H-"=`=`=`=`=`=`=`=`=`=`=!GOXF_UCX$_$^'^P!=!06TO>
M3`>;]):U!.FBH*[F#(Y(&YDY,MF8T/W'$N*O8<#9<4?3Y:-[=Y>VCP1;9\\3
MXK2SA=YL>R-LH0C0Z[5SY'(0<7\PZO0['=YC%V7(#WZE;:;([@SE/BJNK&-K
M%61G'OUVTO+6C)I(XQ8)162Q^@D@DC^@C^@Y<U6TWC+R/:6%7@=O>YZUS%#:
M<Q6_"-,%G1\%R)6-C77T]<=8#36^CRLE@X7TG(4_P551(DZ#?F-L.1Y3:6"6
MKQ\_'BU0_LM$)N+C5Z$P1N;H):TIQQ=5%#>O+N93HY#'S(Z<>*(C_G,YC0MS
MH#H#H#H#H#H#H,]_$W^L?`GXGP_V`+H+\>(+(DC7C#O2:6*>9'PQN26>#TO1
MFD16JDDL/MX_%R]U;X-[?X3L":"HJ1I"YAJNN'EL"XSSY8`AHI#3H58Z$PM\
M<37$EQ.C:K9'JY[5:G9?TZ#@;GJ"RA:/8T=.>.Q8W,@-K`BH6+$DK8E;%/!(
MQJQ-G>C>R?M1[NW^5Z!S@@@%@A&&AB'&'B9#`/!&R&""&)J,CBABC1L<<4;$
M1&M:B(B)V3H.O0'0'0'0'0'0'09[^)O]8^!/Q/A_L`70<[7E?44_,+<=;0YF
M@R$I8PE3)?U^G!L=8"N5?>VE_F=HULF)G.IK5D@<F>E:VR>.),8DK6+%&\(%
MA/D;I.4Z7/!8Z#"C;#3;/0UD1LI\^HR]%D0LR)OZ*RL!J.V",L-$?D;^J'(!
M:8*D%C(4JO1@_IO!I,^1/(]7RE6<=V8.%9=?7..,X;C:RCWUO:7A6H!'/UEK
MG=]`D.0K@\U5J59,&L!FD/"`E216.<U_0<BOEH;()HS:2NR-U!1<QYC.-;6W
M2V<S^);>QT-98Z@V,`E[ZW5Q.P=X1`),C6*-&.Y[?]B]`VV_RAW).[T&5I!,
MO1U`&LVM11WI.#Y,Y1)N:;)TW'#X#9*3CF>(T/ZG=ZRP<TIW_J((-`G?U)>Z
MA,ZOY![&ZU=GQY%2YNEU4G*E_C,K9V45H92W>/K,AL38]:E;">!8.-K=IDG`
M6(39VK!!/`_S:I$?8/>'Y4YLV=;D:N#_`*J'V&KJMKKW'OI->S-5.8QUW596
M*K6M_DLEG9WMY>VJ/]RTJ"`(2-RK#-)X->&AN.-@F_PV9V"@K5RWE9$296K.
MA3:^PC>\6R"B+2.%#!Q;""1D<W@Q)HVH_P`6^79`FW0'0'09[^)O]8^!/Q/A
M_L`70/VJX'P6QN+:VN5TRQ7OF3;406JNP,V;=K1KFH=,^E&+8)%HA:-&01D1
MHQ$6**56K-%'(T.MOP5QW9$2G5U:9CK-5I)`[3"V$^1-JRZ$?0`"'5JT_MQX
M"R*G3F!%.=&]I0;V12HY(8?`/4/!G'8M$?G@JZQ!".+RUDTD:[M$M@+?&,";
M07=;;R$RV(ER/(`R64E)%E*E=(Z99/5D\@3I\?N*(USOM<O``S-5(U(''7S3
M!1G@!CN%$;>M'=']<(&AEF1DQ7J2HI$R^7>1_<&-OQIX\#2I=G3]WCB::J'H
MQ3\EN+ZF/DJ1L_D\TP$TJ,F20V)]?B:Y[UE\GR$P+,YRR/>Y0ET/"W'T5UE-
M&M21/?8O6:O:Y^V(LCY3!K[;U!U+J99I%G1I8EP(>YT@\B.A2>.*5&H^-BH"
M8[A+%E4N<I@)]1G'93ZS%1767U-S1:(0'1%H;?U;KD(EA1%9;D,C?+#(KD;)
M!#)'X2PQ/8%DT5'4YFEJL]1`PUM+25XE555\'FL08`,#!A1V.D<^5Z1PQHBN
M>YSW+^KE555>@=>@.@.@SW\3?ZQ\"?B?#_8`N@FB<JU#]X9@QJ#6FOK+,"AN
M-0%5#$Y:FT-IG8M57TUG/%8NNA9":0F"1"U!6M;*1'"XEL[O30(K6_)'C&T3
M#OA+MX8>0>1+_C#/D%54D,"::C$M#AUL7^J[V-5I@ZZ.2I)<BL-:>'V\5(8G
M0+C^<J.&AP5Y29/<:^3D>:RBSE'G0*%MRK*@`ZQ/)/9?Z.BK1((!P')_]RY[
MG.:B-7NO8.%9SS0V.M&RLV0WE3"9K3,&+JK.MHDR\VS`HYKXK.I.!HS[B,J,
M42>))GA-$?/`]C9E[L5X)ZKY(\8V_P#`5@+MH(^2=SI./,Y.95O@A;HLZ-8F
MQI9O]5WT^OTH0$<M3.[NPUIPB-\7$,:H=ZCG_+:">G^A9S=7%98Q9A]K?5U"
M.359*;8N:F>$TB,L_J;"28I89I_9#&L`&(BG+=!"]']!SI?D+CK\H'Z=3;!]
M%/3YVVMM<^H$3.93^59=NQI0M/(RTDMJZ2:@EBDE*8)+6CR31Q2DLD=XH'T;
MGZB(K6'OQ/)09%F_/)CJ<W.!0V>^CU/OWTTN8[7+Z^%SA:N<DJ"S(K2JX2-9
MS(H(E1RA9&*VE7NJB:TKA;.MF`M+&BNJ2[&B#NJ&\JIO1/JK0>`@P5I$7=DC
M)(9IAYX)8YH9)(I&/<$OZ`Z#/?Q-_K'P)^)\/]@"Z!EW_".RU6\(U]'J\KGB
M&0$R4VFBR9$7(%2DF9(HV9`J\JK>M#TF&EM9ULG0V$$\\4KY(XU3_3+`#`%\
M2Z>K+&J@M?HS,'&,R1U5HK(^_P!,%<Q8,O`#V=+I32E?6?3JL*EG#:V%5%*J
MFR1JBO3P!_K_`(WUQN0X.R7(1M+R"-Q/!9ONUM\]$T/6V]AGSZ?ZPRL>5.-5
M3M+/>1X?[6M\E8WLG9>@9+?XN0)?:'?9.WI*#DZZU&X/CUTU!(:^+,;?.KG)
M*>2#ZA$YMKGV,@)!.B='(QX_H*GMYR&/#F+\3*BN+CJPM?H2L.T626*OT%@?
M?ZBKO5Q4&($M:33'E.>!]'!H:0@%GI+[4JM\V*GFGB#OQUPCR3QL!145-R32
M251@6&DY"LY,G(W0V=_CZJII+:PRR_5I*BI#W-11C#DPDP$K7HDL@[G/D;Z0
M1YGQ?MYW8BJM-)F"*+-93/Y<Z]`RY-1R,^EJ\FF8N\:!I`;:,8S$:AZRDR#6
M<!T@BDSLC5RK!(.$RCXKY;GKZ&2UY&S!-]QV90D\>-%R)@V?)GIJJ]SUE:[0
M22[(LR;+69O0S!RL")@'KGHD\+97*K.@M/CC'6.1K;J6^M1;G3ZW2V.OTYU<
M#+65/U4\8"N@!IP)RCB8*RIIJD02-TLTDTWH+,]4=(K6A870'09[^)O]8^!/
MQ/A_L`706^7L\?7W+\X?J\T%H8ZR:Z?1%WM6-<LIAF2RD6SZN8IAS:R".![G
MSJSTFM8Y5<B(O0+2M#GP82B#;RG#'!KQK8Z<JS"'A#JS'SQAV14LL[&#UY<@
MLC8YGJD<CHW(U55J]@]R7M)%,:/+<U49%;/6C6,$E@(R8`FYDCBJ!S8G3(\6
M>UEF8T9CT:Z=ST1B.54Z!I@WF')/N*H;9Y0BTSTL$%_6P:*HE/HYR2F!#0W`
M<9CB*R4@V5L+&S-8KY7(Q.[E1.@=I[VD&>^,FYJAWQV85)(R>P$B?'<V3!I*
MZI>V29JML[",V%T`Z_[96RL5K51S>X*QC0S?<(&6*6H94H1?MIXI_:F0HQ9A
M"/2>_P!`J))&JZ-W9[?).Z?KT"KH#H#H#H#H,]_$W^L?`GXGP_V`+H*=Y>PN
MVL]MN(<I@[PU=7#9FG$'BXVYQ-HQ>)#,>+JJ/0E.K]EB.00GM93MKD>0`7!V
ME\&L))GA!@T'!O+-A+-C5L#-S4[?'\,U&ET/)H6:6BJ:C!%\EZ&]QQ(/'PF+
ML"QC;4JJA:J-ED7W<BNF=&US4!CAXAYJ?9-V4V?(75V^G^.^/Y*8MC7M'TN9
MX[ML?,=R)5,?82),1DM)0E60T<RM)EJK4J/LZ9L;>@+/C;E:SHLQ@:G`%T*Y
M'%5^7TNG;GL7[R730[G&6IVUPNV*NS2[QNOGJ7W!@AM6Z)'CHXSL5VA>#QM.
M$N;+JTUV<I;&*]CBW1_*E9R!R4)4^5OI*CBWCK+8!@`N!3)CB6V<T,%B0/-(
M$V&-U?$Z5LCG-<H:EX8J[T"OW%AH*(O.%:GD2\U8U6=*',5`'<UE'(UDSP9R
M(%D@)BEA<OE^KHE5$[*BJ%R=`=`=`=`=!GOXF_UCX$_$^'^P!=!H3H#H#H#H
M#H#H#H#H#H#H#H,]_$W^L?`GXGP_V`+H*5Y1W%GGN5-:Z'>6\TB^ZHZ6BH-M
M-7&9,EW$YEM#77W%-G7PB7V>..9)<,U5=-,8).K8'>`P9'0*<QRN:9Q[H09-
M_$9N@^7>+@XZQVA"72P9NVU/#XIX[@$G^H05-B+>D1R/6-&.86[]>STZ".C[
MF.+%UEXWFG7?S;6!5"\Q5"7K3A>-:TOD?)T?(%W!7$#%B<3DX`:T.JQNS!6>
MBDA4S")@GSQ@U6/(6PRW(3I,+O-#N.+..7<@:`\:6]?L2-9E0LWQ8NUI!-%/
M(;8:2VXT*U$UM7R.(G)]=):USW+^Q@6-;\DZ_*\1\$<C"W9MV5M>)JS')%/-
M(7#>\H;['9^RXVO"(G(C93+'65SP72JB>7U7]R?X[!5VKY8W66-Y+BDT>_BR
M0&*M..,MN;B((3+E;;B6LJS;?0U^@4]Q,FJT=@W5PV+I(8XE910^+E\5Z"^]
M'S!0+K.41JGDS//$FX-H++#P`ZJFGC+U+;7F`:T*S<41KOJ%O&ZI"CG2#U'M
M6&)KD1>W<*2R&KVU3PJWDG,:X&YU.8EPUC851OR`O>::32"ZNJ9FS!-,XRI`
MDQTL!UTVS'@'9+ZA0#6^:1NDZ#?F8J":#.TE*;<V.B.K*P,,V^MI/4LKDV&%
MC2[0Q456,G.(1TBL9VCC\O!B(U$1`?>@.@SW\3?ZQ\"?B?#_`&`+H+SEJ*F<
MYMI/65TUDP22O98RA#2'-`F<KY@6EOB4AHDKU[NB1W@Y?U5.@3LSN?C.DLXZ
M*F992LCCEL&5@33I(X5A6*.0M($G>R)1HU:BN[-6-O;_`(IV!3%45,$MB1!6
M5T,]PK'6TT00T<MHZ.)8(UL9&1(\U60*K$]57=F+V_QT`'4U=<.,)7UM>`*%
M#*.&,&&.*.)!.]LD\`T,$;(X(9GL17M8B-<J(JIT"A1!%A@'44=8!G0.&@6&
M/T1W"JU1G01^/A$X=6(L:M1/#LG;MVZ#C/65I(RADUX)`CGS/<+.(/*,KR/6
M]P]8)(W1*^?W$GFO;N[S=W[]U[@UQX_)0J(Z'+YV)U>KU`6.DK&*$LKW2R*(
MK1D499)'JYWAX]W*JK^O0*`,WG:J(B"KH:6MA,=$XN$"K!#B*=`JK`XB,>"-
MD[H5<JL5R+X]_P!.@>N@.@.@SW\3?ZQ\"?B?#_8`N@^7>^WV=Y:N*FVM<`+Q
M=1<?'\DV<[\]H?Y8-2UDDP!HKK9=8E)ZL)4#B5G]BC?;IZ7I^7^WH(]PWS_9
M<F3X,(H7*>]O!>3$U2YFU^MU]59Y&;#6%"'660QA(I'O,UNAI3$<KG1D]V-\
M4:J*';1\\VE)P2SDKV^2$UEOHC\KFZZ_MEI,L5<LVEKG08["U-+A42#Z552%
M2N65OZQN1O\`E$Z!E?\`*,0JRG!IJ8\^.UO^!A\?8CY776-"7GN8'8N4@R^U
M=8"1EZ:P$#TDSAF3EP>3FP^37I(GD#>#\E+_`%51R-+BPLQ:F9;>U=>`=216
MF_\`I/&5K:6]%'MM%CLG8-TUI;PV>2M'OJPW03M$</,J(Q).X+P^=MK/;8)Q
M+^/(,OHQ,S#_`"&$+9$YK:75MH[BCNJ[.[9J,I\#=4PX0LT%/?CO,.,+]@V2
M.6-TO05[5_)?DH[`Y762%Y5AFOO<15MA9P)SPD&;CTM!I[XSVXC[53^2WQ+2
M1CQS4G:&)'.)D[PN9V#:N*L["YRE#:VI(Y=A85\)11(N<O\`(#S22^3D?'F-
M5-/HJ1%9V[CF/6=B]_+_`,=!*.@.@.@SW\3?ZQ\"?B?#_8`N@L?4<:Y+8D6I
M5\$03)=Y=<;:)%8&BQF9M]FVV(K)(QYHV>B62U6S*B(Z2%SHU7P<J=!$KG@/
M`VE_'IZ]=)C[IDKI7$X33V^0CG682O`+:0)2D#"3,/$IPV3HK/\`<@D/EW\$
MZ#S1\`8"BL!C$=J+H*ON+:_J<YI]5<Z+*TMM=_64.,JL[:DDUHDBLT!C8^S%
M2)LRHSMV3L#B#PAQY645QG*^M.#J;NVH+HF`>XLXWC&Y6Q!L\ZE;,A/J5HM.
M36#I!#"K8V10MC1/!.W0(2_C_P`8S!TXU?3F9R>@I:ZDIK;+6UAGKD&&GG&G
MJCDLJV>`@JU`6"1C2)UE>^$LF*3SC)F:\.$7QZXV@)JIXA]$V(%]<1:`.UNA
MDK=C8U-Z7J*VXW`<M@^+4W`NE/F.4DGRDGGD[3+)&UC&@VC_`!NQ8M,!0PZC
ME9*ZE+IC,VUW)^N?/E9:(.QK*]N;*?8+/50I56DPLC&.\91U1CD5&IV"ZJ"F
MCSU-7TL-A<6D=?!Z#+"_M"KJY*3S>_U+"U.?(6;/W?V\WN5>R(G_`,=`\=`=
M`=!GOXF_UCX$_$^'^P!=!*W\LP1\FOXPDPVZC+CJW7LFL>-EV8UE&UJL=;/.
M=JDN&BM/115:H/K).G?P]+_;T#)G?D/Q[J)N+X:U+YCN6R]J#EW&5/M6C%86
M-\UI#>H\E9*IQ\#4>#Y-?[EDC%3MYM[A%:?Y7\?WZ0&U&<Y!-S?K@16VN915
MD=%G8[?=:/CVH,N8YKZ.]]E97F8(D9**$4U@;XYI?3:Y?$+DQ_(F;W%GMJFB
ME+<9@=--E+QI8KA62'CC032E5CW.=[ZK:4^83UT[-]X&1%V[Q*JA.N@.@.@.
M@.@.@.@SW\3?ZQ\"?B?#_8`N@>^0.+;77VNILZO1Q4<NEXK.XR25`YIBJYEK
M<O,.N19XBH.Q45<1(R!.R>$_B]55$5JA35C\3C8I3XLOR-;`B0,M+#)':+W^
MHT>:TML-QX`0<VW,L89#*Z('CZ-D4"HU6>[E3R\>R=!)<7\6,?FM/9Z:V%I]
M)*(\=^$#,$/C#RSJ[=<@[.H6<1MBX"TDKG:\1D4CX?4BF!66-6N<U&!)>(^#
M".*;EMQ#MM#HW7.0CJ=F/?V!UE`?J![XS1PWN=A*)ECSM;):::\DD"9YM538
M^SD])?,-"=`=`=`=`=`=`=!GOXF_UCX$_$^'^P!=!99O)_&M;<EYVQY#PU?H
M`(YICJ(W6T`MR%$,"MH1*763V$9HT<%:U2'N>QJ-@3U%[,_7H%^>W6(US6OR
MFQRNG8Z0F%K\]H:BZ:Z8*,24R)KJTPE%D$B/@=*W_,;9HU=V1[>X/A-G6ADA
MAF6`(IE@A3@!"2QX"3D!A]P:H<$LC924#'_V2^".]-G[G=D_7H$!.HS(4`!1
MFBHA!K45QU603;U\$%D$U@\KC`)I2&1F"MC+B<LD:N8C9&+W[.3N'8G04`;Q
MXS+NH%D+:`X5A-D%`\EMH</5UCAVRS-=,VQLRXAX%;W]:>5D;.[W(B@[]`=`
M=`=`=`=!GOXF_P!8^!/Q/A_L`700_G'C6\TMCRK8T65;8SW?QNUF4JC1!JA3
MC=8:<<X2L&>:^-76$P<C48LRI`J*C7N[=TZ"+T!6LS^DP&M(PG-NL#J&<F4=
MBZVP_%]#I0I=-#QM/53?1L85F:>:@<E`4BE*R0I)VJQW=GI]@D?*^2Y7ON7,
M[O\`,TE230\3LS#JH:P:0NDO7:&W?_V<W'2PV@]8*XG%^@"_W\3O5E8]L?C_
M`,E"%`<.[9]L*);9=Q&>X^Y"Q.#PT9!(!;"^)@=1:ZZXOV0J2J05[ZBXJ:::
M%[6SO=GW*C%8]BJ#_BN`3]E3VX7+0]M629@O/8/&/#-`0H[-<3UEY6XG=-(:
MT]8C3-!HR+T5C_"2(T4.25BK"C.@V<B*B(BJJJB(BJO;NJ_^5[(B=UZ#[T!T
M!T!T!T&>_B;_`%CX$_$^'^P!=!H3H#H#H#H#H#H#H#H#H#H#H,]_$W^L?`GX
MGP_V`+H(WI<07?\`.MY5"<@<FYYEKQ&7>"0U&_U$5)2Z2>X?FQ;L#,+:)1*X
M$9&RM&="HLD[?-\:N<Y5"C;O8;6RP.4WFUY$BH['5G[NU.QM1R3;\55+Q\57
MB94*'$[N4&>K9<5Q-83>)36?I#6\]A,DSGP5S>P.,G(9I@A>JBY&UL/*SM[2
M4]#QG874M2XOCFQK:F;UK+C:"2.OAE+P)A.D)MV#^L&?&]C"6P#^V0(#2\C\
MAE5%-B-GR18@6]%Q?PQ86&@O=#=82HY'J=9H+`^CLS-YGZ\HG%7.PJPWTY]M
M#&GC;@/A_:PN+N%_NV<5IQ7PK+:;+4YS$:/<VN:V^RL-B$-=1U],)NH:>ODY
M,H9`X9J6\UM""$-?#3036XCX7>JDIJJH5W<;8)`=H4/S9L5(QF)JS^`)"-/+
M6D\E63K330AG2U4<8,7+RV^EKA:!$G@-84"R$B/M*>A4H5C<Z/E^`'761&IV
MF#_E(W/H-+K4Y1N=:':6M3R:705=5F,5:`I28*^P8,?O!4@F<AM>#,Q&RM]Q
MZ(.6@Y1VM]N9Z/5:=<Z10:[0Y;5TMGS7I.`<VS19WC'C8B:>FU5-761Y=1<$
MV\EQ7">FK)AK'U7N22)R=!/,O=[YW-E8>^[T8N)*YB/R,&J+Y:OM-D;``7C(
M`NNP"<?$@+213WQTKI@+YT[)2"8%<KO7)B@F#]#.@.@SW\3?ZQ\"?B?#_8`N
M@T#Z4?J>MZ;/6\/2]7P;ZGI^7EZ?GV\O#R_7MW[=^@1DU56:/&&96@%B13QD
MQ"DACSCQD12+-$1'!+&^)D\<J^37HB.1WZHO?H/;ZZOD,2Q>`&^P05P*'O%@
M<8@+Y/5>&A2L6=!7R_N6/R\%=^O;OT'F>LK2H)!BJ\$D:85`IAYQ!YH)0D_5
M!)(I(W1O%15_^FJ*S_\`3H/LU;7$@.JR``IZQ\#175TPL$H#AF-:Q@SA'QN'
M6!K6HB,5OBB(GZ=!\DJZR:0"66N!EEJE5U7)((.^2M5T20N4![HU<&KH4\%]
M-6]V_I_CH.KP@Y(VQ2""OB9*^=D3X(G1LFD619)FL<Q6ME>LS^[D3NOFO_E>
M@2'T=+:(K;.GJ[%JR>LK3Z\0M%F2)L*2JA$,B>HD+49Y?Y\41/\`'0*F!!1Q
M-AC$%9"R2*5D3!XFQ-E@]-8)6QM8C6R0K$SP<B=V^*=O\)T"KH#H,]_$W^L?
M`GXGP_V`+H(=MOD5<X?:G9^QIJ22GSFJN8M8>V8V,NMP\V'S5EC+F)BRNA]_
M<[O6#5DGG_J6."96-1Z)V".7?RCNZ0G=4A86)@TN.X+)VCZMUK,19-Y0HL=4
M;C44!>='.==)E!*+45\@\K4;/,^$J/S5S&]`CK?D3R5:9^[L:^+*VE71[:/.
MV7)@7&'++<[4B1Y4ZYLH+3C28[^?L)J[R$,$D^.=P`S+!DST_P!4D?0/EU\G
M3AM'/FZ9O']I8IPQ-LQ!*_3)<D6/(J90KD`;/U,(TP1MKCC,773$16;!X_4?
M)#_Q\E;T"ZE^2Y%CJK2N(J!%SD.CM[2FL:8&]O[>YXBJ,Q=BOTX-+41&6-E>
M%<H4,M=#`)!,D@LL7C&LKN_0:.QFWS/(-*W0Y,^:QJ5+)!]P15V]/*PP)S8S
M!I`;L"N/BF$F58Y6NB18Y6N8[L]CFH$LZ`Z`Z`Z`Z#/?Q-_K'P)^)\/]@"Z"
M6ZWA+C?;E[`W243SB=W193-Z:1EC8B^^J<5>&Z+/P1M&)B:)(/:GO?))$C))
MVMC9(KFQL1`2WG`_&&B"L`[//^<EK>Z+16-I`:8+=EGZH&XJ[F.>Z'FCLI*Z
M>JO)Q6"K(L$0Z1L8UJ11^(*M-PSC=/;GZ%\FCH=%8%UI\M]E--<9VSB.K:HJ
M@]Y!+7%1Q,(L:`EH1;E8ON1Q14?^X4=T8<*?@GBV@&KAJC+CA?2;^OT5<4P@
MJ6Q%,JZH:@#%99SS2GOJ6Y\1@+Q'R.@E$5T;VN1SNX*L;PMQW@3LQ8Y>DD`,
MQ^!7C.BGDLK$QP^0=:"W3P9_=DS(84^R#;*I,OF0JN>GGV>Y%"U.@.@.@.@.
M@.@SW\3?ZQ\"?B?#_8`N@D5ESGAJ?2!Y6R=;AV9FMT>.\I:[L&+8YG%";TTP
MTI)U:-4DT=B,@TRI_M))BB\45W=`9O\`\C^.4&T$[OY`R7.8G%[@P%].YIA(
MF\8.ZCI`&J1Z$^CBDL0&%CK(R,1;(59)$9+YM!S@YRS"":B:WH]AF;#&8ZVV
MVCHM!3C"6P-33$64),4"#61E=:$SLK'2CO$(G%GBD8K)E57(T&,;Y-\8%6&H
MJ637L=EDZD:\.#FJ%B>963[^ZXUF)JI%(]N;]/TU*J$M\VOA')'D<G:9$0.\
MOR"I_IUG<@\?<IV](+66=U27=;FZMU7L:BE,A%M+'.%%Z`1(AX8)O=P?4DKG
MV(3'3!-):G0)1ODAF)Z\*TDQG)`@/T.LU.GGGHZ>9F!R]V03%2W^P]AHC?0#
ML0PY3?2!]^6,!&I!,,$?95"2XCG3`\A3TXN:)LB)[FWY#HHXB`/;O!M.,K06
MKT8]DUTSE'2=3H"`GIYL+#GCF8O@]JJ'B3F[/0;@O%E9[9"CAZNNPLNVDJ07
MXG^86U'57]90.L![:>W&(.&NAH8IIP8A'F2M@2;U'L1P.8'+-+9["7*`T&O(
M$BN[++KM(J5DF+=JJ<*4^TS_`-1C-?91D!,&EB>5(&RM]Y$\5"5)1(E"TN@.
M@SW\3?ZQ\"?B?#_8`N@C7)_QN)Y!O.2KH37MI)=M08H"F3Z6\M^9O:.Z"GU-
M]%(AT'N)-1F\_55W@U(UB8(Y5<])/%`1F?&FTCM+34TF]FBTE[8[EEQ4Z0"3
M5<;%Y74)7PU^5;A#RXP8@QZS(9^O,D;(V0@0.=6+%)*QT81>'X>5=M5ZR+:,
MPMJ9=8719?(5D>:+LL]Q8==DFDP/Q":&QL;,*I")FC*]%DD'8M9%A2"+TXHP
M[VOQ)+M:^_8NV@$N3]12W]5:CT\G_K5T/(>UU6JSEC$X_P!0VLU>;V#J^1&O
MC](D>(M$5\4;6A)ZWX_ZZ"V`:;M*Q,]E>/-)QMEDKA-(-;7&>MJXBLSP^U!?
MI'90J3)#3]TG&`:2=.ULGJ#M187`X&\&Z\>O.S^;UU"'0;C!Y/!\D+9T)QEJ
MV#-T,N8,NL9+!:CB"'WN=G458C8YXA9(HB&^HJ20R@S9KX[7G'FIQFSR-_7E
M$4%)?9V]S9@,H]1=NT&RIR`]/$0PSW(5SF\,A8$BKZOOTA#1W9!VL<$EL^(M
M^=L-)/#JLF-A+GD?/\K1UKJ"WFU$VDRN?R0='3FVGUN*LBS[='CA#2'1#>YE
M@:X=JL5ZRH#M2<?\JYNSLH*7:Y0;)E:#2[F,"3-GS6Y&EU;;"QL\[8FNMO0_
MAK-?:SV3)(&162Q)$)ZB-8^:4+]Z`Z#/?Q-_K'P)^)\/]@"Z"[%T6?0J$);V
MG0P@\RJ'$6S"0J>TKP7V9];"/Z_JRG@UL3B)H6HLD4#5D<B-15Z#A%J\O.%%
M90:2@FKIYY!H#XKBND"F(A"ELIAXBF$+!)/%7#R$.8CE<V!CGJGBBJ@1B3F'
MB2$RPKYN4N.8CZD><NU!DV^9896""L9(258#.LTF"''9(UTCY&M:Q'(JJG=.
M@<H>2..R,T3LX-[BY\>%/[4S5PZFCES0A/KPB^V)O6'.JX)_<DQQ^#Y4=YR-
M;V[N1%!XI=-F])!"5G=#1WXQ`4-D.12VP%K!/7$$%B#GPR@D3QRA3EU\\3)6
MJK'202-155CD0/,VJRXXLYT^DH8`A3+2O*,FN*Z,48^C@-*N@9R'D-BA,IQ:
MXB0J)RH\>."1TB-1CE0$UQM\9G1)[#0:[,40`L=;*2;<7]56"#17#YXZB6<D
MTN"&&.U>+*T9SG(DZQN1GEXKV"103PDPPDC31$#D11SP3P2,EAGAE8DD4T,L
M:N9)%(QR.:YJJBHO=.@Z]`=`=!GOXF_UCX$_$^'^P!=!2',/$G)UAM>1--B<
M\ACZAE#N.-)XC:T5QNZVH-'QOR(*WW!4+Q7U.!R;YG22>#)5MW(Q7N\VH"$W
M@+?5X)<-,7J):,/D_D&:FX_[8F/-0YLGAK98W/Z*$E*B+3(2;9%C1I')9JQL
MA"JZ%L:?M!\V_%6MGR&^2NR1KK0[AWX[4P+Z03,$WT]YB]AJK76"U<5Q+]++
MMJH`N"1K#%40EZL8JR-1S4":VN8VFUX7$H:]NY"T:<H<?GM/Y$RG&P%^!7TO
M).3O3KN7-Y".OQUA6556)+)&QS$GG;"Y'(Y_CW!HSF8T7!6[T<M7C=SR<S78
MD`R32T-9D:ZM(W/\RY+TET'8`LMJ,?.`S+H@VCM'&FC1KW/D>^7U'O"F"."^
M:ZW&W&)ML_0:AUU#H]M,=EHW"5LVRUW`_+F%V8EM'HKPL@JWT>LLJPB6:/TQ
M)9+"1R-C:V1>@?EXEY!R-W?PR9?86.;Q,W'%9Q/L,45C[G75F9JL[RR*(R?*
M;!AE5J/XE#N_XV9`2C)I:]T)T#UF;(K`VGQ:#=UG'&(KM)35&=O0<S4"VE%0
MPPC4]05`)'&^OKQ12#!!!Q4:C4AAFF@A5%9'(]C6N4)[T!T!T&>_B;_6/@3\
M3X?[`%T%RQ:>CGTQN.B.1VCKZ8'0EUOMRFK%3V1AH`1GNG0(%(DQ=?,SP;(L
MC59W5J(J*H5\=SKQO7%RA$V5RLL<]@R-X^2U98Y@=-[EM[=5I(M-+#99^AE#
MD8:=`Z089Z-1[T]2-7A\"YUX\.=4>B3HFCWKH%J["?%ZX>M(#,.KJP&V=834
MK!1Z4^QMAH83)','D?*G9_9'*@?3.=./!(Z^=A6AL!+4:Q*`.J,;K;4*=M5H
M(LJ=#[H&FFAC*BOR8!TB>K9)%)A<Q',E8Y0?ZWD_)6A%N-%+<B/H:E;BXDM,
MUH:L:N@B`"M"A"2SZR`:.W!K;(:></S]S''.U59_R\03@<MX.R4EXEJ6\(/-
M0:PJVDH[R"F&J"*D.^8A%K/71A063:2P@*<&][2TBE1?3[HY&@PF\]\=5C9E
MMIM54^T@BF.;:8+;`.KE+4YM8-8-)H(U#+NEKY4!BD[.+5&I&CG.:B@M_P"[
M,%$1[<Z;0U",,HZXHJZQVJJ0*^RTIX%;15UF>=40B5QEB5:#^+)GL\8YFR/\
M6=W("-.?.-I2_8"&Z"P,>?/6!CUV,UQTEH:%%ZUE#4^WI7MLEJ8^REK"KD'\
MD\U3NG0=6<[<=2NEBB+T4Q<;W+%70XG93V9H44]@.5<5E?#1O+LZ,&:I);.7
M`R2")T7BYR.?&UX6YZT?H^X\O]/I>MY]E[>GX^?EV[>7_']?\=^@H#XF_P!8
M^!/Q/A_L`70:#[)W\NR>2IV5>R=U1/\`"=_\]D[]!C#VG!T^RJGZ>7>7K<C>
MZ&LS%#K\!;/R.0=:65:-<PQS28X>.:K;<W@#8SC2)VP,4=C9DB1ZN!M'P/Q]
MK<P?=NU9\HV58CJ;2`9+/@7N0.EU9=4/;TSZ?#"D6&@(OL7+`I9$)<QD$:+(
MLD4L;W`O^D\"/H3<C3F[@09\9PLN63+Z/36F9@FML>3;$V>?TN:T!S*D2RX[
M$E*2PBG$:TIZ*BL)A3H%IM?PK3DZ:"^Y#T$C&5&CXYOJH:F"I8XQ,=G*'5["
MKA3)Y"J-4%F6&'2""&1PH_OIHZ]L<Y"-:'R2AX2RYJLCUNQMA=`#K<34Y.K#
M*T-@P<V.&6WK@#:W/D[$NLJ1K!DX<)AA`@\CG$1(LG=Z`S"<9<%[`K8R6%]K
MK#8VUF",?K+S+!T]HR:WN+GCLF/-PD8L*@FJ+RVN20+1D`\HTQ+EGF1LBI*H
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MHS[2XI+J#Z8^SRUY9F9L];K.3F5A;0+`0C+#>FJM>Q\:R1RMD8_L@1AWQDP,
M8EA35UEJJS+7,`$%SE8[0:RJ['Z0-+%4O>5>U]K=#H&21(0Z.(ID4\K^TK'Q
MHD?0=3OC5A)8K,:H-N\P#:"F5,M;1-H8JX3.V=P7H;+/U@9E$9#7!SWYCC89
M8T0H(AK%'EB8U&=`LN_CG@-#?EZ"RGT;YK&WBN+$*"W]H"9*QY3IQW^V&B-A
MA.24=A#HIHYI(P1V^:(QWF#$1\5>-'!U4(;2Q#:>QM#Q[8JLR6@.,BL7"L@K
M;M-+F[@:_`I0@HAP4,CFE@9&UWFLJ(_H)4)P/DZD>X_CQMGG;2_(J;*WNZH7
M.QG6%[1;*?;U5\8/-135A-B)9ES0_O@=&\-Z1.:OIQ.8"K/\*YVINP+^ZL#]
MH?227<V;=IZW+RLSA.BO6:2W,JEJ\_62QF3V\:2,E>Y[X6HC6*U$3H+CZ`Z`
MZ#/?Q-_K'P)^)\/]@"Z"X91]6NI%)ALJ1N-;4$Q&53ZLM]_+=N(A<*7!;)8M
M#B`C&:]'1J,KE<O^5[HK0R[:<]\AKH:2AS5/E+\_2DZJ82DJPK6UO,Q#EBC@
M(Z#91MOZZ"NL]`1"Q6GN]&`'T26N&(2))'`QUOR5W<D.7M+.IS,5/8^VL=+/
M#7Q^RSE.1>9VJD?97PO(EK!4!C0VT[VV!0C7320M8\&!'>70.D_R`Y"*SXFB
MKZS,U/I`W3KO/WV=TH]V"<+L,/4U/II>7^-9#";FN1`#'-*8/&LT3VMG]*1L
ML82H#G:V&)U+;U^7*91XF>]K@:."8BULKD.MS<[PI8J?1ZY@I!=IHXQ65_99
M5\X'BDG),Y(`<N-.:K3;ZNOI+%N=`C*H7-)JAH+5+T/6U(5=)IP3(S"8["FC
MK["8B.,2RK`I'C-AG81*^20>$-(]`=`=`=`=!GOXF_UCX$_$^'^P!=!H3H,8
M7_R%+S5G+*!B,Q(3?.N-"+[1FK*NGT.;;>U9QVE?28HX6&P]:HCAFF:3-#4,
M(5AJQL8CY`^5',-P^*)0^*\S6!Z)-K8G014NH=%)598ZL!*?8'`9%U79,-?9
MM\[)KWUC59V]5WDWH&&]^5,CX+9TG&-<6-7T-+_+`+*6Q/?7Z'04XLR9ZU*"
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M2F#JYLDK$@5TC`M8?E"]?C-=9+79L[6Y?1`9MU946-[)53E6ZT$H$L4EI0U5
MG9.:'?MDAB!A)6T2-J!O>\AD;0ZY_E.QT-OG1Q1<G%4%4N;-OC"-(8,6^RU,
M5Z@0>5#.I`Y;5H1>?FCE84T,EZJ]J1L>/(QP79T&>_B;_6/@3\3X?[`%T%U)
MHJ-="_)I9B+I(Z:/1/IO4_\`>;22G25L=FL7;_[5Q\+HO+O_`,T[=!7Y=OPU
M02:32O@R(YC-%)FM3:5U$.9:RZ6:N:2156CJRN)LBSUJCO4F:Y'^,$CG/[-\
MUZ"+5DWQGL)'_3:?BY5&NZP6&7^)TXD)%U?7/\>JY:HF>H@@M'V-XSVC"!72
MQNG1&J_OVZ!;:7_QV-=6WEJWC>TDN@V-!M9J*IM92*LYA&=?-,8VN)D&J$CJ
M'@$33.8/"V%(97-3Q:H/!)_"M!FI(I`L8)F$>!+]+"SPA`D\VCJ"'`J/1@5L
MTAD]G033+VC@>]0UE5W:)']@=\B?QEI*^2FQHE`?29Y)@HAZVB;%GAHS?=#E
MPU$ZU\5,9`1VF9/[1\C%57(__EV4).7D\M8068QV:H#1KHOW]P.73UQ$-J=[
M..N][912CO8<7]/A9!ZDJ.?Z+49W\41.@]0Y7+C#!!CYNA@$K9X2:\6&GKXA
MP"1A8@1R`X&#MC%G@"A9"Q[$:YL3$8BHU$3H&L?CO!!@'50F+RXU39CJ+8U$
M%'6PU!HZD.+=&55QCMKYT<0[S571JJJB=U_:G8%+</BF3UQ+,AEVD4XTH=3.
MV@JFRU8D_;UA:^1!$<$/+V_<R-6M7_Y3H)3T&>_B;_6/@3\3X?[`%T%X)25"
M6SKU*P%+IPRANM4&B2P<&JL7VJE^/K*-Y1M7P[^/=._;OT&,M!FN'X@])2R\
MK'/./UHEW?\`URMO-.`3IZV382:&Q$`&<&QE0]AY41:A3MKZZ0!C9'-5DC'`
MT`\=<$P#5X@')FR47T;99C`!=(C[JYIC[9P>NCMQ*M8(ZO..U4[25%5E,9,\
M>6;]\3%<#D#1<48NS2WSO.4E.3:X>A%M#!Z@*XJYLQ85;+XVUJ9HP9ZRAM-V
M_P!*Q&>YTS927S+!!,^94:#U2UO$6.!:!BN05QEM4RT=\(7;92T46"PI<.9E
MRV&UEP+7>]M;S-%RSM!;/&8KO3EBC<Q.SPFN!M.%.$\K5@@:4EHFGET-U';V
M%;?S%6CP+"T.MUL(H:U1ZHRE=)-'/`Z(1\?I.\XVJU>P6V!R=@;-P,8FGKU(
ML6$O$"(]P%8.0.^K,N4V:N-@'.$E'T%T(*]DL;'I*0Q.W9>_0(TY?XU^IE5+
M]?5PF!%3`DN(0H8%APTP\!0#;0@>*KF.$>5&LT+)G2Q,=YO:UB*Y`60\FX>?
M-%:Z*\1]"$<-6$E)76R$QV!LX0X(:53@$MY"#WV0ZCM;`Y9XYXWQ^3'M<H.U
M=LLK;DTH=;?5IA>BHR=+2#0D-4BQH@IZ\8RS'A7M(HXI%J/')W1',?*C51%1
M40)-T&>_B;_6/@3\3X?[`%T&A.@Q4[CKBW8'VQ5MR7?&9W*TVM^EU,XEWFJJ
MBJ!BK.&SNXC#4%K=%+FK"X=#&>-$D4L':$KW7=7J$2KLKQ:&\").5ZZ!]=_)
M9))3N-;ZI>!_)R??&QW,DY@06?TZKF9%!A(8,KH6JK`Y&NC=T`SA3AO8DN_C
M_*1`H>J*$R])4F4;A[`(\7(RVU?79IMC'4D#4EC5@%&JUX\T)0<KX19HV>FJ
M!.[7C/C7-2)=6NZ2NV-3HAH!+"FHC260V]34Y^>FI*[%K/H4L+`0IU:8Q(FS
M'S^M(.QZ0D21]!.J7%9/;91^.AY".U1%.)HG7QK)2)24AY9HK(T>)8K(H\T*
MNCIM#Y@0O(FDB':QCI%5J]`D=\9Z04U;.CUNEJ#J^XBLLNQTWU"KI0X+,O1,
MJ#JLJ;TM+`[3GRE.(,<XU8$B'29K(6*@)Y/BUDRV%36%]<DVMS8'&Z6RCC&@
M2U9:NI2[(<2O?ZX%*]UK2I+!/`SW$,$T@[GR1/=W"9#\0G&55]2:[:6>F"T.
MDH-4=(QIU1/%8T=I3F^UJU'MYY*2N/AHH?5B$EB:TF6:2%L+'-B:"B/AJM$U
ME+KZN\LJDO,PUU1G:D%%BSM?E`Q[0<B@GIFD(-8S'?62)''2]R62I$J+VC[.
M"YN@SW\3?ZQ\"?B?#_8`N@T)T%`/X!IQH(0Z*\+H@R@]6'I6P5M<43?_`,JM
M0KJ4_P!R2US:ZSK["OB=%(V.2-Z-[21N3H&BP^-%#>V-WIM'I;:TVVA]HVTT
ML0-:#'Z(]+:YJ00.D9%-7#C29^R;$Q7I+/#..PADJ2>7</3/CK&KZRS,WVE-
MTF8K*:NQ]C&P>IKJ9,S.(1GGG4E2X8711CN$\2(S72L(;-+V2/NU&`_ZCA1=
M-:VUD_6DBP6,Z6T-1+04MI6#Z&6OH*BP-)8?$^8^L-K<["Q!5?')!+))-%.V
M1(5A!WXXX@`XX,)M!M/J]#:6U?[/1&Z.W(L4NB(#7$U5A[69[A*R>J$FE%8T
M5D39H7HLWJ2-1_06]T!T!T!T!T&>_B;_`%CX$_$^'^P!=!?31YFF2DJ:2^"2
M"*)E>Y@?M()(W/<\F)[!6'+-.UZ->CYGQHC4\6M7NJACHW`\SZ+4U@8EKLLN
M%&?JI-UHK376I%)9VD\IC\?=86FS^RKC!`:JNE5/:2,&`<]P\90L[X9'M"-4
MN-Y\A%H[7U-K*=E?1LK^NL+^]#L=6?#>YZ<P:E<1S#=9HTLRK#+8KS1H:B6*
M9\<8(KW(_H'\_`\VOS3'71>F,UE)77@ZFYCD'3D5MVVPU^"OPWLK8=)@/J)-
M?36>AKXVR>RF:..V)I"=AY>@D-16<M!F:AU54;!Q%A@65E$3I](4+4UMW.#G
M*RJD@$)W>W>QHAOOS25EBDM`_3F\S+!"!V,!VXQJ>5ZW;A-V@6D(@#S;J.QN
M"M7):9HEM,.#75EM7-^L,9:FW\H3R9T*HP;&&>>:5Q3X96#1AI[H#H#H#H#H
M,]_$W^L?`GXGP_V`+H-"=!C34?'_`)-OS;<P7:`5R-#CCK(1[>\BFO+,BUDF
MNKFZ.?7%NI9;.K]&-8A8B6KZ;QI%D$>QL0(R?C_RQ()H4J=?7YNPL`S!0)!M
M+;E"RBV*40DE8=&!E*%\$=>"$2\8AJSK"4L:Q0QQK*Q02UWQOY.[',,W$%<]
M2R[*GL0KXNR.`:E<@U/1=I,E3^W@K2G.D86.^)D"^+QQ(WHO<+$-X1T5]FHJ
MBVLJNN.$T95A7&5MKH#GAUQN?KZVPE?*:R&.P/L;L-Y[HB(7P^3T1ZR/5[W@
MQ_\`2W,,%/=TT7(8)D%]G#,S%*^RTE>3FTBDJPZN]`FC0YAQ<]13M=*,R,%@
MQ!#V,EE8U7R`X4'"O(>>MW.@V8Q]<RP9])L#3[=IV=K?0N(CGU=%`/%31%6[
M+(=CX8Y(H(%`8Y/4;*^)H1J?@+D>8JSL);B@(&.E#J8<DW3Z<(`/-J)VM3(-
M(VF+LUOY+-TI`[5&]LDTL9$OF2/YS![KN#.5P*ZI$K]'1TU@*.,&;:KI=#<_
MZ$)>I\XPP]!FYR#"(IT?Y$3O<0H[&D.?)Z1,`/DO&/.]!C+\?/<CC6NPD-A(
MI;`N<@>*"IJI+B$2BA@L@+J%C;8604J9TSWS-L'RL>3,*R)J!((\-S8QYA3]
MA62O*`K&#C+;EQD@'`U5M5ESML4R[Q2S;86Q@:LRAQPCSA(2D$CYG-C!S^*X
MLH7QMX+$G4=TPW%F*AE<(8'8#*^.B#:Y8#JX@H$N)53]LD,DD;D_5KE3]>@N
M-:ZP6Y;8I?GMKTB1BT""U*@.>D4L:S*4H"VR/=(]K^R$>/DQ$[>*JBAEDRWY
MJ.GT3JZ\Y#%EKKK03AL@PE*/4F`LSW(IM-5#17_'J6"M'N,Y4CR*.18Q3(8U
MT9\SBV10`FJM)\AO?14%O7[`<8=NB!N]&)3Y>VF`*NJ@>7$&@6SLIG:_1,`M
M*V1\[P:.6`2&U:.>B3".E<'D*]YL&(L@;>YY!E#;_%AY+6#%CD6@@1^1SMK;
MGUM;6\+_`$:8]-:7+7/EC.M7!P23/?6M49TD8/O'6RY4M[FOEV\?(%",V:O9
M6U"\<,E#O@9@#OK1.MM!Z"-E"2"0+%(/Z<X#W*_Q2"=9$@B!OI.3N8F+8Q:W
M);2G)?/36E7'!Q]87T+J2\W()DXCB\C6Z$.(S/XLJ<*6&>6,Y?;-F?"V9_0<
MKG>\_%Z,B#+YF_AS\F@CHJNWML:T<!\Y6U%MPRK((N(74"4"X,5U;.?[1!AY
MC72OF:1`C>@89=YSC9T<5FD7)6>T%CH!!OXM_P!:R-KZK'3&5T[;8O0P<<;>
M430LC(F&(;$+:)XM_0.)K5,0-GT[YY*BKD*DGE)?7`O(E*C=$3).X:)99"(G
8UM,^.=\BJKVJ&(J.[HL,7_!H./0'0?_9
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g693672ex99_1logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g693672ex99_1logo.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`+`%\`P$1``(1`0,1`?_$`,\```(#``(#`0$`````
M```````)!P@*!08!!`L#`@$``P`"`P$!``````````````8'!0@!`P0)`A``
M``8!`P($`P,)!0,-`````0(#!`4&!P`1"!()(1,4"D$B%3%1%C)"(W6UMA=W
M.6&1)#<9<7:W,T-STW0E)C96EA@X.A$``0(%`@,$!0@#"PL#!0```0(#`!$$
M!08A$C%!!U%A(A-Q@9$R%*&Q<K)S%38(0E(CP='A8J(SLW0U%C?PDL+20U-C
MDR1U./'#%U1D)288_]H`#`,!``(1`Q$`/P!UO<,[Q_-#B1RTR-@7$'"4V8Z!
M4(RB/8;(0061GH32UHI,'995$'->-])4"*DY-5KLG\Q?)V-\V^JKC&#6"]65
MJY5UP\BI65@HFV);5E(][74`'UQ&\NZB9)8+\]:[?;144K81)>UTSW-I4=4`
MIT*BGU:Q0JT>Y,YYTB%<V2Y=OB'JE>9'13=SEABLJ0\2V4<JE1;D7?OG"#9(
MZZQP*0#&`3&$`#QTQL]*\:J'`TQ<U+</`)+1/L&L*C_67*J5HO5-I0VT.*E!
MY('K(`C\:E[E3G9?H<MBHW;^@[A`'<*M"35:C<IS469T@(E6;E?1[A=L*R)@
MV,7JW`?MUR_TJQJF7Y51<U(<E.2BV#[#'%/UFRFK;\ZFM*'&IRFD/*'M`(A@
M7;R[Q?,WEORCIV$,O<)E,/4:PQ%ED)*^!!Y$8A$KPT8=ZR2.XL1ABP*_<%\K
M8WS"(^&EK)\&L%ELZ[A07#SZE*D@(FV9@F1]W72&S$>HF29!?&[9<+;\/2K2
MHE>UT2D">*P!REVZQ#M=[FG-!_WV)#A0ZRE%J<;T,AR<"E1@QWC\CXL4WKJC
M]%L-O)72VTQR.R@;S!>=8AX".VO>]B5A1T[3?TLG[U+(5OWKE/=*>W=MX<I1
MCVLVR-75`XTI\?='GE.SRV_="`9;MN^<^>Z-4VHY%T@T00:((-$$&B"#1!!H
M@@T00:((-$$&B"#1!!H@@T00:((-$$&B"#1!!H@@T00:((-$$*.[C/=VQ5VX
MK_B:@9!QA=KX^RTR.^BWU7D(UDVC$TYE*&$CLKU!8ZRGFJ=>Q=OE#;3KB^$U
MF4TK]53/-MI8,B%`DF8GI*$#+\_H<0JV*.J8==6^DJ!20``#(\>)[H:S7IA&
MPP$'8&Z2B"$Y#QDP@@ML*J*,FR0>II*B7P\Q,BX`;;PW#2:Z@M.*:.I2HCV&
M4/;3@=:2Z-`I(/M$XH+W1.1'(7B]Q/L65^,=$_B+E2.LM:C6-<_#DC:O,C))
MRJE)._H\6(.UO3)E`=P\"[^.F7$+7:[Q>D45W=\JB*5$JW!.H&@F=-85,XN]
MWLEA77V1KSJ\.(`3M*]"9$[1J9#6.&[57)3DCRIXOIY/Y2X^'&V3#76P0OX?
M_#$E4^J&CRLQ9.PB941=E!1190O6/@;IUV9G:;39KQ\)9G?.H_+2=VX*U/$3
M&FD=6!WJ]7VQ_&WYGR*[SEIV[2CPC@9'76&5Z4X=(-$$&B"#1!!H@@T00D/F
MSW:;#P_Y11V&'6,:_9**G$U2<G9X7LHE9DXZ;7<DD?IR*3@(\SAD@W$Z93IF
M`XATC]NX5C$^G%/D^/JN@J%MUNY:4ID-DTRE,\9&<:7]9OS47+I+U-:P]RUL
M5-B#3#KKV]8>"'"H+V)!VDI`F)C6'%8]O]4RE2:SD*CR[:=JEMB&<U"R;10J
MB3AF\2*J4#=(CY:Z)A$BA!\2*%$H^(:F-;1U-OJG**K245+:BE0/(C_+2-N;
M!?;7DUFIK_974OVNK92XVM)T*5"8]!'`CD01'<M>6,O%.>;G,.E<,<-R.1;"
M5O+V9\H$51*<9QY3FRSJ@`80/T&!9**CD=UG2I?R2`!0^8P:9\3QBJRFZIH6
M9IIQXG'):(3V^D\`.<2'K3U=LO1W#W,BN&UZYK/ETM/.2GW3P&FH0D>):N0[
MS$0]MKG!:^<./KU<K52Z_3'%3LS6#:MJ\YD7#=X@Y8^L\U;ZDX<JE63$>D=A
M`H_=K*9WB5+B5:S2TKRWDNM[B5``C67*%/\`+IUJNW6JP5UWNU%3T3U)5!H)
M:4M04"G=,[R3/E%1N0W=2Y#8[Y67+C/A[CM7\J2L`Y21B&[=>>6L,HD6+:R3
MMP9LTDFK7H1*Y_-`NP!X[Z9;+T[L=;C;.072N<IVUSW:)VI,Y#4]L2?/OS0=
M0K#U6K>F>'X]372KIMOE^-WS7`4!2CM29>&<<"Y[F?<-KZ9I&T]O:90AVX=;
ML[-G:"N"IE\3B0Q9"2V-T@/_`#1M=J,"P>H/ETU[27#PGLE^Y'D=_,;^8.W#
MXB[8`H4:?>*/B"J7.6BOFBP7&[O%\?LQ69GCK*,)/\?<BNUTF2$;>=PK[J15
M$4R,OK:K9@I&NEU=BID=($*._B<-8:_=+[U:Z<U]O6BMH`)[F_>`[=NLQVD$
M^B'WIW^;K`LON:,>R5BHL&0J4$A%5HVI?ZOF23L)/`.)'>89%EC--`PO5D;=
M>)11M%.ETFS$(]`7[I^JJD9</2(I'*51(J!!.8XF`A2!OOI$MUKK+I4&FI$S
M<`F9Z`>F-B<HS"Q8A;1=;TZ4TJE`)VC<I1(GX0.(EJ3.4M8Y7&.4*AEVJM;C
M2GJSR(<K+MC%=ME&3YHZ;'Z%VKQHKN=!=,?AN("`[@(ZZZ^@J;;4&EJ@`X.P
MS!!Y@QZ<<R2TY5;$W:SK*Z11(U!2I*AQ2I)X$1(6O%&>CQL'W!_=H@A(_N'#
M"7M69Y*&P`><Q<!@V#X9%K@AL(AN`[A\-/O3/\84WH<^HJ)GU=_`E6/XS?\`
M2)B,O;2"(]LJLE';8N5LG"'@&^YIL!'<=MQU[>JWXM6?^"W\T>'HL?\`]*1_
M6'?K1H%V#[@_NU-8K4?/WS!R#QOQ7]PUE+/.67SYC1L?9!G9:6-%L5)*3=&&
MJJ(-&,>S3$OG.GCI0I"]1BD`1W,8`\=;+4=MJ[QTR8MM"`JI=:`$S(>]J2>P
M1J9<KO16'JV_=K@2*1E]15(3/N"0`[288#8>^AW3,PIR>1>*G;SFU,)-SJN(
M>?GJ1?;F_E8E'<Q7RKV%:L(OS%4B]1BM#.DB_FG-]NEIOIWA]!*EO-T1]X<T
MI6A(![)&9]LH:W>J><W))K;#9W/NP<%*0M9*>W3:/9,=\6P[9_N"Z]RHRS'\
M:^3^-&^#,S3+]6%K$LQ=O#U*>L*`&ZJW+,IA!I+U:?74()$4U2JI'4V()RF$
M`'"Y9TS<LU";M9WOB:!(FH:;DI_6!$PI/:1&?POJXS?;BFR7QCX2Y+,D'78I
M0_1(.J5=@,P>$YQH[L]GKU+KDW;K9,1]?K-;BWLU.SDJY3:1T7%1Z!W+Q\\<
MJF*FD@@@F)A$1_L#<=2QIIU]U++*2IU9``&I)/`"+(^^S3,JJ'U!#"$E2E$R
M``U))C*OF;W%&6,LY;E,-=M#BO-9^<1;EPW+=IF,L$B$RFW4%$9:)J==:J.6
MM?64*;RG,@X:BH4`-T``@(V.@Z7T5%1)K\MK44J5`>`$"4^14>?:$@RB$7+K
M%75]R5:\+H'*M:21O()G+F$#@GO41Z(Z(CW^.?G%:XUUGW"^"[ZF4.Q.TVY+
M!7XBPU*222,8/-4A_KP/:[..FZ>YC-O6HJ"4!^.O0>FV-7EA:L7N27*A`]U1
M"AZY2('?(QY?_EG*[#4H3EUJ4U2K/O)2I!'T9E25'NF(U(\=>1.)^5.(:CF_
M"MG;6JA7)B#J/>I`*+QDZ3'RG\/,,3CY\;,1;HID7""@`8BA1^T-A&072V5E
MGKEV^O045+9D1V]A!Y@\08N=GO%!?;>W<[:L.4C@F#S':".1!T(A"=>[\LI$
M]QK,O%+-%-QOC?!.'I/(Z4WEEU894TT2-I%:6FV:PQ9V0-7#^5=D(W(@D<RA
MSG`"`8P@&J*[TZ0YBS%YH''7;B^$2:"1*:U2X]@[8EC75)QK,'[%<6V6;4QY
MA4Z5&8"`2-.95*4HJ)?/<K9RROF9I3.%_%E2QXY2MD1"K6NUQUCL=FDXIY+H
M,EY1:O59NHSKB*K1054@6<J'*7Q.`#N`9VGZ46^BH"_?ZP(JO+)VI*0`0)RF
MKWO4/1"W4]:KC<+DFEQRA*Z/S`G>I*E*()E.2=$@\ID]\-\[G?=F>=NZ*P_%
ML^/-SR_>LTPT@ZK`QSDD746LO%I1GJX5^Z12D9M66,>3*HFV0:',=(AAW`2C
MI)Q'"TY2M]1JFV*>G(W3U5(SU'`2TXSBA9QGZL.;IT)HW:FJJ4G9+1,Q*8)$
MS/702A.KCO?]XYZR4NL7VXGK2D)E%V8%<<9:>&]"`"IUA(#$-E3$!+Q\P&XA
M\=M/`Z?X*DAA=V!J>&BV^/H_AB=JZG]1%)^*19EBEX_S3AT].A^2&%=M#O[8
MSYHY)9<><UX\7P#GB2,X:5]HK)*2%/M<LQ*H9Y`M'C]M'2D+8BE2,8K1T@4%
M.D2D.)P$NEG+.FU98:0W2@=%3;1+<0)*2#S($P4]X,-N%=6:'):X6>Y,FDNI
MT2"9H61Q2"9%*OXI'H,3QWENYMD3MI8\P_<<?8YJN0G&1[E*5J10M,K(1:$8
MW80J\H1RV&/;.5%E5%$>D0,```#OK&X)B5+E=6\Q5.K:2TV%#:)SF91ENI&;
MU>$T5/4TC"'EO.%)"B1*29\HH%ESW&$C(U[%F.>'^`7?([DM<J/`3UYC*T2>
ME*31K!)L$',C7HQ*&C7E@M#R(<*BFL<$D&J8AL*O5N`,M#TN2EQZKOE2*2TH
M<4E!5(+6`9`F9DD'EQ/="G<.L:E-L46/4BJR].-)4L(!*$*(!*1(341/7@.^
M*W3/?P[H7&>6BISF!P,1@<>2#M)-9R>LWG'ZQ6ZP_D,)V6;2L.K(`0=TTEA3
M\P0V$0UE6^F^'W9!;L=SW50'#<E?M`D9=LIQAG.K&;V5Q+N16DHHU'CL6C^4
M2H3[C*-*_!7GQ@3N"8B2RMA&9<=;!=.-N=)FRHM;;1YPR7F&C9MBDJJ0R2I0
M$S=RD8[=PG\Q##X@$HR+&[EC-=\%<$C430L:I6.U)^<<1%HQ;*[3EUN%PM:C
MH9+0K1:%=BA\Q&A'"/9YQ\[\#<`<0.,M9PFETR.U5HZG4V&(DZM=XGB)>:6*
M@F*JJ)!*F4Q3+N%3$0;D$!.;<2@/&/8Y<<EKA0V](F-5*.B4#M)^8<3RC]91
ME-JQ.W&X71<@=$(&JUJ[$CYSP`XQG$A.^#W9.3/U&^\0>WT67Q`W=KIQLJ[K
MUPN!Y%LB8P``SS4D)$.'PE+^D39^H`AO`##]NJFOI]A=IE37RZ;:XC4`I3+U
M:F7IE$<;ZG9[>=U5C]G4JW@Z$I4N<N^:03VRX19CA1[AAO=\TL.,O/#"CSC%
ME:4EFU>B["L65:5D)]X<J3&+M<386;"9JBDBJ8"H+F!9J8QB@90O4`CB;_TQ
M53T!NV.5`K*)*9E(D52'$I(T5+F-#&:QGJ\FJN8LF4TJJ&O4K:%&83N/`*"M
M4SY'4=XAL?=#YEVK@CQ!N'(ZD5.#O4W79VGQ36"GG[IA%.F]EG6D4LX.[8I.
M%@%NBY$Y.DH@80TEXA8F<BOC=JJ%J;;6E1F!,^$3X&'W.,D?Q7'G+S2MI==0
MI(VJ,A)1`G,1Y[7/,FV<\N(--Y&W6HPE(G[+8+=#N("OOG<C&(HUV85C6ZZ+
MEZB@X$[E,@&,`E#I'PUQEUC9QV]N6IA:G&T)2=Q$B=PGP$<X/D;^58^W>*EM
M+3JUK&U))'A,N?;%VLE6=S2,=7ZYLVR3UW4:7:+.U9KG,F@[<0,&^E4&RRA`
M,8B2ZC4"F$`$0`=8"E9%15-L$R"W$IGV3($X9JU]5-1NU*1-3;:E`=NU)/[D
M)'[1'=KRKW&5.1Z%UQ14:0KAADT<01*M+RLJ>=7='?D*V=IOF;<Z9NIJ4`\O
M?<3:H&;871XL*4T[RW`^2#N`$I2_?B:8!GU?E_Q?Q+#;1IT`IVDF9,]#/T1D
MQ[P7-GDGRPS;BN4SSQR>X,?XI>3,31F#Z)M<>I=V#6VBY2?)A8XB,4=D5<-B
MI@+8%B#U>`CN&K+A-@M-EH'D6VK%2AX)*R"D[#MX>$GMYQ!,_P`HO=]NC+MU
MHE4JV`M*`0H;T[O>\0'9RAU&/N^9W.R$H56#MIV!*$\BI099?\*9>$JD69*/
M8DDR*#3"-"IN&@@J41-Y90,`]73XZ1*GI[B4G7C=F_,\2I;D<=3+WNW2*+2=
M4<W`:8%D<\OP)GM<X:"?N]FL:`NX[S)N7"GA/;.3M8ID/:+574JB(5:P/'D?
M&^;85T$79'#AJ@L[(+(5!V`";B(;#J:XO8V+]?D6EYPH95N\0`)\(F/;%<R_
M(:G',<7>6&TK?24>%4P/$0#[(\=K;F7;.>?$*H\B[K4H2DS]AL=KA%X&O/G<
MA&(HU]^1H@NDY>H-W`G7*?<P"7P$/#1E]B9QR]KM;"U.-I0DS(D?$)QQ@^1O
MY5C[=XJ6TM.K<6G:DDCPJD#KVPNSN(>X!Q;Q<R,^X\<;*`XY+Y]9/@A99M$O
M%R4JNSQC^5]!,]B6TE*62PHG'8[5BB<A#?*=0IO#31B_32MO%*+I=7!26PB8
M)]Y0[9&02GO/J$)V8=6Z"PUAL]G9-;=@9$)]Q*OU9B94KN2/28H%-=Z7O3XW
MB`R=DKMY%9XN2*#]VLXQSDN&(VBP#S3JNYKRGRD>D5`-Q66;%(7[1TRHP+`J
MM?P=)=`:SA[Z#KW#2?MA2<ZE]2:-KXZMLQ%"-3^S<$AWF9EZ2F'1]L7O%X$[
MD;60JD+$RF,<YUN*&8L6+YM4L@D[BD3IH.YVJS[9,K:6B6[E4I%"JE0=)"<O
M4GL.^D++L&N6**#SBDO6Y9DEP::]BAR/M'?%+PCJ+:<S26&DJ8NB$S4TK73]
M9*N!'L([(A+NB][>N<(<C1/&O"&,7>?N3DVA&J+55LN[2@JL><3(K"L)#Z4U
MD)>8L4DW4*LFQ:HB()F*)SE$=@R&(8`[D%(J[7!X4MH22-QXJEQ(G(!([3&,
MSCJ8QC%8FS6U@U=Z4`2@3DG=[H,IDJ/$)'K(A=,GWJ>\7AYLE=\W]MQTECL!
M*[>+HT_(U?,TC1`%CJ.)0L?,ILA3;COU+HIE`?MVTTHP'!:X_#V^[)^*Y>)!
MF?1I/U&$USJ7U$MJ157.RJ^#XF2%ID/3XI>L0^[MK=Q"H=Q_"LKENIXUO&-1
MK=@&J3T;;&[96,=3:3?SW8U:>9JG;3K!J/R*FZ4U$5!`JA"F\-3;*\8?Q6X"
MA?=;=W)W`I.LN6X<C%7PO+Z?,K8;@PPZQL5M4%C2<I^%7Z0]DN8A.'/7$E2S
MMW?L?8DNX.PK=[I=5@7SABIY3QB9>%M:K20;&^PRK)Z@FITCX&`HA\=5W#[C
M46GIF_<J27Q#+RE"?`ZIF/6(^>_7#&+9FOYM+?B=YW?=M?0M-+*3)29MO%*A
MWI4`9<^$2CP*S7=^WYR9M'`3D1(+)X^L%@.OB.W2)CI131U*JG&'=,W2XE23
M@+6F!2'+X`V?`&_2`COXLQM5+FM@;S.R"=8VB3Z`/%(<9R_21\J88NAF97OH
M+U(J>@_4%PBPU#Y-!4*,D!2SX"DF4FWQ*8_1<GP$:)[S=JSCBGV*]W&5;0M8
MJL2[FIJ3=*%31:LF:0JJ&W,(`9100`I"AXG.8"AXCJ(TE)45U4W1TJ2NH<4$
MI`YDQ]`KU>;=CUIJ+W=W4LVRE:4XXM1D$I2)GU\@.9D(RVM*G<^[%F/-?)+)
M",S"\9L&4ZY)X_@O.5;I2;F*AW[Z%B&O2'EF?R+ENF^E%@$!33!-+?<=M;!N
M/TO3>U4MAH]JLAK'4%U6AV@D`D]PX('KCYE4UMO/YI\RO'4>_P#FL],K'25`
MI&M4^8M#:E(0G^,HCS'E#AHCLBX/8$331PMF])(O2DEDMFFF7??I(2)$I"[_
M`!V*&EKK0)7>D'_V_P"[%8_(:9X5>O\`N8_HQ$/4LQB]]ZQ=)A+U(SA1V';<
MIJ3&`)1_L$-9.K$^CK?TQ]>%&RDC\]-7+_<J_H$QI=U!8^C\+HY[]OO%7+G&
MT^X;5V)KN9H>-=R%,O46Q2:2+F2;)&<)P\\9JFF:7CY(Y`3W5ZE4CB4Q#``"
M`O&&YI<<:KT!2U.6I2@'&R9B1_23/W2..FAYQK[USZ"8MU8QU]Q%.U3Y@RVI
M5-5(2$K*P"0VYMEYB%G0[ID3!!TE"_\`M592/R;QQ<^(W(XK^<NG'J7(\JDL
M^=`>=2@V3Q>$=1+ARN"XOOH#X/(_3$.51LN4IM^D!TY=1;:+!7-9+8Y(I*Y/
MC`'AW$;I@"4MPUTE(COB$_E@RA?4C'ZWI1U#WO7K'W065J/[0-)46R@DSW>4
MH;?$#-"@#.4X>[CS'-6Q?74ZS4F:K:/!RY?+JN5A<O'KYVH*KEV[7$I`464,
M/YI2E*`````:D-;75%P?\^I,UR`$M``.`$;O6#'[9C5O%MM2"FG"BHDF:E*4
M9E2CS)]`'8([UKQQFH-$$)%]P]_2MSO^O,7_`/$2NZ?NF?XPIOHN?4,3/J[^
M!:OZ3?UTQ&7MH_Z9E;_FKDS]MZ]G5?\`%J_LD?-'@Z*_@I']8=^M&@?4UBMQ
M\_[)F#*1R,]R!8,5Y'8)R](E\XI2%@AU@ZD)AE!1"<O]+<@.X&:OE&@)J@/@
M)!$-;*4UPJ+7TL164AVU`II`]FY4ICO$:G5UKI;QUB705HW4RJR:D\B$I!D>
MXD"-^$7$14'&LX:&C6,3$QS5%DPC(YH@S8,F;9,J+=JU:-R)H(((I%`I2%*!
M0`-@UK<M:W%EQPE2R9DDS),;7-MMM(#;:0EL"0`$@!V`1A4]Q9B^IX7[BW&G
M+V-8QM5+;D".@+197,.D1@#ZT4^ZQ2,9/'].!`]>J@L4JI]NH_EE$=];$=+:
MIZOQBKHJLE;#>Y*0=9)4@DCT3X1JWUDHZ>V9=0W"B2&ZA[:I1&DU(6`%>DB4
MSW0TOW'O(RZ4'MTXKI=?DG$<\Y!3]=B;<[:J'05<U^+@6L[*QPJIB4P(2CI8
MA5"[[&*78=)O2VUL5&4/5#@!32H44@]I5('U#A#YUAO#]+B%/2H44_%K2%D<
MTI3N(]"C*8[(I?VH^ZWVF^W[Q8IU`>.K^EFJQ-AL&:+.RQF9\[DK4Y55Z(M&
M9(\24<P\(P!-!N4H`3P,;;<PZS^989F>37ARJ3Y1H$F322X!)/;+D2=3"Y@.
M<X+B=@:I5"H^\EC<\L,DS6>05S2D:#E%I^6_?'[/W+OC_DG!>2'F29J*N=9E
M&46N\Q:L=S!6/TBIH&>BW1WYSL9"+D_+5(H780Z1`?`1UA[+T]SBR7)JXT@9
M2MM8)DZ-4SU!',$<8SV0=2\!R"TO6NL%2I#B"!-A7A5+PJ!Y$'6<5.]J9G:<
M-;>4/'`\JYD:6UC:WE"KH+JF,FRDG#Y]7IA1N@8QBM"/V3%JH<A=@%3<1\?'
M68ZQV]LLTEU"0'R2A7HE,>PSC`="+@^ARMM"B32Z.(!F)&<E'U@IA4.7^+S[
MF5WSLO\`'1J_<Q3#(7):<:V65:;^?&U*,8M)>T/$/@#E*$8K^5OX>:)=].-#
M=TV+IZS="`5M4HV@\U'1/RPAW.QKR/J<[9DJVH>JU;CV(!)4?8(^A?@#C)@W
MC#CFOXLPICFLTFIUYDW:H(1D6T(]D%T4RD4DYB0%(7DG*O#@)U5UCF.<YA'?
M6L]RNUPN]4JLKW5N/*,]3H.X#@`.0$;;VJRVRRTB:*VLH;82):`3/>H\23S)
MXQ1+N,=T[A5P+?5N-S8W3R-F)-JK.4_&M:B(Z<M<4V=%,U"6=OGI%&]4;2`%
M,FFJ<?,5Z1V*(>.F/%L/OV2!2K>?*H9R4XHD))[`![TNSE"MF&<XWBRD(N0\
MZXRFAM(!4)\R3H@&6A)UA3R/N8;C+=4I7.VUG&3I@F$49%)Z]<&59[_*J"S6
MHF8&W3\?EW+_`&Z<CTH91X';K3)?[-!\A5.$0=9GUCS&K/4FG/,;CIZ4ME/R
MRA!G-SF9BCDMW`\`\E\$X0NO&^]?BC')\@P-C1;L%Y"Z1EP;)IV-H#)C&%,X
M=Q:I$%U?+`ROE[F^T=4C'[%66G&JFTW&H;JZ?8O84S(""CW=9\#J(DV49%0W
MC+*2]6JF<HJHK;\Q)*9E86)*\/:-#/C*'I^ZB<JR/&SB$\7'=9]D*0<K&^]5
MS1UU5!``^\YQU/.CJ0+O6H'#RY?RHIO7A9-EMRSQ+Q/\B&I]DG@YBSBCPMQ3
M;(BNQ+G+&9ZC#9"R'>E&B"TR_4L#8LC&0;9^H4[EM"PS!=--)`I@+U`8P@(C
MI-S_`""KO-_>96I0HV%E"$3T&W0F7:3SA^Z9XQ0V'&J=]"$FOJ6TK<7(3.[4
M)!Y`3X=LSQAK>2<9T/+]*L6.LEU:&N5,M<4[AIV!G&*#YD]8O43(JE%-<A_*
M6*!NI-0FQTS@!BB`@`Z3J6KJ:&H354BU-OH(((,B"(?*VBI;A3+HZUM+E,XD
MI4E0F"#&'GM@-YO@%WW,D\0ZG+/'.-;;8+UCIY''<JG;N(MJBM/4YVLAU"F=
M]&J@0GF"'5T>`CMX:V!RU3>2].FKT\D"K0E"Y]AGM5+N/&-9L(;<Q3J>]86%
M$T2W5M2[1(K03]&4AZ3VQ%O>SS_2\N=WNO8^Y(3=A9\8L$2E)K-CBX5!:0=I
M5T&+>TVY5A%D43*L\L,@[!JH(;'%`0\?E#7MP&W/T6#JJ+4E/WO4A9!.@G/:
MF9[`-8Q_4B[4UPZBHI+PI8LU)L20D;C(^)<AVJX3XC2'R4SW%?:5QS58&C45
M[D:M5&K1C2%K\)#XH58Q\?&,$2H-6[=LC($(0I4R!OX;F$1$1$1$=3I_I=FE
M4\JHJ`RMY9))+H))/&*M3=7,$HV$TM**E%.VD!*0PH``=T(E[Y?<![='/FD8
MXOW'9W<&G)*A6)./5F9*C'JXS=%=)F6.A(S/JU17<0$DD59F`AUD%4^P[;`%
M"Z?8SE&-ONTUT\LVIU$Y!85)?:!WC0Q+^IN4XCE+#%;:0\+PTN1*FE(W-GD5
M=QU'/C#%^8N<)SD/[:G'&2[.[5D+&Z9XIKTU(+J"JL^>U'(*%;*Z54-\RBJS
M6-3$YAW$Q]QW\=*]AH&K;U6<I61)D%Q21V!2-TOEALR6Y/77HPU5U)G4;6TJ
M/:4+V_N0QWVY?]+7$W^^N3OWH<:5>J'XP?\`LV_JPX='OP.Q]J[]<PWG/_\`
MD1FK^4N1OW/F-)=M_M%C[9'UA%"NO]EU/]7<^H8R2^U*_P#-W-/_`+35_P!J
M26K5UD_F*#TK^81!.A7\_<?0W\YCIONFOEY(\)P*!2@6%<"`%*!?$;XS'<=@
M#<==G2'^R;A](?5,>?K;_;=N^Q7]81LMQHDD;'./S&33$PTFJ"(]!=]_H3`=
M_L^_4,JR?BG!R\Q7SF-B*(#X-K[)/U1"@?<-?TL\Y?K:D_MPFG;IG^+J?Z*_
MJP@=6/P54?:-_6$+;X(\@)_C)[<6]Y:J2RC6VQBV482L/4_RXZ9M%C9P*$B0
MP?,15@D^453,'B50A1#QTUY%;&[OU2:H7M6%!HJ[PE,R/7*4).+W=VR=''KA
M3Z5"2\$GL*E[9^J<_3'K>V)X@4":QID?G%D"*:7#+EIODW4*E,SB2<FYJ\;&
M&!6?DV!W)53(S%@D7.YU_P#E2I%$H#L;7/5N^52*MK'J<ENB0V%*`TW$^Z#_
M`!4@:#MCGHICM$Y1.Y-4I#M>MTH0I6I3+59$_P!)2C(GF!&M]=LW=(*M72"+
MALLF9)9NND15!5(Y1(=-1)0IDSIG*(@("`@(:BP)!F#(Q?2D*&T@%,5EP;PQ
MXR<;+IDW(6$L0U/']OR]+!,7F8@V":"\@X`1.+9F78214:=<PJF;-@31,J(G
M$HCXZRUPOMVNM.S2U[ZW&&$R0">'I[3RF=91A;9CEELU0]5VVG;:??5-9`X\
MY#L$R3(2$S.,A_<XQ%RQ[>/=?/W**=B-;-N)YVQ)6V.D5(E[.PL4=]%)1L[4
MK`6/(X?5N0CRD/\`3W@`!03Z3@(>(:M>)UEFR?#1BS[_`,/6H24D3`)UF%)G
MHH'F(U_S2@OV(9TK,*>G^)MZW`L$@E(.W:I"B)E$M9'T>B&J\>_<N\"LOE8U
M[-41=./]A>%2:R*-OBD[+34'!^E)P#F>C4BBV:"<1$`5;;@7P-X@.D^Y])\D
MH9NT"FZEH:C:=JO8>?H,/=HZRXO<0EJXI=I75:'<-Z)\_$G@/2!#X<)/L*S&
M/(>?X_K4-UC*Q'<ST._QP6*+69%>45%T^?HA#E(U]8Z74ZENH`5ZQ^<`'4ZN
M":]%4INY>8*M.A"Y[A+@-==.45&V+MKE(EVTEHT2_$"W+:9\3II,\^<(#Y(?
MUS\#?JRD?L:WZM-B_P`(ZWZ:_G3'SWZA_P#FU8?L6/J/0R?N7\&V7+S$GU:I
M(HQV<,;).9K'LRELW<2H(E]0[J;QT3I4]-*>4'D&$?T+D"G#2-@67+QFYANH
M)5:'R$NIX@3TW@=HY]HC8C\R'1)CJWBGQ-K"6\UMR5.4CHT4HC4LE0UDN7A/
MZ*Y&$3LN0G+GN&0V'>WRO#RE;EJE)*1^:[HY4<IOI:%JSD&A']O0\LOI!K[1
M/H.D(_XQX!1'J$-5Y5EQK"7:K-DJ2XTXF=.C204L3DCMW'_-3.-(F<^ZK_F`
MH[/T#<;<IJVD=*;G4'=N6VPK:%/B7A\L#4?[1S:3.<:4B82H_'?A[;\1X^CD
MV%>J>(+HT*H"9"NI60-5Y$TC,R*A0ZG$A)NNI10QA$0W`H#TE`-0=5UJ[WDS
M=RK5;GW:E![@-XDD=@`CZ,C#;)@'2:KQ2P-ANW4MIJ$C35:O)7N<6>:EF9)/
MHX"%=]@C_)K.7\SFO[*'5%ZT_P!KTG]7_=C6'\AGX)O7_<Q_1B(:IO\`7>L/
M_13?[E1FLE5?X.M_3'UX4+-_YTU?V2OZ!,:7M06/I!'@QBD*8YS`4I0$QC&$
M"E*4H;B8PCL```!XCHXZ#C'!(`F>$9B^V4!;'W5.6-JJ@>93D&V2RN'#4-F2
MBCNWP[9H;<GZ,06=ME3$^_81#5\ST^1T[MM/4Z51+<@>.B#/Y"(^;OY;RFX_
MF?RNY6O6U)1534/=UJ$@=VJ@HB-.NH''TC@T00:((2+[A[^E;G?]>8O_`.(E
M=T_=,_QA3?1<^H8F?5W\"U?TF_KIB,O;1_TS*W_-7)G[;U[.J_XM7]DCYH\'
M17\%(_K#OUHT#ZFL5N,,E1__`%!RW\VIK]TEM;#U'^$2?L!]>-8&/\;E?UE7
MU!&YO6O$;/QB(]S]_P#</AE_NF\_?F#UL'T@_L.O^E_H*C6+KG^(+9]#_P!Q
M,-M[X/#FX<M.VG57V.(MW/7[!S"LY,BX&/0%Q(S<&WKK9M:6,>B7=5=Z6-*"
MJ:9`$Q_+$`\?`4?I_?&+-EBTU2@FFJ"ILD\`2KPD]T]#%%ZEX]47W#&UT:=]
M72A+@2-21MDJ7:9:@<Y10GLL\@^UQGS`M/P5R/P_QLH_)#&;(U:=/<DU*JPP
M9,BFKA<8^=:V&>12;N["DD;T[QLNL1SYJ744@@;P8\]MF7VVY.7&UO53EJ>.
MX;%*/ED\1(<$\P92E"ETUN^$72U-VF\T]&U>F!L)<2@>:!P4%*T*I<1.?,3A
MON?(3LN\:J-)W[*]'X=1$7'M%G+:+C8"@SUFG%4TC*IL8&MPQ'LO*.G`EZ2^
M6D)`$0$QBAXZ2+:YGEUJ!343E<I9/$E82.\J,@`(H=V3TXLM*JKN#=N2V!.0
M2VI1[DI$R3ZHY'M2YWX&\IJ3=<Q</,!0V%9>)ES4B\-4L=QE2ES)MSF?Q:)I
MJ&0-$S#%TU7*X!-%PH9`YQ*J4AP$-?G,K=D=GJ&Z"^5*GTE.]/C*AV'0F8(X
M:C7E'ZP.[8M?J5RXX]2)IG$JV+_9A!TU'B`DH$:Z'2<9S^%H`/N8<R;@`[9'
MS4(;@`[#^`W`;A]P[:J%\_PH8^S:^L(D6/?XSO?:/?5,;HM:]1L['SX\@R6+
MZ;[B"\3//]HDKC`,P+NTEKNB9Q5$(UQ3FR.+9201<E,V5I3.4(B*FX"V*<B@
MG#8JFME:5-6_TQ0WC9_ZSR1[GO3W?M`):[B)]_9&IE<N@INKJG,K$Z'SR9KG
MLU'[(F>A2/#.6FFL;LT<S\>:W2$+"VRGAV#QVTC0<-99K<Z;'5)"*(CUE,U<
MH2*441H"`?*!!VV\`#6O)H;F[4>467U51/#:HJG[)SC:$7*T,TP=2_3IHP-"
M%H")=QG*48%.\CS+P-R[[B>%S\=R0<K1L735'J+N^0<8VCFEWL"MV:OY-^U.
MDW;K24:R%8B"#E3?S@(82?)TB.R&"V*XV3%Z@73<FI>2M003,H3MD`>PGC*-
M4>HN1VK(<PIC:-JJ1A2$%Q(D%JW@D@RU`X3AL7NEA$.+W#@0^T+PY$/]H4)3
M29T@,KQ7'_A_Z</?7:1LEM!X>:?Z.)[['G>`P1<N/=!XL\B;[!XCS;B6):U2
M"=9`D4*Y`7ZJ-4RA77;"=E1:1K.:;QYB)+-7"B1E.DITNLIM8[J#A%Q8N;EY
MM;:G[<^HJ.P;BA7Z0($S*?,>N,OTPZAVNJM#5AO#J:>Z4Z0A/F':EQ(]TA1D
M)@:$&7:(<1R>[DW#CBGC>;R#D#.6.Y-PPC7+J#I=2MT%9KA:Y`B0F9QD/"PK
MU\Z#UBPE(+A4I&R0&ZCG``TC6C%;Y>:M-+2T[H!.JE)*4I',DD`:=G'L$42^
M9GCE@HE5E;5,D@>%"%)4M9Y`)22=>WA&67L?XUR9SO[GV9NY#=8%Y%T:L3MP
MFF4BJBH6/=7*WD691%:8.3%!%\O`Q"@*N#)B()F``'81`-5_J#54F.XFQBU.
ML*J%)2".>U,B21RF>$0_IE1U^49I49A5(4FD2M:YG@5K!"$@_P`5)F?4><<?
MWXN/DWQ-[BN*>?KG&,?E'!MYG*C(W6`FHPLI5G5CK;9.#L53L22Q#-4CV&O)
ME<LO.Z4U'`"'5\AM?OIS<D7K%W\:#Q9N#:5;"#)6U6H4GF=JM#+64=?5&TN8
M]F3&6K9#]J>*=Z2)IWHT*%<O$!I/29[1#_N-"?9AY78V@\E8RQQQ$\J5CV[N
M6J\_7<?UZW59^JD4[N+G:_*D92#19HL)B>8"8H*;;D,(:FUU_OW9JI5)5NUL
MTF04"LI4.1!$QK[8K%D5TYO]$FMH6;?)0U2I+:5I/,*29$2]$CRBL?,[D[V-
M.&3BO0L[A'CMEBY3<XPC7U/Q!1J+<I*M1+A4A'D]/O&)3Q3%)D4X"#3SQ>K#
MX)I"/VY:PVCJ%?@MQI^J982DG<XM2`H\@F>IGVREWQA,DOO3''"AIVFI*BI4
MH`H90A92GFI1&@`[)S[HFCNNX,K&8.SKDB"XNTMK$4QA4:;F"E4VLU=>O$-5
M8>;B[A*E:U@6;1VQ<%@Q<.3HBB53J((;;CKP8;<7J'.67;PX5/EQ3:U*5N\1
M!2/%K/60G.,AGML8N/3E]NQM!-,&DNH0E.WP@A1DF0(,IF4H7[[;WN(<>X7C
M$IQ'RGD2J8RR30KA9)FL)W6885J,N5>L[T9(!B9>67:QRLI&NSG15:F4*L8`
M`Q2F`?!EZI8O<UW;[[HVENTCB`%;05%"DZ:@:R(UGPA5Z.9?9V[)]P5SS;%:
MTXI2=Y"0M*C/0DRF#,2X\X9]W1.Z=Q;XP\9,IQL7E>BY!R]>:58*?0L>TFRQ
M-IE7$I9HQU#DE)@(5V]1AXF,3=F6.=P9,5!(!"`83>"EB&'WB\79I:F7&J%M
MP*6XM)2`$F<A.4R>&D.N<9U8K'97T(J&GKBZTI#;:%!9)4")G:3("<R3"4?:
M<+*N9WF&Y7V\YRC2G"VP;!YR[MZJKL'P#K..G[K*`&:$#A-?S")QT&)4Y<"?
MU6_G,<#[JMF[C,W\+K8[:N"U]"&FTU9$J*AT"K1%L823YOUE*)?4)LU2G`F_
M48!\-?OH\0NWU["3^U*DZ>E)$=?7(%JZ6ZI6/V/E+$^_<-/3+7T1I]Q1SEX>
MN\#XPO1>2F%V]>D*=36B"CO(=8;R19)>.CHXD0M"*2)9A*7+(&\@S84`5!3\
MW;8=22LQ^]IN+U.:5_S0XK]!4I3)G.4I2UG.46N@R?'E6IBJ^-I@RIM`$W$@
MS(`E*<YSTE*<4D]PHLDX[5N;7")P417D:,LDH7\DZ2LTD=,X;_`Q3`.L_P!-
M`1E[`/':OZL+G5<@X2^1P*V_K"*4]K;C?_\`+7L`6+`*"J+>7OJ^66M:=.!`
MJ+>T1TZVE:^94YA*5-):39)I',([%(H(C]FF#+[K]R=247,S*&@T5#^*4R/R
M&%;![*,AZ3KM$Y+>4\$GL4%S3\HE%!^Q3W#JWV^+QEG@#S0,ZP^T#(,@]KEF
MM;5TQC:E=0-Z*:@[.=0AC1L5/"D1=J]$OI0';J,!#"?3'U#Q=W)J=G)+!)\^
M4-R4F94GB"GM*=01Q]D*_3',&L2JG\5R?_IAYDTJ4)!"QX2E78%``A7MT(,;
M`;+R\XK5"H.;]8^1F%(VGM60R!YXV2ZBY9JM0)Y@&9`SEG"\@JH3\A)N114X
M^!2B/AJ(-66\/OBF:I:@ODREY:IS[YC3UQL$]D%BIZ<U;U93)IP)[O,1*7=(
MZ^@:Q1KA'WC>-?/#D)E;`>'H:]>=0&QY2MW>1@U_PO?()F;R)*6;+($.M7$R
M.1`&R<B5!1T3YB!O\HL>08+=L<M;-SKE-R=,E(!\2">`/ZW?MG+G"OC'46RY
M7=G[5;DNS9$TK*3M<2-"1^KKPW2GRC]*YWG>WE><^Y.XPV#+$-5YVE3:U24G
M,@MF\7C:[2+<WI)AA#V1\96(,FP?E.W/Z_TR:PDZDQ.40UP[@>3T]L9O#;"E
MM.)W21,K0.1*1KKQTG`SU)Q"JNS]B>J$H>;5LFX)-K(T(2HZ:'0SD.R(.[A7
M$KL\9,P-DS(^4R<>:#(L:E.3,'DS&5HJ%<M!9Q&,<'B#0S"L/P96EX\D!2*#
M86C@[C?8!+N)P]^,7K.*2XLTE%\4X@K`+:TJ4F4]9E0\,ASF)1C,NQ_IW6VI
M^MK_`(-I8;44NMJ0E6Z6FT),E$F6DC.%R>U(E\F+4KE7`JOYI]A"&MM?&G!(
M"X&,:6IRDY-)EB"*[H-3O(HJ2SI)'8OFB`F#JTT=8VZ45%&Y)(N"D*W2X[1*
M4_09RG"ET*<K#35S4U&VA:2F<Y;S.<NR:9$RXZ$ZQ:'DA_7/P-^K*1^QK?KU
M6+_".M^FOYTQK1U#_P#-JP_8L?4>C2MJ$Q]%XBBHX/Q71+_?LHU.FQ,+>\G'
MCU+K8&B(E=S)HQ(4FW7U&,FW`PB)U02`@+*CUGZC>.LC4W:XUE&S;ZEU:Z.G
M!\M).B9\?X.P:0K6G"L7L5^K\FM-&RQ?+F4&I=2)*=*!),^SM,I3.IF8\YV_
MR3R]_+*]?NS)ZXM/]J4WV[?UA'ZS;\&W7_MU3_0KA&_8DNE-K&'LW(V6W5>O
M+K9+;*(H3D_$Q*ZJ818E%1-%^[;J'3`WAU`&V_AJO]8Z:IJ+O2FG;<6!3ZE*
M2H<>X&-)/R,WBT6S"[PBY55-3K5<@0''4()'E@3`4H$COBY<3Q5X_1/-9_S/
M3Y)556>?%=]5+-.5`L<0[R(;Q!Q^KA8C+F3*DW`P%\@/F^.E1W)+R[B2<3-`
ML,I(/F;5[M#/AME\L6&CZ58'2=:G>LZ<CIS7NI(-,7*?RQ-`1[_F[N`GPB_L
MMG?",$R6D9G,&,(QB@0RBKI[?*N@D0A`W,/4>4#<0#X!N.DMNT75Y00U35"E
M'D&U_O1>JK-<.HF345=VMK;"1,J54L@#VKA.'./NPU)]"2''_AHI(9;S!?TU
MJJE9:O'/7L3!IR:8M'05X?(*O8)PZ*IBIJ(E%JWW%0ROR^%1Q'IQ4H>3>LIV
MTMK9\92L@*5+4;NQ/;S/"4:@=:_S4VE^D<P'HX5W?,*^;`>80I;;6_PGRS*;
MCDIR(&U/O%1E%H>UKPB?\1,./Y:^D35S-E59I.W<WF@Y4@VB95%8VM"[#?U#
MEL9R=5V<!$IG!]MQZ-Q7NH66(R:ZA%'I:Z<%+?+<>:I<I\!W13ORR=%W^DV(
M.5-^DK,;HI+M29S\L"90SNUF4S*EF<BH]T-$U/XV8@T00:((JQS,XE8\YO8!
MM?';*,C88JFVY[7WT@]J[PC&836KDVRG60(.#D4("9W;$@*%$!`Q!$/CK+V*
M\U5@N2+I1A)?;!`"A,>($'Y#&"R.P4F36IRT5REIIG"DDI,CX5!0^41P7!SA
M7C+@3@UG@3$TK99BI,[#.61-Y:GB;V5,^GW/JGA151323!$JGY(``;!KMR&_
MUF27$W*N"$OE(3)(D)#01U8QC5%BMK%JH%+4P%J5-4IS49GA(1<36#ABA4<=
MVA>.T;SP<=P1"S9$-EUQ97-H&%/+H?A,L@ZCCQBJ8,_(]0+;R#B($$^V^G->
M;W5>.#&2AKX$(VSEXI3GQ[9PAHZ?6A&5'+0X]\>7"O;,;9E.WLG*7*<H:YI,
MA\A6//#M*\>^X)DG&F4,NV/($+/8OC5(J#0J4J@R8N&JLLUESB\1605$RHN&
MA0ZBB`].G'&\VNF,4KU)0I:4V\9G<)G@1I[81<KZ?VC+JQFMN*W4N,"2=A`!
MUGK,'F.4,WA89I!P457VW6LQB8ME$(>H$%#JM635-HGYXB&RACI)AU?>(Z47
M%J<<+A]Y1)]NL.S3:6FDM#5*4@>H"4)3Y?\`8"X*\K[A*9)91%DP5D:<=*OI
MJQ8G=-XV-EI!;8RLD]JSA,T*,BNH'4HLF5,QQ'QT_6/J5D5E8%(5(J*1(D$N
M"9`[`H:R[HFN1=)\6O[ZJL)72U:C,J:E(GMVD%,^TB4XJQC7VNO#NNV)C,Y2
MS%F_,L8Q<D7+6I>2CZW&N2)G`Y4'3F%+]0.BIML<I5"@8NX:S-7U?OSS);I&
M:=A9'O`$GU`Z?)&"H>A^.,/!VMJ*FI0#[IVI'M2)_+&AK#V%L5X`H4'C##=%
MKV/:+76I&D57JW'H1[-(I`V,LMY104=.US;F454$RAS"(B.IA75]9<JE577.
M*=J%'52C,Q7K?;:&U4B:*W-(9I4"02D2'\)[287EC'M"<=<5<X[%SV@+)D-Q
MEFRSEHGWL.^ED%*J1[;(A6&D2ILRHE6%$C9413*8X])P`?AIGJ\WNE9CZ<;<
M0T*)"4@$#Q>$S&L*-'T_M%%DZLJ;6\:]2EG:2-HW@@\I\S*9AKNDV'N%T\Z.
MUMQ'[@K*/<9RI*Z-Y@V2D?7\F5%X:!ND8S.?S2L%Y!N7IEHM-7<Y6SDJB93"
M(AMIGQW+[UC*C]W.?L%&:D*$TD]LN1[Q"AE&#V#+4`W-J54D22XG18'8>2AW
M&8A3E;]KAQ3C9I%:S<B.0UNJ**Y3_@Q22B(5HLU*8!]&K)1J8.P3$ORB8A2F
MVTZ.]7[RM'[&EI6ZB7O@$F?;(P@L=#K"AS]O5U3E-^H=@'M`^:+891]OOP)O
MTIAY]68.SXG98::QZ$/&4.00:DL#F/F2319:TOG:*[Z7EW+E,`5<'/UF*&L-
M2=2\DID5"7E(>54$[BL3E,2DD#0#NX1GJ[I+BM4Y3K82NG33"0""/%KNW*)!
M)43Q5QA=7NKF24;QZXEQR`G,@PR=+LD14'J.9)K37*"8G'XG$B8;C\1TT=&U
M%=UK%'B6@?Y4)?7M(19J!`X!Y0]B(MY6NSSPXY_\+>)]WR75I"DY90P-CUF3
M*F-W*=?LKY%*!:`B6PHIIC'V,4`#]&9T0QR?`VVL&YG-]QF_5M/1K#E%\2O]
MFO5(U/#FGU0S,=/<=RO&J"IK6RW7?"-CS&Y!1\/Z0((5+D2)CD8C;'?M<.&5
M=LS6:R1EW-V7(AHX(J6L2\A%UQDNDF<#E;.G\&D$B=$VP`<"G(!B[@/VZ]E5
MU@O[K1;I6:=EPCW@"H^PZ1X:+H=C=.^':M^IJ$`^Z=J1ZRD3]A$:'L/X:Q?@
M+'\!BW#M)@,?T*LM2M(>N5Q@BP8MR@4`.NH5,H'<O'!@ZE5E!,HH8=S".IA6
MUU7<JE597.*=J5F94HS/_IW17K?;J&U4B*&W-(:I4"02D2'\)/,Q[.5<2XVS
MA1)_&66J9`WVB6=F=E-5JQL$9".>(G`0`WE+%,*+A$P]2:I!*H0P;E$!UQ1U
MM5;ZE-71.*;J$&84DR(CFOM]%=*5=#<&T.TK@DI*A,'_`"[8SMY-]KOPZLME
M>S>+,OYLPO%/G!USU:%D8ZQQ;<JAQ.9!FYFR_4$6Y!'8A!4.!"[`'V:I])U?
MO[+(;JV:=]8_24"#ZP-(D-=T/QRH?+U%45-,DGW1M4/:H3]I,67XC^WTX)<6
MKE&Y)EXRT9\R!".47L',9:=MI&&B7Z!A.E(MZHU2)#*R*"NQDUEBJ&3V#;[]
M8F]]3,CO+!I4J134RA(AN8)'9N.LNT"4XS>/])L7L3Z:M:5U54DS!=E('MV@
M!),Q,3G+E#R3M&IVIF)VR!V1T#-3M#(IF:G;'3%(S<R`E%(R!DAZ1((=(E\-
MMM3W<9[IG=VQ3MJ2G:0-LI2Y2[(SZ\H?;=\&^0%[E\BTB4O?'J?GWSB4F6.-
MUH]Q5EY)TJ99PZ85V734:PPKJ&$QB-C$()A$=@^S5+L_53(;73"E?#=2VD2!
M7/=+L)''UQ);WT;Q>[5*JNG+M(XM1)#>TI)/&25`[?0-([;Q@]O)P;XZR,E9
MYT;GG*\.H27A8NR9-=M'+6M_6(]Q'+2L+76B98E*::)N!,W<*`H=$WB773>.
MIV175`91LIZ;<"4MS\4C.1)UD>8YQWV3I%BUG67W`Y4U120%.2\,Q*82`!N$
M]"9RY1;'M^=K'`W;FD\GRN&K#>YQSE8S`9\MPDT'R+8(YPNY;E8)H(HE2'K<
M"`B.XB&P:PV39C<LI0RBO2VD,SEL$N/;&?Q/!K7AZWEVY;JR\`#O(,@DDB4@
M.WB=8GOF9PBX_<\,4GQ)R!JIYV%;/?J]<FHUT>,LU2G"I&1)+5^70#SVBQB#
MTJI^*:Y`Z3@(;;8RQ9!<L=K/C;:O:LB2@=4J'8H?-V1ELBQJTY10_`75&YL&
M:5#12#*4TGT:$<"-#"6L=>U]X;4B\P]KELOYRN$-!S+*:94]](PT3'&68.TW
MC=!R^BVB;Y5$%$B@.PE,8`\1T_5/5Z_/TRF&V:=M2DE)4`29$2.A,HFE)T/Q
MNFJDU#E14N-H6%!!V`3!F-0)\8=CS!XA8YYH<>K#QNR1(V&'I%B/"'<NZP\(
MTF$/H*Y%V1$7"I%""03)@!P,`@8-(%CO=58;FBZT@2JH1.04)C70Q3<@L%)D
M=I59ZQ2TTZBDS2=1M,QQ_=C\N%/#['/!?`L'Q[Q9*6*7J$#,3DVT>VEVF]EC
MNI]T1T[(=9(B:8(D.0.@H`&P:YO]\J\BN2KG6A"7U)2))$A)(D(_.-8[1XO:
MDVBA4M5.E:E349F:C,\.^($YR=IKAOS\\N:S'0U(G([1J#2/RG1W(5ZYD0(`
M`BVE'C<GDS[)#;Y4795`+\!`-9+'<TON->"@<W4I,RVOQ)]7ZI[Q&+R?`\=R
MO]I<6MM8!(.(T5Z^2@.6X&7*%+1/M6>+2$PFK/<DL^6"KI+%.6L'+6XXIT0,
M!A;FDFR!ETPZ0V`Y"%-\?#3HOK'>BV0W2TR72/>\1^2<3]KH384N[G:RI6R#
M[LD#Y90^GB9PGXV<(Z"7'G';&\72XQ<R:TU,FWDK79WB1/+!]9+([`\G*N`#
M[.L_03?Y2AJ<7J_W6_U/Q5T=4XOD."4]R4C015;!C5FQFD^$M#*6T'WCQ6HC
MFI1U,5#YA=E+@7S+F']QNN,CT3)$@<R[S(&+WAJE,23LV_\`BYQHR*$9.+>/
MB9=(3"(;B.^LW8\^R2PH#-,]YE*."'/$`.P<QZH7\AZ:XKD3AJ:ECRJQ7%;?
MA)/:H>ZH]Y$+L@O:T<1FLT@XM&?>0-OK**Y%?PHZD(6+;J(E-OZ<\FQ0]84.
MGP`Y`(8/MTTN=8;XILAJGID.R]Z1)]AA/9Z&X^AT*?JJIQD'W#L`]$PF?LC0
M7QWXX89XJ8N@L.8(I$70Z%7RG%K%QQ!,N\>+;"[E9=^KU.I26>G#J6<+&,<Y
MO[M3*YW2NO%8JNN+A<J5<SR'8!P`'("*W:+/;K%0IMUK:2U2HY#B2>)4>))Y
MDQ"-VX&XGO7*JI<N)67M*60Z>E%I1T<U>I$@50B&L@S:BX;BF*H[I22G4`&`
M!';[M9VDS&Y4>..XRTAHT+I))(\6I!T/JB3WKH7BE\ZITG5JK>JQD-&E"4(2
ML!D[`I(FF4^"C/773LB[^E*+7!H@CKUMK;*XU:QU*2.NG'6>"E8!^HV/Y;@C
M.78KL')D#^/0J5%<1*/P'7=3/KI:A%2W+>VL*$^$TF8CP76WLW>V5%JJ"H4]
M2PMI1&A"7$E)D>V1TA-!>Q)Q9(98R5XRV@*ZIUE0;SS9`ISG,)A$2IMR@.PC
M\?'54/6+(S_LJ:?T3^_&G2/R,]+$"2:R[?\`-3_JQ_7^A1Q>_P#7^8O_`'*E
M_P!3H_\`F'(_]U3?YI_?C]__`,.=+?\`ZR[?\U/^K'NL.Q;Q,1<$/*VC+DTT
M`Q149+VT[4BI0'YB"LV2*J4#AX#L.OPYU@R=29-HID*[0B?SF.ZG_(_TE0Z%
M5;]T?9YH4\`#ZTI!A@6`.%?&GC(4RV(<7P<#,J)^2XM#Q,9BTN4]@#H6G9#S
MGO2.WB!3%`=)-YRJ_7\__DZA:V_U1HC_`#1I%]P/HYTXZ:IGB-L8IZJ4B\1Y
MCQ'875S5+T$1:?2]%.@T00:((-$$&B"#1!!H@@T00:((-$$&B"#1!!H@@T00
M:((-$$&B"#1!!H@A5O=)_P!+O\$XQ_U//H'X+_%3_P#AI]>_C)Y?XH^E+>O]
M/_!W_O'S/I?7OZO]#M]GS;:<,0_O=\0[_=+=\1L&^7E>[/3^=TX]FL(N<?W(
M^&8_OKM^'WGRY^=[TM?YG7AVZ1?#CY_"'^".+OX`^F_@M^"X+^&/H_KOI/P;
MZ%+Z'Z?\3_\`B#RO1=/3ZS_$;?E^.EVY?&_>#WWE/X_S#YDY3W3U]WP\>S2&
MFT?=_P!V,?=,ONWRD^5+=+9+P^]XN';KVQ,6O#&1@T00:((-$$&B"#1!!H@@
MT00:((-$$&B"#1!!H@@T00:((-$$&B"#1!!H@@T00:((-$$&B"#1!!H@@T00
,:((-$$&B"#1!'__9
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
